Tissue Doppler imaging. Echocardiographic assessment of anthracyclines cardiotoxicity in children,Tissue Doppler Imaging by Kapusta, L.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/19204
 
 
 
Please be advised that this information was generated on 2018-07-07 and may be subject to
change.
Tissue Doppler Imaging:
Echocardiographic assessment of anthracyclines 
cardiotoxicity in children
Livia Kapusta

Tissue Doppler Imaging: 
Echocardiographic assessment of anthracyclines 
cardiotoxicity in children
Een wetenschappelijke proeve op het gebied 
van de Medische Wetenschappen
Proefschrift
ter verkrijging van de graad van doctor 
aan de Katholieke Universiteit Nijmegen, 
op gezag van de Rector Magnificus 
Prof. Dr. C.W.P.M. Blom, 
volgens besluit van het College van Decanen 
in het openbaar te verdedigen 
op dinsdag 3 december 2002, 
des namiddags om 3.30 uur precies,
door
Livia Kapusta
geboren op 25 april 1957 te Tel Aviv, Israël
Nijmegen University Press
Promotores: Prof.dr.ir. J.M. Thijssen 
Prof.dr. O. Daniëls
Co-promotor: Dr. J. Groot-Loonen
Leden van de manuscriptcommissie:
Prof.dr. F. Verheugt (voorzitter)
Prof.dr. P de Mulder
Dr. M. Sobotka-Plojhar, Vrije Universiteit Amsterdam
The work described in this thesis was financially supported by the
Stichting Vrienden van Kinderoncologisch Centrum Nijmegen and the Dutch Cancer Society 
(project nr. KUN 2000-2290).
The financial support of the Dutch Cancer Society for the publication o f the thesis 
is gratefully acknowledged
Cover: Anja Prischmann 2002 
ISBN: 90 3730647 0
Van dit proefschrift is tevens een handelseditie verschenen bij Nijmegen University Press

iC O N TENTS
Abbreviations ii
Chapter 1 General introduction and aim of the study 1
Chapter 2 The current knowledge of anthracycline-induced cardiotoxicity 7
Chapter 3 The current knowledge of the tissue Doppler imaging technique 27
Chapter 4 Assessment o f myocardial velocities in healthy children using 
tissue Doppler imaging
Ultrasound M ed Biol 2000;26(2):229-37 41
Chapter 5 Tissue Doppler imaging in detection of myocardial dysfunction in 
survivors of childhood cancer treated with anthracyclines
Ultrasound Med Biol 2000;26(7):1099-108 55
Chapter 6 Discriminative ability of conventional echocardiography and
tissue Doppler imaging techniques for the detection of subclinical 
cardiotoxic effects o f treatment with anthracyclines
Ultrasound M ed Biol 2001;27(2):1605-14 71
Chapter 7 Tissue Doppler imaging and cardiotoxicity in children treated 
with anthracyclines
Submitted 87
Chapter 8 Regional cardiac wall velocity abnormalities during and shortly after 
anthracyclines therapy
Submitted 103
Chapter 9 Summary and general conclusions 121
Dankwoord 131
Curriculum vitae 135
ii
L IST  O F A BB REV IA TIO N S
A = transmyocardial velocity difference
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MAV = mitral annular velocity
MV = mitral valve
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PWTDI = single-gated pulsed-waved tissue Doppler imaging
Pulm = pulmonary valve
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ROC curve = receiver operating characteristic curve
RVAW = right ventricular anterior wall
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S = peak systolic myocardial velocity
S- score = multivariate discriminant score
SD = standard deviation
SR = strain rate
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TV = tricuspid valve
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G EN ER A L IN TR O D U C TIO N  & A IM  O F T H E STUDY
The challenge of treatment of cancer is to find a balance between toxicity and anticipated benefit. 
For instance, a young person with a rapidly progressive but potentially curable cancer will be 
considered for intensive treatment, where a substantial risk of acute and long term side-effects (both 
cardiac and general) is usually acceptable.
Anthracyclines are cytotoxic antibiotics that play a central role in the treatment of 
leukemias, lymphomas, and many of the common solid tumors. This group includes doxorubicin (or 
adriamycin), daunorubicin, epirubicin, idarubicin and mitoxantron. Many of the long-term survivors 
o f childhood cancer have been treated with this kind of drugs,1 mainly with doxorubicin or 
daunorubicin. Most o f these children will eventually be cured of their disease. It is estimated that in 
the year 2010, 1 out of 250 adults will be a survivor of a childhood malignancy.2 With this growing 
number of survivors, the late effects of their treatment become increasingly important. Therefore, 
the choice of current day treatment o f childhood malignancy lies in finding the correct balance 
between maximizing the therapeutic efficacy while minimizing the risk of acute and late 
undesirable side effects o f the treatment.
For many tumors there is a clear anthracyclines dose-response relationship. However, the major 
risk factor for cardiac side effects is also dose related and rises with the total cumulative dose of this 
anti-cancer drug. In order to prevent congestive heart failure, it is recommended that the total dose 
of doxorubicin or daunorubicin be kept below 450 mg/m2 body surface area. Many centers use 
protocols in which the treatment do not exceed 300 mg/m2. A  small proportion of patients will still 
develop cardiac problems at these moderate doses, indicating different threshold susceptibility 
between individuals.
Anthracycline-induced cardiotoxicity is probably multifactorial. The classical lesion seen on 
endomyocardial biopsy is focal. However, the extent of the lesion correlates well with the quantity 
o f anthracyclines given, and with the cardiac outcome. Clinically, cardiotoxicity can be classified as 
either acute, or late. A  number of risk factors may predispose a patient to cardiotoxicity,3 e.g.: 
cumulative dose of anthracyclines, mediastinal radiation, age at diagnosis (start of therapy), and 
female gender. Cardiac problems may include mild blood pressure changes, thrombosis, 
arrhythmias, myocarditis, pericarditis, myocardial infarction, cardiomyopathy, cardiac failure (left 
ventricular failure) and congestive heart failure.3,4 Acute side effects may develop within minutes 
after intravenous administration of the drug. This acute form is most frequently characterized by 
arrhythmias and conduction abnormalities. In general, the acute asymptomatic cardiac changes are 
transient and do not prevent the further use of anthracyclines.5,6
Late cardiotoxicity following anthracycline therapy occurs in 5-10% of long term survivors 
between 5 and 10 years after chemotherapy. Although late cardiotoxicity is mostly subclinical, it is 
often progressive and sometimes fatal.7 Therefore, the most feared complication is the sub acute 
form of cardiotoxicity, that can progress to clinical cardiomyopathy even 4-20 years after cessation 
of anthracyclines therapy. These late onset cases probably represent decompensation of the 
myocard, being damaged during the original treatment. It appears from the literature that these 
children either suffer from decreased systolic heart function (congestive heart failure), or from a 
loss of heart muscle mass, without dilation of the ventricles (restrictive cardiomyopathy). The time 
course of the development o f myocardial damage is not well known, since adequate diagnostic 
methods are not yet available.
Treatment of most cardiac events induced by chemotherapy is based on the symptoms. 
Screening and modifying risk factors, alertly monitoring for signs and symptoms as chemotherapy 
is being administered and continuing follow-up after completion of a course or of the entire 
treatment is mandatory. Prompt measures such as discontinuation or modification of chemotherapy, 
or use of appropriate (cardioprotective) drug therapy, should be initiated on the basis of changes in 
monitoring parameters before the patient exhibits signs and symptoms of cardiotoxicity.3 Early
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cardiac failure may improve on stopping anthracyclines, and cardiomyopathy developing within a 
year o f treatment may respond completely to antifailure medication for a period of time. In both 
cases eventual relapse is likely. There are limited options in the treatment of progressive 
cardiomyopathy. Still, the best option of treatment is prevention, perhaps by using a better 
monitoring system during or shortly after therapy.
Every dose of anthracycline causes some, usually subclinical, damage to the myocardium. It is 
proved frustratingly difficult to accurately monitor and predict the effects o f damage, especially in 
the case of late onset dysfunction. At present, serial echocardiography is the most common, non­
invasive method for monitoring the heart function in children. It allows assessment of systolic (e.g. 
fractional shortening or left ventricular ejection fraction) and diastolic (e.g., myocardial wall 
thickness, mitral valve blood flow velocity patterns) function, before failure becomes clinically 
apparent.
Ultrasound Tissue Doppler Imaging (TDI) is a recent echocardiographic technique which 
allows for the assessment of tissue motion (i.e. velocity of movement of the heart walls), is non­
invasive, easy to use and causes no radiation damage. This technique has been introduced in the 
Children’s Heart Center of the University Medical Center Nijmegen, and was applied in this study, 
together with conventional echo-Doppler techniques. TDI measurements yield a direct estimate of 
the regional contraction and relaxation properties of the heart muscle. The predictive value of tests 
for regional versus global left ventricular (dys)function is expected to be different.
The purpose of this study was to use the TDI for the detection of early signs of myocardial 
dysfunction in apparently normal children treated with anthracycline chemotherapy for childhood 
cancer. "Is it possible to detect myocardial damage at an early stage with this technique?" being the 
leading question of this thesis. Formulated in terms of hypothesis, or expectation: “TDI is more 
sensitive to detect asymptomatic cardiomyopathy and more useful for follow-up than conventional 
echocardiography”.
O U TLIN E O F TH ESIS
This thesis deals with the exploration of a new ultrasound technique, namely tissue Doppler 
imaging (TDI), for the detection of subclinical myocardial damage due to anthracyclines therapy.
In chap te r 2: the current knowledge of anthracycline-induced cardiotoxicity is discussed. The 
review of the literature includes their mechanism of action, risk factors, clinical significance and 
monitoring techniques.
In chap te r 3: the current knowledge of the TDI technique is discussed. Although not widely 
applied in routine clinical studies at this time, TDI can be used to assess global and regional systolic 
LV function and to identify abnormal LV relaxation in a variety of conditions.
In chap te r 4: assessment o f myocardial velocities in healthy children using tissue Doppler 
imaging, the study presents the application of the new TDI technique to healthy children, in order to 
generate normal reference values for children (age range 4-18 y).
In chap te r 5: tissue Doppler imaging in detection of myocardial dysfunction in survivors of 
childhood cancer treated with anthracyclines, a retrospective TDI study is carried out in order to 
examine the applicability o f this new method for the estimation of cardiac function in long-term 
survivors.
In chap te r 6: discriminative ability of conventional echocardiography and tissue Doppler 
imaging techniques for the detection of subclinical cardiotoxic effects o f treatment with 
anthracyclines, the authors investigate the possible improvement of diagnosing myocardial damage 
in long-term survivors using each technique separately, and in combination. The use of a 
multivariate discriminant score (S-score) is tested.
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In chap te r 7: tissue Doppler imaging and cardiotoxicity in children recently treated with 
anthracyclines, the authors try to find out whether the TDI technique is useful for early 
discrimination of apparently normal (short-term) survivors from healthy controls, by using 
univariate and multivariate statistical analyses.
In chap te r 8: regional cardiac wall velocity abnormalities during and shortly after 
anthracyclines therapy, a typical phenomenon (which was already reported in the previous chapter) 
is being followed in a prospective study (before, during and short after cessation of therapy), as well 
as in a retrospective study of early survivors treated with anthracyclines.
In chap te r 9: summary (in English and Dutch) and general conclusions of the research are 
described.
In ch ap te r 10: acknowledgement (Dankwoord) and Curriculum Vitae are given.
6 Chapter 1
R E F E R E N C E  LIST
1. Krischer JP, Epstein S, Cuthbertson DD, Goorin AM, Epstein ML, Lipshultz SE. Clinical cardiotoxicity 
following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J 
Clin Oncol 1997;15:1544-52.
2. Lipshultz SE, Sallan SE. Cardiovascular abnormalities in long-term survivors of childhood malignancy. 
J Clin Oncol 1993;11:1199-203.
3. Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. 
Drug Saf 2000;22:263-302.
4. Riccardi R, Lasorella A, Mastrangelo R. Principles of cancer chemotherapy in children. In: Voute PA, 
Kalifa C, Barrett A, eds. Cancer in children. Oxford University Press, 1998:57.
5. Balis FM, Holcenberg JS, Poplack DG. General principles of chemotherapy. In: Pizzo PA, Poplack DG, 
eds. Principles and practice of pediatric oncology. J.B. Lippincott Company Philadelphia, 1993:121-24.
6. De Beer EL, Bottone AE, Voest EE. Doxorubicin and mechanical performance of cardiac trabeculae 
after acute and chronic treatment: a review. Eur J Pharmacol 2001;415:1-11.
7. Nysom K, Colan SD, Lipshultz SE. late cardiotoxicity following anthracycline therapy for childhood 
cancer. Progress in pediatric cardiology 1998;8:121-8.
C H A PT E R  2
The current knowledge of anthracycline-induced cardiotoxicity
CH
AP
TE
R 
2

The current knowledge o f anthracycline-induced cardiotoxicity 9
A N TH R A C Y LC LIN ES
Most of the current antitumor antibiotics are natural substances, originally isolated from the 
microbial broth of Streptomyces. Anthracyclines are eliminated through biotransformation in the 
liver and excretion in bile.1,2 The total clearance rate is about 1000 ml/min/m2. Clearance through 
the kidneys comprises only 10% of the total clearance of anthracyclines.2 Changes of serum level of 
anthracyclines may occur in patients with liver dysfunction, but not in patients with renal 
dysfunction.1
A N TI-TU M O R  A C TIV ITY
Anthracyclines have a wide spectrum of biological activities. Although the mechanism of 
anthracycline anti-tumor activity remains controversial,3 different mechanisms have been 
suggested, including:3,4
1. Activation of signal transduction pathways
2. Generation o f reactive oxygen intermediates
3. Stimulation of apoptosis
4. Inhibition of topoisomerase II catalytic activity
Anthracyclines may also exert cytotoxic effects through a direct interaction with the cell 
membrane.3 Because proliferation is an important determinant of tumor growth, interference with 
the genome, through topoisomerase-mediated DNA damage is regarded as the primary cause of 
anti-tumor activity of doxorubicin.3
M ECH A N ISM S O F C A R D IO TO X ITIY
Many hypotheses have been proposed to account for anthracycline induced cardiotoxicity, 
suggesting that the development of cardiac damage is multifactorial. These hypotheses are 
discussed in the following:
1. The free rad ical hypothesis
Anthracyclines (doxorubicin) may cause free radical formation. Reactive oxygen species are 
superoxide radicals and hydroxyl radicals which have the potential to initiate damage to lipid 
biomembranes and to various intracellular components, including nucleic acids, lipids and 
proteins.3,5,6
The heart is particularly susceptible to free radical injury, because it contains less free radical 
detoxifying substances (superoxide dismutase, glutathion and catalase).5,7 Moreover, doxorubicin is 
known to have high affinity for cardiolipin, a major phospholipid component of the mitochondrial 
membrane in heart cells, resulting in selective accumulation o f doxorubicin inside cardiac cells.5,8
There is still controversy regarding the relevance of free radical formation by doxorubicin to 
doxorubicin-related cardiotoxicity.5,9 However, from the point of view of the free radical 
hypothesis, the study of Arai et al. is noteworthy because this study showed how the formation of 
hydrogen peroxide and the down-regulation of the sarcoplasmic reticulum calcium pump are 
related, explaining the pathway whereby the two could be interacting.10
2. The calcium  overload hypothesis
According to the calcium overload hypothesis, anthracyclines induce an excessive rise in
intracellular calcium. A doxorubicin-induced increase of the calcium accumulation in mitochondria
is generally at the expense of ATP production by oxidative phosphorylation, thereby resulting in
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depletion of high-energy phosphates.5 Free oxygen radicals may also cause calcium influx, 
suggesting that calcium accumulation may be a manifestation rather than a cause of anthracycline 
cardiomyopathy.11
3. The anthracycline m etabolite hypothesis
Doxorubicin and other anthracyclines with a C-13 carbonyl functional group can be metabolized to 
C-13 alcohols in the heart. Doxorubicinol, the primary C-13 alcohol metabolite o f doxorubicin, has 
been found to accumulate in cardiac tissue in a time- and dose-dependent manner. In experimental 
models, adriamycinol appeared to be more toxic than doxorubicin, suggesting that this metabolite 
may contribute to cardiac toxicity.3,5
4. P rostaglandines and  platelet activating fac to r (PAF) hypothesis
Anthracyclines alter arachidonic acid metabolism, which suggests that prostaglandines, 
thromboxanes and leukotrienes may be involved in anthracycline toxicity. Doxorubicin stimulates 
the production of prostaglandins and thromboxanes in rats. PAF receptor antagonists have been 
reported to attenuate histological lesions in doxorubicin-treated rats’.5
5. The histam ine hypothesis
According to Bristow et al.,12 anthracyclines stimulate the release of histamine from mast cells, 
which raises the possibility that histamine may be a mediator of anthracycline cardiotoxicity.
Because free radicals are also known to stimulate the release of histamine, free radicals 
generated by anthracyclines could mediate histamine release. How histamine causes cardiotoxicity 
and histological lesions is unclear. Histamine has been found to facilitate calcium influx via 
histamine H2 receptors and to evoke arrhythmias via H1 receptors, which suggests that calcium 
may be involved.7
6. D isturbances in m yocardial adrenergic function
Adrenergic dysfunction may develop by down regulation of myocardial beta-adrenergic receptors.13 
This impaired response of the receptor to catecholamines would tend to diminish the ability of 
myocardium to adequately respond to adrenergic stimuli. This might cause or enhance ventricular 
dysfunction.
7. E laboration  o f P ro-inflam m atory  cytokines
Doxorubicin induces the release of TNF-alpha and interleukin-2. These two cytokines are 
associated with the development of cardiotoxicity. The fact that the amount of cytokines released 
during chemotherapy depends on the type of tumor can explain the difference in incidence of 
cardiotoxicity in different types of tumors in some of the studies.11
The observation that synergism may exist between doxorubicin and other stresses, including 
acute intercurrent viral illnesses, in causing various degrees of cardiac decompensation is an 
example for a multifactorial etiology of cardiotoxicity.14
8. D irect interaction  w ith the actin-myosin contractile system
Few, in vitro studies, focus on contractile alterations that are directly caused by interaction of
doxorubicin with the contractile apparatus.15,16 Evidence has been accumulated that doxorubicin
directly interacts with skinned single skeletal muscle fibers, suggesting a direct interaction of the
drug with the actin myosin structure, possibly by an effect on myosin-ATP activity. De Beer et al.
suggested that doxorubicin impairs crossbridge turnover kinetics in skinned cardiac trabeculae.17
Bottone et al. also studied the effect of chronic doxorubicin treatment on the contractile response of
isolated skinned trabeculae.18 The maximal activated tension progressively decreased upon chronic
doxorubicin treatment, starting from week 2 after the final doxorubicin administration. Calcium
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sensitivity of doxorubicin-treated preparations was significantly decreased as compared to controls. 
Although the authors found characteristic morphological changes of heart cells, such as 
microvacuoles and edema, they did not observe cardiac cell loss or fibrosis, and the dimensions of 
the trabeculae did not differ between control and doxorubicin preparations. It should be mentioned 
that the follow-up duration in this study was short.
R IS K  FA C TO R S F O R  A N TH R A C Y C LIN E C A R D IO TO X IC ITY
"In spite o f  a considerable interest in identifying risk factors fo r  late subclinical cardiotoxicity, 
findings have often been conflicting"}9
Cum ulative dose o f anthracyclines
High cumulative dose of anthracycline is a well recognized risk factor for development of acute and
late cardiotoxicity.19-27 The incidence of late clinical cardiotoxicity increases rapidly at doses higher 
2 11 21 28 2 than 550 mg/m . ’ ’ This sharp increase in incidence has made 550 mg/ m  a kind of empirical
cumulative dose limit.
Congestive heart failure has been reported in adults even at a cumulative dose of doxorubicin of less 
than 300 mg/m2,29 which indicates possible variations among patients in their tolerance to the drug 
(different threshold for cardiac damage).30,31 Others could not find any relation between the 
cumulative dose and the development o f cardiotoxicity, suggesting an all-or-none effect of 
anthracyclines.32 The individually different sensitivity and threshold are summarized by the remark 
of Lipshultz: “If the cumulative dose at which cardiotoxicity occurs was the same for everyone, 
then a simple reduction in the cumulative dose would provide adequate protection”.33
Com bination o f chem otherapeutic agents
Enhanced toxicity may occur when anthracyclines are used in combination with other agents, as is 
the case in all treatment protocols. These drugs are: methotrexate, bleomycine, cyclophosphamide, 
dactinomycin, cisplatinum, etoposide, vincristine, bleomycine, busulfan and mitomycin-C.34-36 
Cyclophosphamide-induced cardiotoxicity is supposed to be related to high single dose as used 
preparatory to bone marrow transplantation.37 Methotrexate is especially hepatotoxic and may play 
a role in maintaining higher doses of serum Doxorubicin.36 It is therefore not considered as having a 
direct effect on the heart.
G ender
27,38-40Females have a higher risk of developing early and late cardiotoxicity. ’ " The reason for this 
gender related difference is still unclear. The volume of distribution of anthracyclines differs 
between genders, perhaps due to a lower clearance ratio in female.41 Furthermore, doxorubicin does 
not achieve high concentrations in fat tissue and obesity is known to slow down the doxorubicin 
metabolism.42 This difference may lead to higher concentrations of the drug in girls, who have 
relatively higher fat concentration within the same body surface area.
Since gender differences in body composition are more pronounced in postpubertal children,43 
it is likely that the risk for developing myocardial damage is even greater in postpubertal girls.27 
However, this hypothesis has not yet been proven.
Age a t diagnosis
Some studies reported that a younger age at diagnosis is associated with an increased risk for
22,27,39developing late cardiotoxicity. This association may be due to a lower concentration of
oxygen radical scavengers in the younger heart,19 higher relative doses,44 or because of a difference
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in the pharmacokinetics of anthracyclines in younger children. Younger age at diagnosis was also 
related to an increase in left ventricular afterload and a decrease in shortening fraction.39,45
Length o f follow-up
In several studies the length of follow-up was a significant risk factor for developing late
19 22 39cardiotoxicity. Cardiac abnormalities increased with time when patients were followed
longitudinally. Patients with longer follow-up periods were at risk of developing a reduced left 
ventricular wall thickness and an increased afterload.46 An increase in the prevalence of abnormal 
diastolic functions as mitral valve early (E) to late (A) diastolic blood flow velocities (abnormal 
E/A ratio) was also related to the length of follow-up.47
Possible explanations for cardiac abnormalities that develop with time are that cardiac growth 
is impaired and cannot match somatic growth, or that cardiac function is deteriorateing after a long 
period with elevated afterload.19
Still, this risk factor remains also controversial. A recent longitudinal study of cardiac function 
in children with cancer over 40 months demonstrated only mildly abnormal cardiac indices after 
cessation of treatment with anthracycline.48 These indices, e.g., the ejection fraction, left ventricular 
(LV) fractional shortening and LV wall stress (EF, FS and LVWS, respectively) did not deteriorate 
during 3 to 4 years follow-up. The results o f this population after a longer follow-up duration are 
still missing.
M ediastinal irrad ia tion
Impaired cardiac function was reported shortly as well as years after mediastinal 
irradiation.11,25,38,47,49 It is likely that mediastinal irradiation and anthracyclines are both cardiotoxic, 
but have different mechanisms of inflicting damage. The damage done by mediastanial irradiation is 
found mainly in the pericardium and the vascular endothelium. Anthracyclines damage the 
myocytes of the myocardium. It is possible that the damage caused by mediastinal irradiation must 
be of certain severity before it impairs myocardial function and thus enhances cardiotoxicity.19
Type o f m alignancy
Only two studies associated the type of malignancy with an increase in cardiotoxicity, but both 
studies did not correct for the cumulative dose of anthracyclines.39,50
R ate  o f adm inistration  o f anthracyclines
When higher cumulative dose of anthracyclines or a higher dose per unit of time are given to 
individual patients, they are at a higher risk for developing late subclinical or clinical
cardiotoxicity.39,40,50,51 This toxic effect may be due to high anthracycline peak concentrations.40,51
An approach to reduce the doxorubicin toxicity is the substitution by prolonged, continuous 
intravenous infusion.40,52 Bolus injections are not used in the current treatment protocols anymore.
E arly  onset cardiotoxicity
An important risk factor for developing late cardiotoxicity is probably the occurrence of early 
cardiotoxicity. Two studies associated late subclinical cardiotoxicity with abnormal 
echocardiography within one year after therapy.22,25 Some of the patients who acquired late 
doxorubicin-associated myocardial dysfunction had more than one episode of congestive heart 
failure during the follow-up period. Their late cardiac dysfunction might be the result o f sequential 
or additive cardiac damage.
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O th er suggested r isk  factors
Acute intercurrent viral illness may trigger late cardiotoxicity, especially in patients who already 
have sustained subclinical cardiac damage as a result of their doxorubicin chemotherap.14 The viral 
infection is in these cases an additional stress factor, resulting in late, sudden decrease in systolic 
function (measured as FS). This phenomenon was observed only in those patients who had received 
> 300 mg/m2 of doxorubicin, supporting the hypothesis that the damage must exceed a threshold 
before evidence of significant myocardial dysfunction might be clinically detected. Other sources of 
cardiovascular stress, such as pregnancy and surgery, are possible triggers o f late-onset 
anthracycline-induced cardiac dysfunction to.11
Patients with pre-existing heart disease (e.g., coronary heart disease, hypertensive or 
hypertrophic cardiomyopathy) known to be associated with cardiotoxicity, are often excluded from 
the studies.53 Other risk factors, which appear to be specific for early cardiotoxicity in children, 
included black race, Trisomy 21, and the use of amascarine therapy after anthracycline therapy.38,44
C LIN IC A L SIG N IFIC A N C E 
Definition
Anthracycline-induced cardiotoxicity is often defined as a condition in which echocardiographic 
parameters deteriorate after a single dose or after a complete treatment with anthracyclines with or 
without clinical symptoms.
The cardiotoxicity can manifest as:
1. Early cardiotoxicity defined as a reversible acute or, an irreversible subacute cardiomyopathy.
2. Late cardiotoxicity defined as a progressive, irreversible cardiomyopathy.
Children and adults may develop restrictive and dilated cardiomyopathy. The type and degree 
of cardiomyopathy, as well as whether during or after treatment the condition occurs, are dependent 
on what risk factors are present (see risk factors).
C inical form s
1. Subclinical form, is most frequently based on echocardiographic abnormalities without cardiac 
symptoms.
2. Patients with a clinical form have all kinds of clinical symptoms and often also severe 
echocardiographic abnormalities. The clinical symptoms consist of signs of congestive heart failure 
(CHF): dry cough, tachypnea, tachycardia, dyspnea, cyanosis, oedema, hepatomegaly, gallop 
rhythm (of the heart) and crepitations of the lungs. Mortality related to clinical congestive heart 
failure due to anthracycline-induced cardiotoxicity is being reported in more than 20% of 
symptomatic patient.21 However, recent reports have suggested a better prognosis,54,55 with up to 
59% clinical recovery, in patients with anthracycline-induced congestive heart failure who are 
treated with digoxine and diuretics.56 Complete recovery of echocardiographic abnormalities 
associated with clinical cardiotoxicity may also occur if anthracycline-therapy is stopped at an early 
stage, but this does not prevent long-term impairment of the heart functio.11
E arly  Cardiotoxicity
Acute and subacute early cardiotoxicity, which can occur immediately after a single dose of 
anthracyclines, during or short after completion of therapy, is uncommon under the current 
treatment protocols (cum. dose <300 mg/m2).11,29,40,45 The early cardiotoxicity may be associated 
with acute myocyte necrosis with inflammatory cellular infiltration of the myocardium. These 
pathological changes are not seen in the chronic and late form of anthracycline-induced 
cardiotoxicit.57 Pericardial effusions might also be found.53
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Several early cardiotoxic effects o f anthracyclines have been reported, these changes are 
generally considered to be part of a myocarditis-pericarditis syndrome.58 First o f all, 
electrocardiographic abnormalities as ST and T-wave changes, decreased QRS-voltage, and 
prolongation of QT interval were reported in the literatur.26 Sinus tachycardia is the most common 
among the arrhythmias; other arrhythmias include also ventricular, supraventricular and junctional 
tachycardias, all occurring during or short after a course of chemotherapy.59,60 Atrioventricular and 
bundle branch blocks have also been reported.59 The arrhythmias are usually transient,61 still sudden 
death within the first hours were also reported.62
The most common echocardiographic parameter reported is a decrease of the shortening 
fraction (SF),30 or o f the left ventricular ejection fraction (LVEF) during therapy, which could lead 
to anthracycline dose modifications.11 Elevation of blood cardiac troponin T (cTnT), a specific 
biomarker of cardiomyocyte damage, was positively correlated with subsequent abnormal 
echocardiographic measurements.63
Early clinically significant cardiotoxicity occurs in approximately 1% of children treated with 
anthracyclines.38,45 A  few cases have been reported in which acute cardiotoxicity resulted in acute, 
symptomatic failure of the left ventricle.57
The prognosis o f early onset (acute or subacute) cardiotoxicity may be different: it may be 
transient, persisting or it may progress to late form of anthracycline-induced cardiotoxicity. Patients
19 22 25with early presentation of CHF can occasionally manifest late CHF. ’ ’ Therefore, development 
o f congestive heart failure during therapy is not a sufficient cardiac endpoint. Late cardiotoxicity 
has become a much more common clinical problem
L ate cardiotoxicity
This form of cardiotoxicity manifests itself after a latency period of one or more years following 
completion of anthracycline therapy. Pathological findings were myofibrilar loss within 
cardiomyocytes and a sarcotubular dilatation, which is characteristic.64 The damaged cells are 
replaced by fibrosis and ventricular failure ensues.
Most late cardiotoxicity is subclinical, yet this does not mean it is harmless.19,20,40 The 
prevalence of subclinical cardiac abnormalities is reported to be between 20% and 75%. So, the
prevalence varies greatly within different studies.22,25,32,29,47,65 These abnormalities include
parameters indicating increased afterload, decreased contractility, or both (see monitoring chapter), 
and seem to be progressive and can eventually lead to clinical symptoms of heart failure. The 
incidence of severe echocardiographic abnormalities increased with the duration of follow-up.11,25 
These findings indicate that the full extent o f the problem has yet to unfold in many asymptomatic 
patients.
Several recent studies have noted occult ventricular dysfunction, heart failure, and arrhythmias 
occurring in asymptomatic patients more than 1 year after anthracycline treatment.22,25,54,66-69 This 
occult ventricular dysfunction may be the clue for the unexplained sudden death in some of those
patients.69
Late clinical cardiotoxicity following anthracycline therapy is less common compared with late 
subclinical cardiotoxicity. It presents 2-19 years after therapy with a median of 10 years and occurs
19 22 25in 5-10% of the long-term survivors of a childhood malignancy. ’ ’ It may comprise all the 
symptoms associated with cardiomyopathy: electrophysiologic changes, symptomatic changes in 
left ventricular function, changes in exercise-stress capacity, and overt signs of CHF. Late clinical 
cardiotoxicity is often life threatening if not treated by cardiac transplantation.19 Half o f the patients 
with late clinical cardiotoxicity presented with clinical problems within one year after therapy had 
ended.19 They were stabilized with anticongestive medication but eventually deteriorated again in a 
later stage. Thus the occurrence of early clinical cardiotoxicity is a high risk factor for developing 
late clinical cardiotoxicity.22,25 Late-onset arrhythmias and sudden death have been reported to 
occur in patients more than 15 years after anthracycline treatment.26,54 An incidence of non­
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sustained ventricular tachycardia ranging between 3%-5% at long-term follow-up has been 
reported.26,69,70 Postma et a l. reported that potentially serious ventricular arrhythmias were detected 
in 26% of late survivors, irrespective of cumulative doses of doxorubicin, suggesting that 
diminished heart rate variability could be a sensitive index for the cardiotoxicity.71
As was found for the form of anthracycline cardiotoxicity that manifests earlier (see risk 
factors), the incidence of late-onset cardiac decompensation increases with higher cumulative 
doses,22,25,51 higher rates of anthracycline administration,39,46 and mediastinal irradiatio.25 Young
22,27,39 27,39,51age at the time of treatment and female gender may be risk factors for late-onset
cardiotoxicity, but these factors are still controversial. However, recent evidence appears to support 
both factors as independent risk factors for late-onset cardiotoxicity.39
M O N IT O R IN G
The nature of anthracycline-induced cardiomyopathy is frequently observed as a (transient) 
improvement in cardiac performance after the completion of therapy, followed by development of 
full-blown cardiomyopathy with congestive heart failure in an unknown number of patients, after 
years o f latency. Therefore, treatment with anthracyclines may necessitate lifelong monitoring of 
the patient.
Different methods of cardiac monitoring have been described in many publications. However, 
almost every significant result was disapproved by other ones, making its clinical significance 
contradictory. In addition, none of the methods of screening for anthracycline cardiotoxicity could 
be shown to be adequately predictive of early or late cardiac outcomes. Nevertheless, when clinical 
evidence of cardiotoxicity is present, anthracycline dose modification is recommended.
A review of the diagnostic procedures used for cardiac function evaluation (except for the 
physical examination) is given in the following sections.
E lectrocardiography
Most patients who were treated with anthracyclines were monitored using electrocardiography in 
combination with echocardiography. Parameters as QRS voltage loss, or ST-T changes, are non­
specific and reveal pathological changes too late for eventual dose-modification.72 ECG registration 
is useful for monitoring arrhythmias (sinus tachycardia, ventricular and supraventricular, AV and 
bundle branch blocks). A few recent studies focussed the attention back on electrocardiography. 
Schwartz et al. found a correlation between a prolongation of the corrected QT-interval (QTc) and 
the cumulative anthracycline-dose.73 Jakacki used this correlation and combined it with the 
shortening fraction measured by echocardiography and a history of exercise intolerance to 
formulate an algorithm to evaluate the cardiac status of patients treated with anthracyclines.67 
Others could not confirm the utility of the QTc measurement, or o f abnormal T wave or ST 
segments, but they suggested heart rate variability as a potentially sensitive indicator for 
cardiotoxicity.71
In current treatment protocols, patients who undergo chemotherapy are not always monitored 
by electrocardiography during or after treatment. Because in some patients ventricular tachycardia 
may result in chronic heart failure or sudden death, serial Holter evaluation is advised.45,54,71
Echocardiography
Conventional echocardiography is a non-invasive reliable method of assessing the diameter and the 
function of the left ventricle in systole en diastole. Echocardiography is used to detect early and late 
cardiotoxicity. Mild to significant left ventricular systolic and diastolic dysfunction, detected by 
standard echo-Doppler cardiography, has been frequently reported.20,22,25,30,39,45,46,51,74-76 
Echocardiographic signs of dilated and restrictive cardiomyopathies were mentioned.44,46,47,77-79
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The following echocardiographic parameters are frequently used in order to define the 
myocardial damage (see also clinical significance chapter):
• FS < 28% (some authors used FS lower than 29% or 31%)
• Decreased IVS (interventricular septum thickness)
• Decreased LVPW  (left ventricular posterior wall thickness)
• Increased LVIDD (left ventricular end diastolic diameter)
• Increased LVIDS (left ventricular end systolic diameter)
• Decreased contractility (measured as stress velocity index)
• Increased afterload (measured as end systolic wall stress)
• Diastolic parameters (mitral valve E- and A  peak flow rates, deceleration times, E/A ratio)
• Prolongation o f isovolumic relaxation time
32 80 82These abnormalities are not always found to be present, ’ " and are even reported reversibly,
i.e. increased LVIDD and LVIDS early after treatment cessation.30 In the literature, a long 
discussion takes place concerning the frequent monitoring of (shortening fraction and) ejection 
fraction during therapy with doxorubicin and modification of the dose on the basis o f such 
monitoring, according to the recommendations of the Cardiology Committee of the Children’s 
Cancer Study Group.83,84 Lipshultz et al. found this monitoring insufficient for the management of 
cardiomyopathy and even harmful for the patients since the efficacy of their anticancer therapy is 
reduced by the withholding of the doxorubicin.33,85 Anthracycline dose modification is 
recommended when clinical evidence of cardiotoxicity is present".33
All the ejection-phase indices of left ventricular systolic function (including FS, EF, and 
velocity of fiber shortening) are able to detect acute drops in ventricular function associated with 
anthracycline administration. However, these indices are also sensitive to the conditions under 
which the ventricle is working and may thus be affected by factors such as fever, anemia, sepsis, 
and renal failure.45 For instance, transient declines in left ventricular function are common during 
treatment with anthracyclines, yet, abnormal hemodynamic are then also common.
Other echocardiographic parameters often being used are contractility and afterload.22 
Contractility is measured in this reference as the stress-velocity index. Afterload is measured as end 
systolic wall stress. The relationship between the velocity of fiber shortening and end-systolic wall 
stress has been used to overcome the confounding effects of loading conditions and to examine
20 86 87myocardial contractility directly. However, the predictive value of such techniques concerning 
late clinical cardiotoxicity has not yet been tested in a long term and prospective way.
The diastolic function of the left ventricle is assessed by mitral valve (MV) early- (E) and late 
(A, after atrial contraction) diastolic blood flow velocities, E/A flow velocity ratio and by 
isovolumic relaxation time. Diastolic function seems to be equally important as the systolic 
function.88 Diastolic filling is significantly impaired during89 and after anthracyclines treatment in 
childhood.47 This impairment was not linearly related to the cumulative dose of anthracyclines, but 
it may persist years after treatment with anthracyclines.47,90 High E velocities and an increased E/A 
ratio were reported by several investigators.47,66 Some research groups found that diastolic 
abnormalities precede systolic abnormalities.91,92 Others were unable to find diastolic abnormalities 
in patients who already had systolic dysfunction.80,93 Several other studies showed impairment in 
diastolic function in combination with a normal fractional shortening.47,94 This combination might 
be due to a restrictive filling pattern (high E and low A  velocities) o f the left ventricle that may 
precede a dilated filling pattern with systolic function abnormalities.88 In other study, however, one 
could not find any E, A  or E/A ratio abnormalities in the late survivors of acute lymphoblastic 
leukemia who received a cumulative dose of anthracyclines of 100 mg/m2.81
There are several studies that question the value of resting echocardiography, using fractional 
shortening as a reliable way to determine myocardial damage in children treated with 
anthracyclines.51 Yeung et al. showed that children, treated with anthracyclines years before, had
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normal myocardial function at rest, with an impaired myocardial response to physiological stress, 
measured as a negative change in fractional shortening.65 The results of this preliminary study 
suggest that moderate-dose anthracycline-administration may cause changes in myocardial function 
that cannot be detected by resting echocardiography. This too has been already contradicted by 
Lanzarini et a l ,  reporting lack of clinically significant cardiac dysfunction during dobutamine stress 
tests in long-term childhood cancer survivors exposed to anthracyclines.82
Radionuclide scintigraphy (RNA)
This method can be used to measure structure and function of the left ventricle and is therefore used 
by some researchers to evaluate the cardiac status of patients treated with anthracyclines.49,66,95,96 
The parameters used are mainly internal diameter and volume, left ventricle ejection fraction 
(LVEF), and systolic and diastolic patterns of motion.
Unfortunately, resting left ventricle ejection measurements obtained by RNA findings are 
relatively insensitive in detecting early anthracycline cardiotoxicity. This is mainly because no 
significant change of LVEF occurs until a critical degree of myocardial, morphological damage has 
been caused.11 Exercise RNA may enhance the value of LVEF measurement in detecting subclinical 
early anthracycline cardiotoxicity. Postma et al. found this method not sensitive for detection of 
cardiotoxicity.71 In addition, this technique has the disadvantage of using radioisotopes. Therefore, 
they did not recommend RNA for follow-up of young patients. Furthermore, radionuclide 
angiography is rather costly and not appropriate for frequent evaluation.
Exercise testing o r  stress-tests
Exercise testing involves multiple organ systems. The coordination between these systems has to be 
normal, especially the coordination between the cardiovascular, pulmonary and musculoskeletal 
systems. There are some difficulties in testing patients during or shortly after treatment because of 
multiple effects of therapy and tumor on the state o f health of children.97 For example, during 
treatment, tumor location, pain or pathological fractures can affect musculoskeletal function. 
Anemia, compromised pulmonary function and systemic effects as fever, abnormal fluid status may 
influence the results o f exercise testing. There are also difficulties in interpreting the results of 
exercise testing years after therapy. Cancer survivors are known to have several clinical syndromes 
after treatment. Growth can be impaired due to changes in the endocrine system. Radiation and 
surgery may effect the skeletal, pulmonary and cardiac status. All kinds of other chronic effects of 
cancer and therapy have been described which can cause problems in the interpretation of exercise 
tests in these patients. So, exercise testing could be a difficult way to evaluate the cardiac state of 
patients but it can definitely be used to quantify potentially subclinical toxicity, not only of the 
heart, but also of all organ systems. In the case of anthracycline-induced cardiotoxicity where other 
organ systems than the heart are affected too, exercise testing may be a good way to assess the 
patients' general state of health.97
Physiological (treadmills, ergometer bicycles)76,98-100 or pharmacological (angiotensin II, 
dobutamine)82,101 stressing of the heart were used in combination with earlier mentioned methods to 
reveal subtle cardiac abnormalities which are difficult to detect with the other methods.102
Standard exercise tests have also been used to evaluate late cardiotoxicity, but the relationship
22,23,98between abnormal results o f resting echocardiograms and exercise tests is weak or absent. ’ ’ 
Hogarty used cardiopulmonary exercise testing to discover subclinical abnormalities and concluded 
that metabolic exercise testing which measures the integrated function of multiple organ systems, 
identifies subclinical abnormalities and can be useful in monitoring functional capacity and guiding 
intervention.97 In another study with exercise testing the maximal cardiac index (cardiac output 
indexed for body surface area) was reduced in 41% of the patients.27
The clinical use of stress tests in (very) young children is still limited.
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E ndom yocardial biopsy
The diagnostic test with the greatest specificity and sensitivity for doxorubicin-induced 
cardiomyopathy is endomyocardial biopsy.56,103-107 Endomyocardial tissue from the right ventricle 
shows typical histopathological changes, including loss o f myofibrils, distention of the 
sarcoplasmic reticulum, and vacuolization of the cytoplasm. These histological markers are used to 
grade injury on a scale o f 1 to 3 (worst grade), whereas in grade 3 "diffuse cell damage with total 
loss o f contractile elements, loss of organelles and mitochondria, and nuclear degeneration" is 
present. With each dose of doxorubicin, progressive injury occurs to the myocardium, so that the 
grade increases steadily with total dose of drug administered. Early in the development o f the 
toxicity, these changes appear focally in scattered myocytes surrounded by normal appearing cells. 
As the toxicity progresses, the frequency of these altered cells increase until a significant 
proportion of the myocardium is involved. Late in the development o f this toxicity, the picture is 
complicated by the development o f diffuse myocardial fibrosis.
Recently, Dazzi and colleagues reported on patients with acute, fatal, anthracycline induced 
cardiotoxicity.53 Their pathology showed dilative cardiac hypertrophy and pericardial effusion, 
with microscopically the typical findings of myocardial fibrosis and perinuclear vacuolated 
myocytes. Interesting is that that in one (out o f 7) patient the myocardial necrosis was 
subendocardial, in one diffuse and one patient had papillary muscle necrosis. Only one patient had 
endomyocardial fibrosis. The authors therefore concluded that, in contrast to chronic cardiotoxicity 
(where the cumulative dose of anthracyclines is the most important risk factor), acute 
cardiotoxicity is not predictable and occurs with large variation in individual sensitivity. Less 
severe episodes are probably missed.
Myocardial damage as a result of myocytes loss heals by fibrosis, resulting in a measurable 
thinning of the ventricular wall. This fibrosis may also cause other disturbances such as an 
increased left ventricular diameter, decrease in the shortening fraction,11,108 and decreased LV 
compliance. Still, if doxorubicin-induced inhibition of myocyte growth would be the full 
explanation, the insult should be age related with maximal impact on very young patients. Other 
studies, however, have demonstrated a lack of such correlation.25
In adults, clinical evidence of toxicity (i.e., CHF) may be present without histological signs of 
cardiotoxicity; likewise, histological signs of anthracycline toxicity may be present without clinical 
evidence of toxicity.25,106 Thus, the attempt to monitor cardiotoxicity by serial evaluation of cardiac 
histology is limited.
There are limited reports about endomyocardial biopsies in children treated with 
anthracyclines. Endomyocardial biopsy or autopsy revealed hypertrophy and fibrosis in 10 patients 
with late symptomatic anthracycline cardiomyopathy.54 Shaddy and Bullock reported another 3 
patients with cardiomyopathy.109 Myocytes hypertrophy without interstitial fibrosis was observed in 
two leukemia patients who had recovered from severe congestive heart failure (CHF) due to 
anthracycline cardiomyopathy at 41 and 47 months after CHF (110). Pegelow et al. had described 
18 biopsies that were taken from patients on reaching cumulative doses of > 400mg/m2, yet no 
conclusion could be undertaken to evaluate its usefulness as a means to predict and avoid 
anthracycline cardiomyopathy.111
Disadvantages of this procedure are that it is invasive and it is not widely available for every 
clinician. International wide studies in children are missing. Consequently, it is not currently 
possible to evaluate the role of the biopsy in monitoring myocardial anthracycline toxicity in 
children.
O th er m ethods o f card iac evaluation
Several newer techniques have been used for detection anthracycline-induced cardiotoxicity. Some 
examples are:
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Indium-111 antimyosin scintigraphy, has been used for confirmation and early detection of 
anthracycline cardiotoxicity.112 This technique uses a monoclonal antibody labeled with Indium-111 
that binds (to myocytes) when cardiac myocytes are injured. Thus, an increased uptake of Indium- 
111 suggests more myocardial damage. In rats, the amount o f uptake of Indium-111 correlated with 
both histologic changes and end diastolic pressure and there was specific immunolocalization of the 
Indium-111 in injured myocytes.113 The value of Indium -111-antimyosin scintigraphy in early 
detection of myocardial damage in children treated with anthracycline was preliminary evaluated.95 
It seems to identify children who are at increased risk of developing cardiac sequelae.
Another method of cardiac evaluation is with Methyl Jodobenzyl Guanidine (MIBG) -scan. 
MIBG is an analog of norepinephrine and reflects cardiac adrenergic neuron integrity, which is 
disrupted with anthracycline damage. Animal studies showed abnormalities in uptake and clearance 
of MIBG, even when abnormalities of systolic and diastolic functions were not seen by echo.114
Positron-emission tomography (PET) has been used to identify metabolic changes suggesting 
cardiac damage in patients receiving chemotherapy.115
Cardiac Troponin T (cTnT) blood elevations were observed after initial doxorubicin therapy for 
ALL.63 The magnitude of elevation predicted left ventricular dilatation and wall thinning 9 months 
later. Methew et a l. did not observe elevations of serum troponin levels in clinically asymptomatic 
children who received anthracycline therapy up to cumulative doses of 375 mg/m2.116
Myocardial high-energy phosphate metabolism (magnetic resonance imaging) was impaired in 
late survivors o f childhood cancer treated with anthracyclines, even in the absence of abnormal 
echocardiographic finding.117
Some investigators have reported that elevated serum natriuretic peptide (ANP) which is 
released in response to chronic or acute increase in atrial transmural pressure and stress, may be a 
marker for anthracycline damage.118 Recently, plasma levels o f both ANP and brain natriuretic 
peptide (BNP) were found to be elevated in children with left ventricular dysfunction (119). _These 
levels were correlated significantly with cardiac systolic function, but not with diastolic function. 
Tikanoja et al. reported its usefulness in late follow-up. However, during chemotherapy, the ANP 
levels were influenced by a variety of factors, making it invalid for routine use.120
TR EA TM EN T
Digoxin, diuretics and anti arrhythmic drugs are frequently used as treatment o f the patients and 
survivors with (sub) clinical cardiomyopathy.54,55,121 However, "prevention of anthracycline- 
induced cardiac abnormalities may ultimately decrease associated morbidity and mortality more 
effectively than treating asymptomatic left ventricular dysfunction".44
The most obvious solution for the problem, namely, reduction of the cumulative dose of 
anthracyclines (< 550mg/m2) is not sufficient. A  safe cumulative dose is different for each patient 
and depends also on other risk factors.
Other strategies proposed to prevent or reduce anthracycline-related cardiotoxicity are: use of 
less cardiotoxic anthracyclines (e.g. idarubicin), alteration of the delivery of the anthracycline (e.g. 
weekly doses), alteration of the packaging of the anthracycline (e.g. liposomal encapsulation), use 
of cardioprotectants with anthracyclines (e.g. dexrazoxane or probucol), individualization of the 
dose of anthracycline according to markers o f cardiotoxicity (e.g. abnormalities on 
echocardiograms, nuclear medicine scans, heart rate spectral analysis, electrocardiograms, and 
elevations of cardiac troponin or atrial natriuretic peptide), adjustment of anthracycline-containing 
protocols based on the presence of factors known to worsen anthracycline cardiotoxicity (e.g. 
female sex or young age), and use of therapies that may reduce myocyte destruction and promote 
myocyte recovery (e.g. intravenous immunoglobulin).122 All these options need to be tested in long­
term follow-up studies. Reliable methods of evaluating cardiac status should be involved.
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Heart failure could be prevented by early treatment o f asymptomatic adult patients with 
reduced left ventricular ejection fraction.123-124 Enalpril, an afterload reduction drug, was given to 
long term survivors o f childhood cancer treated with doxorubicin with elevated afterload. It 
appeared to be safe and effective in producing both sustained LV afterload reduction (end systolic 
wall stress had fallen and stress velocity index showed no further deterioration), and improvement 
of LV performance (FS improved).125 Presently, the "ACE inhibitor After Anthracycline" (the 
AAA) study is being carried out in the USA, intending to provide information concerning the 
efficacy of using angiotensin-converting enzyme inhibitors to offset the effects of late anthracycline 
cardiotoxicity.126
An increasing number of reports suggest that dexrazoxane (ICRF-187) may reduce
127 130anthracycline-induced cardiotoxicity in children. Dexrazoxane is currently the only
cardioprotective agent in clinical use. It has been reported to ameliorate the cardiotoxicity 
associated with doxorubicin (remove iron from the doxorubicin-iron complexes that are involved in
131 133 * 128 129 134 29 135generation of free radicals) in both preclinical and clinical studies . Its mechanism
of action appears to be the prevention of free radical formation by doxorubicin, probably through
131 . . .  129129binding of iron. However, these studies only assessed early cardiotoxicity and it is currently 
not clear whether ICRF-187 treatment will reduce late cardiotoxicity.
Carnitine was recently reported to promote heat shock protein synthesis in adriamycin-induced 
cardiomyopathy in a neonatal rat experimental model.136 Its efficiency in human is to be explored. 
Where all therapeutic agents failed, cardiac transplantation could be the last choice of
54,78,79,137,138treatment. Unfortunately, local logistic problems as well as the unknown consequences
of post transplantation therapy in the long-term follow-up period, are important limiting factors in 
the introduction o f this therapy modality.
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TH E CU R REN T STATUS O F T H E  TISSUE D O PP L E R  IM A G IN G  T EC H N IQ U E
Echo Doppler cardiography is the predominant, non-invasive diagnostic modality, for the 
evaluation of left ventricular function as well as for the assessment and quantification of valvar 
heart lesions. However, assessment of regional cardiac dysfunction at rest and during stress with 
this technique remains subjective and semiquantitative.1,2
Tissue Doppler imaging (TDI) is a relatively new echocardiographic method that was first 
described and clinically applied by Isaaz from France in the 1980’s.3 This modality is non-invasive, 
does not yield radiation damage, is user friendly and therefore repeatable. TDI allows evaluation of 
local left ventricular (LV) systolic and diastolic function along the short and long axes of the heart. 
The technique is based on the Doppler principle of velocity estimation of structures moving with 
respect to the ultrasound transducer. Rather than using the Doppler shift frequencies higher than the 
wall filter limit as in blood flow velocity measurements,4,5 the low non-zero frequencies are used in 
TDI processing and analysis. In addition, the relatively low-amplitude echoes from the blood pool 
can be further removed by thresholding algorithms. In TDI systems, the lowest measurable velocity 
is 0.2 cm/s, a velocity level associated with cardiac tissue motion. As adult cardiac structures move 
in a velocity range of 6-24 cm/s, some 10 times slower than the cardiac blood flow, and have an 
echo amplitude approximately 40 decibels (100 times) higher, it may be clear that tissue Doppler 
images of the wall motion can be obtained without significant artifact originating from the blood. In 
the two-dimensional (2-D) images, each pixel displays one color representing the direction along 
the scan line and magnitude of the wall velocity.6
Due to its relatively high spatial resolution, TDI provides valuable information on regional 
myocardial wall motion during different intervals o f the cardiac cycle, namely during systole, early 
and late diastole (see below, normal values). In addition, by using the single-gated (pulsed-wave) 
tissue Doppler option, myocardial velocity vs. time curves (sonograms, or velocity-time waveform 
displays) can be recorded from locations selected in the 2-D TDI images. The low frame rate (25 
Hz) of the initial tissue Doppler imaging systems provided an insufficient temporal resolution. 
Modern equipment incorporates advanced processing techniques that allow 2-D tissue Doppler 
imaging with a frame rate o f up to 150-200 Hz. Off-line processing enables accurate quantification 
of regional myocardial motion in both systole and diastole, from multiple sites, with an image 
dataset being acquired within seconds. Still, this off-line analysis is time consuming and is not 
widely available in echocardiography laboratories.
Myocardial Doppler velocity imaging uses standard color coding to depict both velocity and 
direction of movement, with myocardial motion away from the transducer coded in blue, and 
towards the transducer coded in red.5 This information can be displayed as a standard 2-D image or 
as a M-mode TDI, where temporal resolution is enhanced. Differences in myocardial velocity from 
endocardium to epicardium are thus displayed, leading to the recognition of myocardial velocity 
gradients (MVG, in adults).7,8 Tissue velocity data can be obtained even from subjects where the 
traditional echo window is suboptimal.
N orm al values
Contraction of the LV occurs towards a central point situated at two-thirds along a (long-axis) line 
from the level o f the mitral annulus to the apex.9 Normal myocardial motion includes three 
components, along the radial, longitudinal and circumferential axes. Simultaneous assessment o f all 
three components is not yet possible by any of the echo techniques. The longitudinal shortening is 
an integral part of global contractile function, and it is thought to play also a role (as the radial 
thickening) in contributing to the LV ejection fraction.10 The potential for quantification of 
longitudinal shortening as a simple estimate of overall systolic function has recently been 
proposed,11 with a better reproducibility than using the radial contraction.12,13
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TDI provides valuable information on regional myocardial wall motion during different 
intervals of the cardiac cycle. Using single-gated pulsed-wave TDI (PWTDI), three (sometimes 
four) distinct peaks in systole and diastole are observed14 (see Fig.l):
• Systolic myocardial velocity may show 2 components in some patients, representing 
isovolumic contraction (S1) and the peak systolic (shortening) velocity (S2, very often titled 
as S)
• Peak early diastolic myocardial relaxation velocity (De)
• Peak late diastolic myocardial velocity, associated with atrial contraction (Da)
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Fig. 1. Pulsed-wave TDI velocity curve within the basal part of the right ventricular (RV) free wall.
S1 = peak systolic myocardial velocity during isovolumic contraction; S = peak systolic myocardial 
velocity; De = peak early diastolic myocardial velocity; Da = peak late diastolic myocardial velocity.
Several studies aiming at determining normal values in adults were carried out.3,15-21 The early 
diastolic (De) myocardial velocities are usually the highest. There is little evidence of a significant 
difference in velocities between sexes. Increasing age has been associated with a gradual fall in
22 * 15 22 24myocardial velocities both in systole and early diastole, increase in late diastolic myocardial 
velocity,25 as well as a fall in the ratio of the De/Da.25,26 Patient age influences both systolic and 
diastolic myocardial velocities because of myocyte integrity, fibrosis, and beta adrenergic receptor 
density.27 Diastolic myocardial velocities vary with heart rate and phase of respiratory cycle at 
which they are measured.28 The time duration of the isovolumic contraction and relaxation phases 
might have application for regional function assessment.
Using the parasternal view, normal values for the systolic and early diastolic transmyocardial
7 8 18 29velocity gradients (MVG) within myocardial segments were assessed (radial axis). ’ ’ ’ The 
intramyocardial velocity gradient was obtained, showing a gradual increase in radial shortening 
velocity from the subepicardial to the subendocardial region, independent of age.18 In healthy 
subjects, systolic and diastolic myocardial velocities are higher in the posterior wall than in the 
septum.21,30 When imaging from the apex (longitudinal axis), longitudinal contraction and 
relaxation velocities of the LV myocardium are the highest in the basal segments and decrease 
progressively when moving the measurement site toward the apex.16,17 In adults, the very apical 
velocities are reversed, as compared to those of the remainder of the LV wall;31 this is in 
correspondence with the location of the LV contraction center.
TOSHIBA
The current knowledge of the tissue Doppler imaging techniq 31
C U R REN T AND PO T E N T IA L  A PPL IC A T IO N S O F TD I
Tissue Doppler imaging has become a useful non-invasive method that complements conventional 
echocardiographic techniques in the assessment of LV myocardial velocities in a variety of clinical 
conditions,32 as is argumented in the following sections.
LV systolic function
LV systolic function can be noninvasively estimated by fractional shortening (FS, %) or LV 
ejection fraction (EF). Gulati 1996 et al. suggested the use of TDI to measure mitral annular 
displacement velocity as an index of global left ventricular function.12 Nagueh et al. reported that 
the lateral base systolic (S) myocardial velocity had a good correlation with LV ejection fraction.33 
Regional LV function is assessed by color-coded 2-D tissue velocity mapping or positioning of a 
sample volume within the myocardium at different sites (See also chapter 4). The color-coded 2-D 
tissue velocity map enables immediate appreciation of cardiac asynchrony, e.g., akinetic segments 
are shown by dark colors representing low tissue velocity, dyskinetic segments may be seen to 
exhibit colors opposite to those of adjacent normal segments. Regional LV function can be assessed 
at rest as well as during stress.34-37
LV Diastolic function
Global LV diastolic function can be derived from the mitral inflow velocities. Based on these 
velocities, ventricular filling can be divided into two components. First, a passive component, 
which is closely related to the ventricular relaxation and postsystolic transmitral pressure gradient 
(LV filling pressure). This component predominates in the initial phases of the diastole (e.g., during 
the isovolumic relaxation and early diastolic phase). Second, an active component, related to 
ventricular compliance, predominates the end of diastole (during and immediately after atrial 
contraction).38
Recently, Zile et al. published new concepts in diastolic dysfunction and diastolic heart 
failure.39,40 According to their concepts, measurements of diastolic function can be divided into 
those that relate to the process of active relaxation (e.g. release of calcium from troponine C, 
detachment of actin-myosin cross bridge, etc), and those that reflect passive stiffness (e.g. the 
stiffness o f the myocardium, LV mass/volume ratio, etc).39 For a given individual, the proportion of 
LV filling during the early and late diastolic phases depends on the elastic recoil (suction), rate of 
myocardial relaxation (active process), chamber compliance (stiffness), and LA pressure (preload). 
Myocardial and extramyocardial mechanisms, cellular and extracellular mechanisms, as well as 
neurohormonal activation each play a role in the development o f diastolic heart failure.40
The European Society of Cardiology proposed that evidence of abnormal relaxation, filling, or 
diastolic stiffness is needed for the diagnosis of diastolic heart failure.41 Measurements of diastolic 
function can be divided into those that reflect the process of active relaxation and those that reflect 
passive stiffness. Similar to systolic function, these measurements are load dependent. Additional 
indices that may be less sensitive to the load, e.g., tissue Doppler velocity, are therefore currently 
under investigation.
Tissue Doppler imaging offers the ability to measure regional diastolic function, with pulsed- 
wave TDI allowing quantification of diastolic myocardial velocities from a small sample volume 
placed in the region of interest in the same way as for the systolic velocities. Characterization of the 
normal myocardial velocity pattern during early (De) and late diastole (Da) was done in healthy 
subjects.16,17 TDI Mitral annular velocity (MAV) during early diastole has good correlation not only 
with the parameters of LV relaxation, but also with those of LV systolic performance.42 Normally at 
end-systole the muscle fibers are contracted to lengths shorter than their equilibrium length, 
resulting in a LV end-systolic volume smaller than the equilibrium volume. This condition stores 
elastic energy in the muscle, which is released during relaxation, resulting in elastic recoil o f the left
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ventricle (at end-systole). LV end-systolic volume in an individual heart is recognized as an 
indicator of its LV elastic recoil. LV relaxation depends on early diastolic release of elastic energy 
that is accumulated during systole as well as on calcium ion uptake by the sarcoplasmic reticulum 
during early diastole in myocytes (i.e., active relaxation). In the study of Ohte et al.,42 MAV showed 
no relation with heart rate, LV preload or age.
Clinical applications for assessing abnormal left ventricular diastolic function were recently 
reported.26,43,44 Early diastolic myocardial velocity (De) was higher in healthy subjects than in 
patients with either delayed relaxation, pseudonormal filling, or restrictive filling.39 Furthermore, 
parameters derived from the early diastolic velocity of the LV posterior wall, assessed by pulsed- 
wave TDI, were closely related to the calculated time constant o f a decrease in LV pressure (tau, a 
load-independent measure of relaxation),23,44 regardless o f LV filling pressure. Controversy exists 
regarding whether TDI parameters are influenced by preload. There is evidence that diastolic tissue 
velocities, in contrast to mitral flow velocities, are not influenced by acute preload manipulations 
(e.g., saline infusion and nitroglycerin administration),23,43,45 and there is lack of concordance 
between the two velocity parameters.46 In early diastole, the ratio o f mitral blood flow velocity to 
the velocity of the mitral annulus (E/De) showed a better correlation with the mean LV diastolic 
pressure (as estimation of filling pressure).33,47 It appeared that E/De < 8 predicted normal filling 
pressure, E/De > 15 identified increased mean LV diastolic pressure. Others reported that early 
diastolic mitral annular velocities were volume dependent (hemodialysis-related acute volume 
reduction),48 although to a lesser degree than mitral inflow velocities. Chronic increase in preload, 
as seen in LV volume overload from aortic or mitral regurgitation, influences the De as well and 
may be lower in patients with aortic regurgitation.49 However, the role of myocardial damage (in 
these conditions) on the TDI measurements has not yet been ruled out. M ost of the investigators 
still conclude that De is relatively independent o f loading and superior to conventional mitral (blood 
flow velocity) Doppler indices in the assessment of LV relaxation.23,26,43
Yip et al. have very recently reported that in adults, with diastolic heart failure (e.g., ejection 
fraction > 0.45) and evidence of left ventricular hypertrophy, isolated diastolic dysfunction is less 
common than previously thought.50 Their patients showed also systolic left ventricular impairment, 
detected by measuring the left ventricular (TDI) long-axis mitral annular velocity and amplitude.
In summary, the multiple determinants of diastolic myocardial velocities have not been 
adequately defined to date. Active LV relaxation is a major determinant of mitral annular De 
velocities, as supported by the inverse correlation between De and the time constant of LV 
relaxation, tau.23 Other factors that may play a role include LV preload, LV afterload, systolic 
function (with its secondary effects o f LV recoil and relaxation), cardiac chamber size, and heart 
rate. Additional studies are necessary to define the relative role o f these various parameters.
C ardiom yopathies
Systolic myocardial velocity (S), measured by single-gated pulsed TDI from the parasternal and 
apical approaches, correlates with the peak value of the first derivative of LV pressure decay (peak 
dP/dt, obtained from the LV pressure curve) and LV ejection fraction in patients with dilated 
cardiomyopathy,51 hypertrophic cardiomyopathy and hypertensive heart disease.52 In particular, the 
peak systolic myocardial velocity during the isovolumic contraction (S1) along the long-axis was a 
useful parameter for evaluating LV myocardial contractility.51
Both early and intermediate stages of diastolic dysfunction (delayed relaxation and 
pseudonormal phases, respectively) are characterized by a reduction in De velocity to < 8 cm/s, 
falling further still in the most severe, or restrictive, stage.43 Garcia et al. reported that a De velocity 
of 8 cm/s reliably separates restrictive cardiomyopathy (RCM, characterized by a low De value) 
from constrictive pericarditis (CP, normal/high De velocity if systolic function remains normal, 
indicating normal ventricular relaxation), despite similar transmitral flow velocities.26 TDI enabled
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the differentiation of patients with Chagas’disease with normal LV diastolic function from those 
with the pathologic pattern of pseudonormal diastolic function.53
Palka et al. used TDI for the discrimination of patients with RCM  from those with CP.54 
Doppler myocardial velocity gradient (MVG), as measured in the left ventricular posterior wall, 
was lower in patients with RCM  compared with both CP patients and normal controls during 
systole and early diastole. During atrial contraction, MVG was similarly low in both RCM  and CP 
patients compared with the controls.
Patients with LV hypertrophy have a reduced De compared with that of healthy controls, 
despite the lack of differences in conventional mitral Doppler indexes,55 as well as a delay in the 
onset of De relative to mitral valve opening.55,56 Similarly, patients with hypertrophic 
cardiomyopathy (HCM) also exhibit reduced myocardial De velocities.56,57 Nagueh et al. reported 
contraction and relaxation abnormalities, irrespective of cardiac hypertrophy, in a transgenic rabbit 
model of human HCM.58 The same author reported later that myocardial contraction and relaxation 
velocities, detected by TDI, are reduced in patients with familial HCM, including those where the 
LV hypertrophy is not yet present.59
The myocardial velocity gradient was also used to discriminate between patients with 
hypertrophic cardiomyopathy (HCM) and those with hypertensive LV hypertrophy (LVH).60 
Reduced myocardial velocity gradients in early diastole were reported in patients with hypertrophic 
cardiomyopathy.56 Dutka et al. also reported reduced myocardial velocity gradients in homozygous 
patients with Friedreich’s Ataxia with HCM  during systole and early diastole with the strongest 
relationship between the early diastolic parameter and reduction of frataxin protein.61
Ischem ic h e a r t disease
Patients with ischemic heart disease often have abnormal LV diastolic function. Color two­
dimensional and color M-mode TDI are used for quantification of systolic myocardial velocities in 
these patients, both at rest and with pharmacological stress testing. TDI enables measurement of 
regional systolic and diastolic myocardial velocities and, furthermore, is particularly useful in the 
identification of abnormalities of LV diastolic relaxation (see also above, LV systolic and diastolic 
function).
The presence of regional asynergy caused by myocardial ischemia or infarction can negatively 
influence systolic myocardial velocity (S).36,62-64 The increase in S velocity after angioplasty was 
thought to be the result o f hyperemia and increased catecholamine response. Recent work by 
Derumeaux and colleagues with pulsed Doppler and color TDI in ischemic animal models showed a 
recovery of S after reperfusion, yet the velocities did not return to baseline values.65,66 Myocardial 
velocity changes were more apparent in the subendocardial rather than in the epicardial layers, and 
a relation was found between myocardial blood flow velocities (measured by microspheres), and 
TDI myocardial velocities. Especially, color-TDI may be useful in determining intermittent or 
persistent abnormalities, as well as a subendocardial velocity response to reperfusion. TDI has been 
incorporated in diagnostic protocols to assess myocardial velocities during pharmacologic or 
postexercise stress echocardiography.67,68 A  lack of increase in S after exercise was reported to be a 
sensitive indicator o f ischemia in studies by Pasquet and colleagues.37,69 Recently, additional TDI 
parameters were reported to be useful in assessing regional systolic myocardial function. Wall 
motion velocity during pre-ejection (isovolumic contraction) in dogs, was proportional to the 
regional content of viable myocardium following reperfusion for acute myocardial infarction.70
A new load-independent systolic index, the myocardial acceleration during the isovolumic 
contraction period, has been recently suggested as a measurement o f the RV contractile function. in 
animals.71 This parameter might be equally well suited for the assessment o f acute changes of LV 
function in clinical sudies; further research should be performed.
Several studies have demonstrated that De is often reduced, De/Da ratio is < 1, and regional 
isovolumic relaxation times are prolonged in patients with LV segmental dysfunction due to
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ischemia.36,63,65,72,73 However, Da velocity remains unchanged, suggesting that (“post systolic”) 
early diastolic changes reflect an active, energy requiring relaxation process, whereas late diastolic 
filling merely reflects passive stretch after atrial contraction.72,74 Quantification of diastolic 
myocardial function by color68 and pulsed Doppler75 TDI during dobutamine stress test were shown 
to be a sensitive alternative to the generally used echocardiographic and scintigraphic imaging 
techniques for stress test.
Both systolic and diastolic transmyocardial velocity gradients assessed by M-mode TDI were
8,29,30,76consistently lower in the recently infarcted myocardial walls, with compensatory kinetics of
the opposite wall. Recognition of transmyocardial velocity gradients has led to the suggestion that 
persistence (of its normal range values) could represent viability in an otherwise hypo or akinetic 
segment.30,77 A  marked asynergy corresponding to the infarct regions, and especially at the mid- 
papillary muscle level, could be clearly identified in infarct patients.
Rhythm
Change of velocity (or acceleration) and patterns of velocity propogation along the heart walls can 
be easily observed using the 2-D TDI image sequences. The application in electrophysiology 
enables recognition of the site o f pre-excitation in the Wolff-Parkinson-White syndrome.78-80 It 
might be also useful for evaluating pacemaker rhythm,81,82 or detecting the origin of other rhyme 
abnormalities.
Early diastolic myocardial velocity (De) was an accurate measure of abnormal LV diastolic 
function, despite the presence of atrial fibrillation.83 The late diastolic myocardial velocity (Da) may 
not be evident during atrial fibrillation or tachycardia.
C ard iac  m asses
Bartel et al. emonstrated that using TDI patterns increases the detection of vegetations in infective 
endocarditis as well as of thrombus formations.84
RV function
Peak systolic pulsed TDI measurement of the tricuspid annular ring provides a simple , rapid and 
non-invasive tool for assessing right ventricular systolic function in patients with heart failure.85
Regional wall motion and abnormalities of electrical depolarization and repolarization are 
common in patients after surgical repair of Tetralogy of Fallot.86 All patients in this study showed 
decreased S and De velocities and prolonged isovolumic relaxation time. Reversed diastolic 
myocardial velocities in the RV free wall were sometimes associated with reversed systolic RV 
myocardial velocities and, in addition, reversed diastolic myocardial velocities in the septum. These 
patients had also electrocardiographic abnormalities.
TD I and  pediatric  cardiology
Very little is known about TDI application to children. Normal values in children were achieved 
with heterogeneous patterns in the different locations and age-and heart-rate related changes.87-89 A 
comparison of TDI velocities and velocities o f transmitral blood flow in children with elevated left 
ventricular preload due to left-to-right shunt demonstrated that the velocities obtained with TDI 
were less dependent on mean left atrial pressure.90
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Assessment o f myocardial velocities in fetuses is also feasible with TDI.91-92 Age-related 
alterations in tissue Doppler velocities (De and De/Da ratio increase with increasing gestational 
age) suggest maturational changes in diastolic function during this period of prenatal life. Others 
could studied the origin of fetal tachycardia by using the TDI technique.93
DISADVANTAGES O F TH E TD I T EC H N IQ U E
As a Doppler based technique, angle dependency of o f TDI wall velocity measurement remains a 
crucial issue. The technique as applied at present cannot reliably quantify, for example, the velocity 
of contraction of the lateral wall in the parasternal short-axis view. Contractions of mid septum and 
of posterior wall, which occur parallel to the scan line, can be accurately assessed in this view. 
Inability to correct for translational motion of the heart within the chest is also a disadvantage of the 
modality. However, when measured from the cardiac apex, the impact o f translational motion of the 
heart within the thorax becomes much less important.32 The influence of adjacent myocardial 
segments on velocities measured in the segment of interest is also to be noted. This effect is 
minimized when measurement o f velocity is relative to other myocardial regions (e.g., by using 
transmyocardial velocity differences and gradients), or to different points within the same region 
(achieved by the introduction of myocardial strain rate imaging, see next paragraph), rather than 
relative to the ultrasound transducer,.
N EW  A PPLIC A TIO N S- M Y O CA RD IAL STR A IN  AND STR A IN  R A TE IM A G IN G
Strain rate (SR) is a measure of the velocity of deformation of myocardium, and is given by the 
formula SR = (v2- v1) /  distance, where v2 and v1 are velocities o f myocardium at two points 
separated by distance; this gives the difference in tissue velocity per unit length,94 and it is often 
described as the rate o f  deformation. Integration of this parameter with respect to time gives the 
myocardial strain, a measure of the relative shortening and lengthening of the myocardium, during 
systole and diastole (relative deformation). The datasets are not influenced by the function of 
adjacent myocardial segments, nor of the global heart movements, and are less dependent upon the 
direction of shortening and lengthening relative to the scan line. These methods allow identification 
of akinetic segments, where strain rate and strain will be zero, and may allow identification of 
inducible ischemia and viable myocardium.95-97 Recently, TDI-derived myocardial systolic strain 
rate was reported as a strong non-invasive index of LV contractility.97-99
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ABSTRACT
The objective was to determine the normal range of tissue velocities in paediatric hearts as 
measured by tissue Doppler imaging. A prospective study was carried out involving 160 healthy 
children (mean age 10.8 y, range 4.0 - 17.9 y). Using tissue Doppler imaging (TDI) from 
parasternal long-axis and apical views, peak velocities and peak myocardial velocity differences 
across the right ventricular anterior wall, interventricular septum and left ventricular posterior wall 
were assessed during systole, early and late diastole. The existence of transmyocardial velocity 
differences between the left and right side of the interventricular septum, as well as between the 
endocardium and epicardium of the left ventricular posterior wall was observed throughout the 
heart cycle. With range-gated TDI from apical four-chamber view, peak velocities were measured 
within the basal, mid and apical parts of the interventricular septum, and the left and right free 
ventricular walls. The highest peak systolic, early and late diastolic velocities were measured within 
the basal parts of all myocardial walls. The ranges of the calculated velocity ratios (early-to-late 
diastolic velocity and early diastolic-to-systolic velocity) for the various wall parts appeared to be 
overlapping. The correlations of peak myocardial tissue velocities and their ratios with age and 
weight were weak and practically irrelevant. These normal values of peak myocardial velocities, 
transmyocardial velocity differences and the ratios of peak wall velocities can be used as reference 
values in future investigations of ventricular dysfunction in this age group.
Key words: Tissue Doppler imaging, Paediatrics, Myocardial velocity, Ultrasound 
INTRODUCTION
Tissue Doppler imaging (TDI) is a recent echographic technique that enables quantitative 
assessment of myocardial tissue velocities. This technique is being mainly applied to adults.
In paediatric cardiology, the noninvasive assessment of regional and global left ventricular 
function is based on conventional echocardiography, namely B-mode (i.e., M-mode and 2-D 
ultrasound [US] images) and the Doppler blood flow velocity measurement method. The recently 
developed TDI technique has an important advantage over B-mode imaging for quantitative 
analysis of the movement of the myocardium. TDI uses the amplitude of the echographic signal 
returning from the interrogated myocardial tissue, which is much stronger than the echoes 
backscattered by blood. For this reason, the TDI signals are not so much deteriorated by the 
attenuating effect of the chest wall and, thus, are relatively less disturbed by noise. In addition to the 
2-D imaging, TDI M-mode enables a quantitative analysis of local myocardial velocities as a 
function of time. The quantitative analysis, however, is limited since the velocities have not been 
corrected for the angle that the muscle is moving with respect to the US beam. Consequently, some 
of the differences in velocity may be due to a variation in positioning of certain walls within the 
heart with respect to the transducer.
The normal features of TDI of the adult heart, that are important to some of the pathological 
conditions described later, have already been described by others.1-7 Changes in the magnitude and 
direction of regional myocardial tissue velocities were accurately characterised by these authors. 
Special attention was paid to the transmural velocity gradient of the left ventricular wall.6,8 
Applications of TDI echocardiography were evaluated in various clinical settings, mainly in adults 
with ischemic heart diseases7,9 or cardiomyopathies.4,7,10 TDI 2-D and M-mode images were used to 
detect local myocardial abnormalities by visual inspection of the colour coding. In addition, TDI M- 
mode images were employed to quantify the velocity of wall movement throughout the heart cycle. 
Furthermore, transmyocardial velocity differences across the interventricular septum (IVS) or left
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ventricular posterior wall (LVPW) were measured, and it has been suggested that the gradient itself 
might be an important predictor of myocardial contractility deficiency.1,11
In the paediatric population, TDI is already being used to localize the origin of premature beats 
in patients with various forms of arrhythmia.12 The determination of normal pattern and magnitude 
of myocardial velocities in children is obligatory to assess whether these are altered in pathological 
conditions. Analysis of regional ventricular function is of particular importance in the early 
detection of local abnormalities, (i.e., before any change is apparent in global function 
measurements). The aim of our study was to generate normal values of peak myocardial velocities 
in children, both during systole and diastole. These referential values will be used in studies 
concerning the early detection of abnormal myocardial function.
MATERIALS AND METHODS 
Study population
A total of 165 healthy volunteers without history of cardiac disease or serious medical illness were 
recruited for this study (from different preliminary schools in Nijmegen). An informed consent was 
given by the parents. Only 5 children were excluded from the study: 1 child for a previously 
unknown mitral valve abnormality, another 2 for irregular heart rhythm, the fourth 1 for 
asymmetrical septum hypertrophy and the last 1 for mild aortic valve stenosis. Before the TDI 
measurements were performed, the remaining 160 children underwent a detailed standard 
echocardiographic examination and showed no evidence of cardiac disease. The study population 
consisted of 77 boys and 83 girls. The mean age was 10.8 y (range 4.0 - 17.9 y), with a mean weight 
of 39.3 kilograms (range 17.5 - 83.5 kg). Electrocardiographic recordings were made 
simultaneously with the US images. The children did not receive sedation, and all showed to have 
normal sinus rhythm and regular breathing pattern at the time of study. To reduce the influence of 
respiration on myocardial velocities (and for the fact that breath hold is not feasible in young 
children), three cardiac cycles were recorded and the cycle with the highest velocity was selected 
for further analysis.
Standard echocardiographic study
The study was carried out with the “Powervision” echographic scanner (model SSA-380A software 
version 2.5 0ER000, Toshiba, Nasu, Japan), at the Children’s Heart Center of the University 
Hospital of Nijmegen, The Netherlands. Images were acquired with a 5-MHz phased-array 
transducer (facilities for pulsed-wave, continuous-wave, colour and tissue Doppler). 
Echocardiographic examinations were performed by the same, experienced paediatric cardiologist 
who was assisted by a sonographer. The images were evaluated online. The standard examination 
consisted of M-mode, 2-D and pulsed-wave Doppler blood flow velocity measurements over the 
heart valves. M-mode measurements were taken at the level of the tips of the mitral valve leaflets in 
the parasternal long-axis view of the left ventricle. Standard parameters measured in systole and 
diastole were: left ventricular dimensions, right ventricular anterior wall (RVAW), IVS and LVPW 
thickness. Left ventricular fractional shortening (FS) was calculated from the left ventricular 
dimensions. Doppler blood flow velocities were measured for each valve separately: for the mitral 
and tricuspid valves using apical four-chamber view; for the aortic valve using suprasternal long- 
axis view, and for the pulmonary valve using parasternal short-axis view. The following Doppler 
indices were measured: peak E wave velocity and peak A wave velocity of the mitral and tricuspid 
valves, as well as maximal systolic velocity of the aortic and pulmonary valves. Accordingly, the 
E/A ratio was calculated from the measured peak velocities over the mitral and tricuspid valves.
The mean heart rate was obtained from 3 to 5 successive cardiac cycles.
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Tissue Doppler Imaging
The same Toshiba scanner was switched to TDI mode, thereby resulting in: 1. lowering of the 
velocity range (0 to 20.5 cm/s) to encode myocardial velocities; 2. changing of the image 
magnification to display optimally the region occupied by the moving cardiac wall under study; and
3. setting of the Doppler receive gain to achieve maximum colour Doppler information in the 
myocardium while suppressing the colour appearing in the blood pool. The TDI software provided 
with the scanner was capable of displaying colour-coded velocities of the myocardium as numerical 
data.
Using M-mode TDI from parasternal long-axis view, we measured peak myocardial velocities of 
the ventricles during systole, early and late diastole (after atrial contraction) (S, De and Da, 
respectively). The peak myocardial velocities were obtained at standardized sites: the RVAW, the 
right ventricular side of the IVS (IVSR), the left ventricular side of the IVS (IVSL), and both the 
endocard and epicard sides of the LVPW (LVPWendo and LVPWepi, respectively) at the level of 
the mitral valve leaflets. Peak velocity was defined as the mean value measured within a 3*3 pixel 
size marker, at each of the three phases of the cardiac cycle. This parameter of peak myocardial 
velocity was chosen because TDI M-mode velocity measurements that are lower than 0.2 cm/s 
show a marked increase in standard deviation due to poor estimation of low myocardial velocities.13 
The peak wall velocity was expressed as positive when movement was towards the transducer and 
negative for movement away from it. Transmyocardial velocity difference was defined as the 
difference in peak velocities between the left and right ventricular side of the IVS (IVSL-IVSR), as 
well as between the endocardium and epicardium of the LVPW (LVPWendo-LVPWepi). These 
transmyocardial velocity differences across the IVS and LVPW were calculated for each cardiac 
phase separately. Tissue Doppler imaging was also obtained from apical four-chamber view (4- 
CV). After visualisation of a colour-coded signal, single-gated TDI was performed (with 5-MHz 
transducer frequency and a sample gate size of 2 or 3 mm) and a velocity-time display was 
registered.14 Care was taken to aim the US beam along the IVS and both right and left free 
ventricular walls (RVW and LVW, respectively) to minimize the angle of incidence between the 
US beam and the longitudinal direction of the wall motion. We assessed longitudinal peak 
velocities during systole, early and late diastole, within the basal, mid and apical parts of the right 
ventricular free wall (RVW), interventricular septum and left ventricular free wall (LVW) (Fig. 1). 
These velocities were expressed as positive or negative when moving towards the contraction center 
of the left ventricle (and, thus, towards the transducer) or away from it, respectively.2
Ratios of peak wall velocities in early vs. late diastole (De/Da ratio), and early diastole vs. 
systole (De/S ratio) were calculated for all acquired TDI measurements.
Statistics
The results of all measurements for the study population were expressed as median and 5th -95th 
percentiles. Differences in tissue velocities obtained from different positions were compared using 
the Wilcoxon signed rank test. The relation of the myocardial velocities to other quantitative 
parameters was assessed with Pearson correlation analysis. A p  value of 0.05 or less was considered 
statistically significant. In case of multiple comparisons, the Bonferroni correction was used.
Intraobserver variability was assessed by analysis of three sets of consecutive velocity 
measurements in 5 different, randomly chosen subjects. After logarithmic transformation of the 
data, the pooled standard deviation was considered to measure the relative intraobserver variability.
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Fig. 1. Scheme of apical four chamber view. Analysis of 
myocardial velocities was done within the basal, mid and 
apical parts of the three walls. RVW -  right ventricular free 
wall; IVS = interventricular septum; LVW = left ventricular 
free wall.
RESULTS
Table 1 shows the data obtained from standard echocardiographic examinations of our study group. 
These data were correlated with the TDI parameters as described later in this section. The median 
heart rate was 77 beats per minute (range 55 - 106 bpm).
TDI velocities could be easily obtained from all healthy volunteers (n=160), except for the late 
diastolic velocities in the apical left ventricular free wall (n=140). Representative examples of B­
and M-mode TDI of a subject are shown in Figs. 2a and b, respectively. During systole, the peak 
wall velocities of the RVAW and both sides of IVS are expressed as negative (direction of tissue 
movement away from the transducer). At the same heart phase, the peak wall velocities of the 
LVPWendo and LVPWepi are expressed as positive since the LVPW is moving towards the cavity 
of the LV, thus moving towards the transducer. During early and late diastole, the peak wall 
velocities of the RVAW and IVS are expressed as positive; those of the LVPW as negative. 
Consequently, during systole, the velocity difference is negative when the left side of the IVS is 
moving faster than the right side of the IVS (since both IVS velocities are expressed as negative), 
and is positive when the endocardium of the LVPW is moving faster than the epicardium.
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Fig. 2. (a) 2-D TDI image drom the parasternal long-axis view during systole. (b) M-mode
TDI tracing presenting peak velocity difference measurements within the LVPW
during systole. The change of direction of all wall movements during one cardiac cycle can ben noted.
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Table 1. Data of standard echocardiographic study (n = 160)
Median (5th-95th percentiles)
IVS thickness (mm)* 5.4 (3.7 -  7.2)
LVPW thickness (mm)* 5.4 (4.0 -  7.0)
LVDD (mm)* 42.5 (35.6 -  53.4)
LVSD (mm)* 27.4 (22.1 -  34.7)
FS (%) 36.0 (28.5 -  45.0)
RVAW thickness (mm)* 2.0 (1.4 -  2.9)
RVAW thickness (mm)* 4.2 (2.8 -  6.1)
MV max. E wave velocity (cm/s) 85.2 (57.9 -  114.5)
max. A wave velocity (cm/s) 40.5 (20.8 -  61.8)
E/A ratio 2.2 (1.4 -  4.0)
TV max. E wave velocity (cm/s) 59.5 (41.5 -  85.4)
max. A wave velocity (cm/s) 31.0 (16.1 -  55.0)
E/A ratio 1.9 (1.1 -  3.3)
Ao max. systolic velocity (cm/s) 107.0 (73.0 -  141.0)
Pulm m 84.4 (63. 8 -  107.5)
* in diastole; * in systole. IVS = interventricular septum; LVPW = left ventricle 
posterior wall; LVDD = LV diastolic diameter; LVSD = LV systolic diameter; FS 
= LV fractional shortening; RVAW = right ventricle anterior wall; MV = mitral 
valve; TV = tricuspid valve; Ao = aorta; Pulm = pulmonary valve.
Table 2 shows median values (and 5th-95th percentiles) of the peak myocardial velocities 
and their calculated De/Da and De/S ratios, obtained from parasternal long-axis view. The 
results show a wide range of normal peak wall velocities. The early diastolic myocardial velocities 
are the highest. The various cardiac phases have distinctly different peak myocardial velocities and 
different directions of wall motion.
Table 2. Median (and their 5th-95th percentiles) of peak myocardial velocities (cm/s) obtained from long-axis view (n 
= 160).
Velocity (S) Diastolic Velocity (De)
Diastolic 
Velocity (Da) Ratio Ratio
RVAW -2.3 (-0.7 - -4.2) 3.2 (1.2 -  6.0) 1.0 (0.2 - 2.4) 3.0 (1.1 -  10.8) -1.4 (-0.6 - -3.0)
IVSR -2.1 (-0.9 - -3.5) 3.6 (1.5 -  6.4) 1.5 (0.6 - 2.9) 2.5 (0.7 -  7.9) -1.6 (-0.8 - -5.9)
IVSL -3.2 (-2.1 - -4.5) 4.9 (3.0 -  8.4) 1.9 (0.8 - 3.5) 2.6 (1.1 -  7.4) -1.5 (-0.8 - -3.2)
LVPWendo 3.9 (2.4 - 5.8) -9.8 (-5.3 -  -15.0) -1.2 (-0.4 - -3.2) 8.3 (2.3 -  27.0) -2.4 (-1.6 - -3.7)
LVPWepi 2.2 (11 - 3.5) -3.7 (-1.8 -  -6.7) -0.7 (-0.2 - -2.4) 5.6 (1.0 -  19.0) -1.8 (-0.8 - -3.6)
De/Da and De/S ratios were calculated
Table 3 reveals median values (and 5th-95th percentiles) of the transmyocardial velocity 
differences both in the IVS and LVPW. The peak velocities assessed from left side of the IVS were 
always higher than those from the right side of the IVS. Similarly, the peak velocities obtained from 
the endocardium were always higher than those from the epicardium of the LVPW. These 
differences in peak velocities were present in systole, early and late diastole. Both in systole and 
early diastole, the transmyocardial velocity differences were statistically higher within the LVPW 
than within the IVS (Wilcoxon signed rank tests, p  < 0.017).
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Table 3. Median (and 5th -  95th percentiles) of the differences in peak velocities (cm/s) across 
the IVS and LVPW obtained from long-axis view (n = 160)
S De Da
IVS (L-R) -1.1 (-0.3 -  -2.0) 1.3 (0.2 -  3.2) 0.4 (0.0 -  1.1)
LVPW (endo-epi) 1.7 (0.5 -  3.0) -5.6 (-2.3 -  -10.5) -0.4 (-0.1 -  -1.4)
Wilcoxon Signed Rank test p  < 0.001 p  < 0.001 p  = 0.027
A representative example of TDI of the paediatric heart is shown in Fig. 3. Using single-gated 
TDI from apical 4-CV, the maximal myocardial velocities and their directions were measured as 
described in the Methods section. Examples of velocity traces are shown in Fig. 4. The myocardial 
velocity pattern within each part of the wall showed three major distinctive waves: a positive wave 
toward the apex (and, hence, also towards the transducer) during systole and two negative waves 
away from the transducer during diastole. The first diastolic wave occurs during early filling, and 
the second corresponds to atrial contraction. As can be seen in Fig. 4, the cardiac walls display 
different systolic and diastolic velocity patterns. Table 4 shows the median (and 5th-95th 
percentiles) of the peak myocardial velocities obtained from all 160 volunteers. The De/Da and 
De/S ratios were calculated as well. Using signed rank tests, it appears that the De/Da ratios of the 
basal, mid and apical parts of each wall show small, but statistically significant differences. 
However, the ranges of the De/Da ratios are nearly identical within each wall. The same applies for 
the De/S ratios except for the left ventricle free wall.
Fig. 3. Tissue Doppler imaging of apical four-chamber view during systole.
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Fig. 4. Pulsed-wave TDI velocity curves within the basal parts of the RVW (a) 
and IVS (b) during the heart cycle, using the apical four-chamber view.
Table 4. Median (and 5th -  95th percentiles) of peak myocardial velocities (cm/s) obtained from apical four-chamber 
view (n = 160)
S De Da De/Da Ratio De/S Ratio
RVW basal 12.8 (10.7 - 16.5) -16.2 (-12.6 -■ -21.1) -8.6 (-5.5 - -12.1) 1.8a (1.3 3.0) -1.3a (-1.0 - -1.6)
mid 10.9 (8.6 - 13.7) -13.9 (-9.4 - -17.7) -7.1 (-4.7 - -10.0) 1.9a- b (1.3 - 3.0) -1.2a (-0.9 - -1.6)
apical 8.0 (5.7 - 10.8) -10.8 (-7.0 - -14.3) -5.3 (-3.6 -  -7.8) 2.0b (1.2 3.2) -1.4b (-0.9 - -1.9)
IVS basal 8.1 (6.5 -  9.8) -14.3 (-11.2 - -18.5) -5.8 (-4.4 -  -7.9) 2.5a (1.7 3.6) -1.8a (-1.5 - -2.2)
mid 6.1 (4.7 -  7.5) -13.0 (-9.2 - -16.2) -4.9 (-3.5 -  -6.5) 2.7b (1.8 3.8) -2.1b (-1.4 - -2.8)
apical 4.6 (3.1 -  6.4) - 9.0 (-5.9 - -12.7) -3.7 (-2.4 -  -5.0) 2.5a (1.6 3.8) -2.0b (-1.3 - -3.0)
LVW basal 9.7 (6.3 - 13.5) -17.6 (-13.0 - -23.0) -5.5 (-3.8 -  -8.0) 3.3a (2.1 4.7) -1.8a (-1.3 - -2.6)
mid 9.5 (6.2 - 13.3) -15.9 (-10.0 -■ -21.0) -4.6 (-3.2 -  -7.1) 3.3a (2.1 5.0) -1.6b (-1.1 - -2.3)
apical 8.7 (5.0 - 12.4) -10.7 (-6.5 - -15.3) -3.9* (-19 -  -5.8) 2.8*b (1.7 - 4.5) -1.2c (-0.8 - -1.8)
De/Da and De/S ratios were calculated. ^number of subjects = 140. Different letters indicate significant differences 
between positions. For each wall and each ratio, the overall significance level is 5%.
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It appears that the highest peak systolic velocities were obtained within the basal parts of all 
myocardial walls (Table 5), whereas, in the left ventricular free wall from both basal and mid 
positions, maximal peak systolic velocities were obtained. Accordingly, the highest peak early 
diastolic velocities were again obtained within the basal parts of all myocardial walls but, in some 
children, could also be obtained from the mid part of the IVS. In late diastole, the highest peak 
velocities were registered within the basal wall parts.
The assessed myocardial velocities and their De/Da and De/S ratios, from both long-axis and 4- 
CV, were not significantly correlated with gender, length or body surface area, nor with heart rate, 
wall thickness, LV shortening fraction or blood flow velocities over corresponding heart valves. 
Although some myocardial velocities and their ratios were significantly correlated with age or 
weight, the correlation was weak (R2 < 20%). Therefore, reference values were given independently 
from age and weight.
The intraobserver variability for the tissue velocity measurements obtained from the apical 4- 
CV was rather low (4-10%). The measurements obtained from the long- axis view showed a 
relatively higher variability (20-30%), especially the late diastolic measurements (40%).
Table 5. Relative frequency (%) of appearance of the highest peak 
myocardial velocities (cm/s) in 160 subjects (using the apical four- 
chamber view).
S De Da
RVW basal 92 84 83
mid 8 15 16
Apical 0 1 1
IVS basal 98 70 93
mid 2 30 7
Apical 0 0 0
LVW basal 53 79 85
mid 32 21 13
Apical 15 0 2
Frequencies are presented for each wall separately
DISCUSSION
Tissue Doppler imaging is an accurate US method that can provide quantitative information about 
the myocardial wall velocities and their directions (i.e., the component of the velocity along the axis 
of the transducer). The available spatial resolution of TDI-mode allows velocities to be determined 
at different levels within the myocardium. Our study proves that quantitative assessment of 
myocardial tissue velocities in healthy children is feasible with TDI, both using M-mode and the 
single-gated Doppler technique. Using the TDI M-mode technique from the parasternal long-axis 
view, the maximum myocardial velocities measured in the same relevant cardiac phases from the 
IVS and the LVPW differ significantly in children as it does in adults.3,5,15 The low values might 
explain the relatively high intraobserver variability found in our study. Using the single-gated tissue 
Doppler technique from the apical 4-CV, regional myocardial velocities were quantified, showing a 
marked heterogeneity of myocardial velocities, as was earlier found in the normal heart of the 
adult.1,3,5 Moreover, our results demonstrate that, in certain cardiac phases, the different myocardial 
wall parts have distinctly different patterns and magnitudes of wall velocity, all of which can be 
easily seen on 4-CV view using the single-gated TDI technique (see Fig. 4). None of the assessed 
myocardial velocities (nor any of their calculated ratios) had a practically relevant correlation with
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age, gender, weight, length or body surface area, nor with heart rate or any of the conventional echo 
Doppler parameters. Therefore, we suggest that TDI parameters could provide additional 
information about the regional function of the healthy myocardium.
Recently, Rychik and Tian16 have published data on myocardial tissue velocities in a group of 
30 healthy children in a wide age range (6 months to 16 y). Their study compared the velocity 
patterns of short-axis (posterior wall) and long-axis (mitral annulus) left ventricular tissue motion 
with mitral blood inflow. The highest velocities of ventricular motion occurred at early diastole, as 
was previously described in adults. This finding was confirmed in our study in all TDI 
measurements taken from the apical 4-CV. Rychik and Tian also recorded that the pattern of mitral 
annular motion in diastole was found to mimic that of mitral blood inflow, whereas, the pattern of 
posterior wall motion differed, suggesting these latter velocities provide a new form of assessment 
of diastolic function. Our results were achieved from a larger population with a smaller age range, 
but also from different cardiac views than the former group; therefore, no comparison of peak 
myocardial velocities is possible. We did not find significant correlations between the assessed 
myocardial velocities and the blood-flow velocities over the heart valves, neither in systole, nor in 
early or late diastole. Garcia et al.3 found, in adults, a poor correlation of the peak De with flow 
velocities over the valves, suggesting that peak early velocity of longitudinal axis expansion may be 
relatively preload-independent. However, their measurement of longitudinal axis expansion 
velocities provided a clinically useful distinction between constrictive pericarditis and restrictive 
cardiomyopathy, and may prove to be valuable in the study of diastolic function.10 In adults with 
dilated cardiomyopathy, transmyocardial velocity difference (between the endocardium and 
epicardium of the LVPW), or gradient, were significantly lower than that in healthy subjects.4,7 
Therefore, the velocity difference or gradient may have potential for the detection of regional left 
ventricular contraction abnormalities in patients. Patients with ischemic heart disease were shown to 
have reduced transmural LV wall gradient due to regional myocardial dysfunction.7
Our results confirm the existence of a velocity difference across LVPW (obtained from long- 
axis view of the left ventricle) in healthy children. These velocity differences, in contrast to adults 
(in diastole),8 displayed low correlation with age (R2 < 20%), at least with our age group. In 
addition, a velocity difference across the IVS was found in all volunteers. This latter finding was 
not described earlier, either in adults or in children.
Furthermore, during both systole and early diastole, the transmyocardial velocity differences in 
the LVPW were higher than those in the IVS. In late diastole, there was no significant difference 
found between the transmyocardial velocity differences of the two walls. The clinical relevance of 
these difference measurements for the detection of regional abnormalities and their follow-up is a 
topic of further study by the authors.
In adults, myocardial velocities obtained from apical view are higher at the base of the heart 
than in the midventricular region.2 This characteristic pattern of contraction was also present in our 
study group, yet the velocities obtained within the mid part of the IVS (in early diastole) and LV 
free wall (in systole) were not always lower than those measured within the corresponding basal 
parts. Furthermore, in adults, the apex is moving in an opposite direction with respect to the 
movement of the basal and mid parts of the myocardial walls. Because our measurements were 
obtained from the apical parts of the walls, but not directly from the apex, they should not be 
compared with the results of Erbel et al.2. As can be seen in Table 4, the velocities obtained from 
the apical parts of the walls, were higher, and in an opposite direction, than expected from Erbel’s 
results. Further studies of the location of the center of contraction and the forward and inward 
motion of the myocardial walls in children, as well as the movement of the total heart, are therefore 
indicated.
The normal range of peak velocity ratios for left ventricular segments in healthy young adults 
has been determined before.2 We calculated these ratios for different segments of the heart as well 
as from different views. In healthy children, using the apical 4 CV, identical ranges of the De/Da
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ratios were obtained within each wall. Therefore, for practical applications, the ranges of the ratios 
can be used as references; thus, independent of the location of measurement within the specific 
wall. These normal values are not dependent on the imaging plane, nor on age and body weight.
The establishment of tissue Doppler imaging values in healthy children opens new perspectives 
in the assessment of quantitative systolic and diastolic myocardial function. This new technology 
can be utilized for the assessment and follow-up of patients with congenital (e.g., single ventricle 
and Fontan circulation) and acquired heart diseases (e.g., cardiomyopaties).
Limitations
The normative data as obtained in the present study are restricted to a certain age range, namely 4 - 
18 y. Similar data should still be derived from a younger paediatric age group, particularly infants. 
Furthermore, the timing of peak velocities, relative to the electrocardiogram, has to be studied.
CONCLUSIONS
The determination of normal pattern and magnitude of myocardial velocities using the noninvasive 
TDI in healthy children provides a new perspective in paediatric cardiology. The diagnosis of 
paediatric heart diseases that are accompanied with abnormal wall contractility or motion can 
potentially benefit from the quantitative assessment of peak velocities and velocity differences or 
gradients across and along the IVS and ventricular walls.
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CHAPTER 5
Tissue Doppler imaging in detection of myocardial dysfunction in 
survivors of childhood cancer treated with anthracyclines
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ABSTRACT
The applicability of tissue Doppler imaging (TDI) was investigated for estimating cardiac function 
in long-term survivors of childhood cancer treated with anthracyclines. A total of 62 children (age 
range 7.8-17.3 y) underwent standard echo Doppler cardiographic studies of blood flow velocities, 
left ventricular dimensions and fractional shortening, followed by measurements of peak 
myocardial velocities and direction using the noninvasive tissue Doppler imaging (TDI) technique. 
All 63 were late survivors (median 7.1 y, range 3.5-13.5 y after end of therapy) who had received 
mean (± SD) cumulative dose of 242 (±141) mg/m2 of anthracyclines. The control group consisted 
of 160 healthy subjects (age range 4 to 17.9 y). Standard echo-Doppler anatomical parameters that 
were found significantly (p < 0.01) different for the study group are: RV wall thickness (decreased); 
LV diameter (increased); and LV fractional shortening (decreased). Studied hemodynamic 
parameters were not found to be different between the two groups. Quantitative TDI parameters: 
peak late diastolic myocardial velocities, as well as transmyocardial systolic and diastolic velocity 
differences, were significantly lower in late survivors than in the healthy pediatric population (p < 
0.01). Qualitative local functional impairment of the movement of the left ventricular walls was 
detected in 20% of the patients. TDI might become a useful noninvasive method for detecting 
subclinical myocardial damage in apparently healthy children who received moderate doses of 
anthracyclines for treatment of childhood malignancy. Prospective studies with TDI for the 
detection of regional myocardial abnormalities are recommended.
Key words: Anthracycline; Cardiotoxicity; Echocardiology; Tissue Doppler imaging, Ultrasound 
INTRODUCTION
Anthracyclines are potent drugs in the treatment of cancer. Many of the long-term survivors of 
childhood malignancy have been treated with this kind of drug, both for leukemia and pediatric 
solid tumors.1 Congestive heart failure, high-grade arrhythmias, cardiac conduction abnormalities 
and sudden deaths are clinically significant anthracycline cardiotoxicity effects that can occur even 
many years after completion of therapy. Three distinct types of anthracycline-induced cardiotoxicity 
have been described. Acute or subacute injury can occur immediately after treatment. Chronic 
cardiotoxicity can present within 1 y after treatment with anthracyclines has ended, and is now 
considered as a form of early cardiotoxicity. Late anthracycline-induced cardiotoxicity is defined as 
cardiac abnormalities manifested more than 1 y after chemotherapy has ended. Although most late 
cardiotoxicity is subclinical, it does not mean that it is harmless. The late abnormalities appear to be 
progressive and reflect future clinical heart failure.2,3
Late sub clinical abnormalities of left ventricular structure and function in long-term survivors 
of childhood cancer treated with anthracyclines are very common.4-6 The incidence of 
cardiotoxicity, as diagnosed by endomyocardial biopsy, is approximately 85%.7,8 Because serial 
myocardial biopsies and stress testing are not practical in younger children, and radionuclide 
angiography is rather costly and not appropriate for frequent evaluation, noninvasive tests such as 
echocardiography and electrocardiography (ECG) still play the main role for serial cardiac 
monitoring in these age groups. Because standard noninvasive tests have not proven to be of 
consistent value, a new noninvasive technique would be of benefit if it demonstrated a cardiac 
abnormality when other standard noninvasive evaluation was still normal.9
Tissue Doppler imaging (TDI) is a noninvasive echocardiographic technique that enables 
quantitative assessment of myocardial tissue velocities. Untill now, this technique has mainly been 
applied to adults. Applications of TDI echocardiography were evaluated in various clinical settings, 
mainly in adults with ischemic heart diseases10-12 or cardiomyopathies.11-14 TDI two-dimensional (2-
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D) and TDI M-mode images were used to detect local myocardial abnormalities by visual 
inspection of the color coding. In addition, TDI M-mode images were employed to quantify the 
velocity of wall movement throughout the heart cycle. Furthermore, transmyocardial velocity 
differences across the interventricular septum (IVS) or left ventricular posterior wall (LVPW) were 
measured, and it has been suggested that the velocity gradient itself might be an important predictor 
of myocardial contractility deficiency.15,16 In the pediatric population, TDI is already being used to 
localize the origin of premature beats in patients with various forms of arrhythmia.17
The determination of normal pattern and magnitude of myocardial velocities in children has 
recently taken place.18 Using TDI from parasternal long-axis and apical views, peak velocities and 
peak myocardial velocity differences across the right ventricular anterior wall (RVAW), IVS and 
LVPW were assessed during systole, early and late diastole. The existence of transmyocardial 
velocity differences between the left and right side of the IVS, as well as between the endocardium 
and epicardium of the LVPW was observed throughout the heart cycle. With range-gated TDI from 
apical four-chamber view, peak velocities vs. time traces were measured within the basal, mid and 
apical parts of the interventricular septum, and the left and right free ventricular walls. The highest 
peak systolic, early and late diastolic velocities were measured within the basal parts of all 
myocardial walls. The ranges of the calculated velocity ratios (early-to-late diastolic velocity and 
early diastolic-to-systolic velocity) for the various wall parts appeared to be statistically 
overlapping. The correlations of peak myocardial tissue velocities and their ratios with age and 
weight were weak and practically irrelevant.
Analysis of regional ventricular function is of particular importance in the early detection of 
local abnormalities (i.e., before any change is apparent in global function measurements). The 
purpose of this investigation was to determine whether tissue Doppler imaging is useful for 
detecting functional myocardial impairment in survivors of childhood malignancy treated with 
anthracyclines.
PATIENTS AND METHODS 
Study population
All survivors of childhood malignancy (in remission), in the age range of 5-18 y, who were treated 
with anthracyclines more than 5 y before the present study took place, were recruited from our 
outpatient clinics and asked to participate in this study.
A total of 63 survivors (33 boys and 30 girls) and their parents gave an informed consent. 
Patient information was obtained by medical record review. The median age of our 63 patients was
13.5 y (range 7.8-17.3 y). The median age at start of chemotherapy was 4.4 y (range 0.9 - 11.2 y), 
with a median follow-up period of 7.1 y (range 3.5-13.5 y) after anthracycline therapy had been 
completed. We considered the sum of the cumulative doxorubicin and daunorubicin doses as the 
cumulative anthracycline dose; the median cumulative dose given to the patients was 241 mg/m2 
(range 50 to 950 mg/m2). All patients received anthracyclines as part of combination chemotherapy; 
other chemotherapeutic agents used included vincristine, methotrexate, bleomycine, etoposide, 
cyclophosphamide and cisplatin. No patients underwent mediastinal or spinal irradiation. No 
patients had symptomatic cardiovascular disease, ischemic heart disease, or cardiomyopathy before 
receiving anthracycline. One patient had echocardiographic evidence of mild subvalvular aortic 
stenosis before therapy, which remained stable y after. None of the patients had suffered from 
rhythm disturbances or from symptomatic congestive heart failure after therapy. The physical 
examination revealed normal findings in all patients, except for a systolic heart murmur in two 
patients, considered being innocent. This protocol had institutional review board approval.
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Methods
The same experienced pediatric cardiologist, who was assisted by a sonographer, performed all 
echocardiographic examinations. Before the TDI measurements were performed, the children 
underwent a detailed standard echocardiographic examination. Electrocardiographic recordings 
were made simultaneously with the ultrasound (US) images. The children did not receive sedation, 
and all were showed to have normal sinus rhythm and regular breathing pattern at the time of study. 
To reduce the influence of respiration on myocardial velocities (and for the fact that breath hold is 
not feasible in young children), three cardiac cycles were recorded and the cycle with the highest 
velocity was selected for further analysis.
Standard echocardiographic study
The study was carried out with the “Powervision” echographic scanner (model SSA-380A software 
version 2.5 0ER000, Toshiba, Nasu, Japan), at the Children’s Heart Center of the University 
Hospital of Nijmegen, The Netherlands. Images were acquired with a 5-MHz phased-array 
transducer (facilities for pulsed-wave, continuous-wave, color and tissue Doppler). The images 
were evaluated online. M-mode measurements were taken at the level of the tips of the mitral valve 
leaflets in the parasternal long-axis view of the left ventricle. Standard parameters measured in 
systole and diastole were: left ventricular dimensions, right ventricular anterior wall (RVAW), 
interventricular septum (IVS) and left ventricular posterior wall (LVPW) thickness. Left ventricular 
fractional shortening (FS) was calculated from the left ventricular dimensions; a value of > 28% is 
considered normal in our clinic. Using the apical four-chamber view, peak early (E wave) and late 
(A wave, after atrial contraction) diastolic Doppler blood flow velocities of the mitral valve were 
measured. Accordingly, the E:A ratio was calculated from these measured peak velocities. The 
mean heart rate was obtained from three to five successive cardiac cycles.
Tissue Doppler imaging
The same Toshiba scanner was switched to TDI mode: 2-D, M-mode, and single-gated TDI were 
performed as previously reported by the authors.18 The TDI software provided with the scanner was 
capable of displaying color-coded velocities of the myocardium as numerical data.
Using M-mode TDI from parasternal long-axis view, we measured peak myocardial velocities 
of the ventricles during systole, early and late diastole (after atrial contraction) (S, De and Da, 
respectively). The peak myocardial velocities were obtained at standardized sites: the RVAW, the 
right ventricular side of the IVS (IVSR), the left ventricular side of the IVS (IVSL), and both the 
endocardial and epicardial sides of the LVPW (LVPWendo and LVPWepi, respectively) at the level 
of the mitral valve leaflets. The peak wall velocity was expressed as positive when movement was 
toward the transducer and negative for movement away from it. Transmyocardial velocity 
difference was defined as the difference in isochronic peak velocities between the left and right 
ventricular side of the IVS (IVSL-IVSR), as well as between the endocardial and epicardial sides of 
the LVPW (LVPWendo-LVPWepi). These transmyocardial velocity differences across the IVS and 
LVPW were calculated for each cardiac phase separately.
Tissue Doppler Imaging was also obtained from apical four-chamber view (4-CV). After 
visualization of a color-coded signal, single-gated TDI wall velocity measurement was performed 
(with 5-MHz transducer frequency and a sample gate size of 2 or 3 mm) and a velocity-time display 
was registered.19 Care was taken to aim the US beam along the IVS and both right and left 
ventricular free walls (RVW and LVW, respectively) to minimize the angle of incidence between 
the US beam and the longitudinal direction of the wall motion. We assessed longitudinal peak 
velocities during systole, early and late diastole, within the basal, mid and apical parts of the RVW, 
interventricular septum (IVS) (Fig. 1), and LVW. These velocities were expressed as positive or 
negative when moving toward the transducer, or away from it, respectively.20
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A paradoxical movement was diagnosed if the myocardial movement along the US beam 
appeared to be opposite to the one expected from the study of the healthy subjects. Consequently, 
akinesis was diagnosed if no myocardial movement could be detected. It was then characterized as a 
“drop out” in the wall, while using the color-coded TDI signal.
Fig. 1. Right: apical 4-CV with the sampling gate of TDI velocity measurement 
indicated at dotted line. Left: longitudinal velocities during systole (S), early (De) 
and late diastole (Da) within the basal part of the interventricular septum (IVS).
Control group
The healthy control group for comparison of the standard and TDI echocardiographic data consisted 
of 160 healthy subjects (age 4 to 17.9 y) who were recently studied according to the same 
protocol.18 Data from this healthy control group showed that left ventricular size and wall thickness 
was closely related to body weight (or body surface area), and that adjustment for body weight 
effectively eliminated these dependencies. In healthy subjects, the assessed myocardial velocities, 
from both long-axis and 4-CV, were not significantly correlated with gender, length, weight (or 
body surface area), nor with heart rate, wall thickness, LV shortening fraction or blood flow 
velocities over corresponding heart valves.18 Therefore, all TDI values were given independently 
from age and weight. The data from the normal subjects were used for statistical comparisons with 
the values in the present study group.
Statistics
All measurements were summarized by the median and 5th to 95th percentiles. The dimensional 
parameters were adjusted for the effects of body weight. The results of left ventricular size, wall 
thickness, fractional shortening and transmyocardial velocity differences of the study group were 
compared with values from the controls with the use of a two-sample t-test. Differences in tissue 
velocities obtained from different positions were compared using the Wilcoxon signed rank test.
After logarithmic transformation of the TDI data (except for the transmyocardial velocity 
differences), the myocardial velocities of the patient group were compared with the data obtained 
from the controls, using the paired t- test.
The potential effects of gender, age at diagnosis, total dose of anthracyclines and length of 
follow-up on the myocardial velocities were evaluated with use of multiple-regression analyses.
For all the statistical tests, a p-value of 0.05 or less was considered significant.
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RESULTS
Standard echocardiographic study
Standard echocardiographic results are summarized in Table 1. The diastolic thickness of the IVS 
and LVPW did not differ significantly between the patient and the control groups. However, the LV 
diastolic diameter (LVDD) and LV systolic diameter (LVSD) were significantly increased (p < 0.01 
and p  < 0.001 respectively). As a consequence, the calculated left ventricular fractional shortening 
(FS) was also significantly decreased compared with the controls (p < 0.001), yet only four of the 
patients had FS value lower than 28%. The thickness of the right ventricular anterior wall was 
significantly decreased both in systole and diastole (p < 0.01). The blood flow velocities over de 
mitral valve did not differ significantly between the patient and the control groups.
Table 1. Standard echocardiographic data. Results are expressed as medians with 5th and 95th 
percentiles in parentheses.____________________________________________________________________
Study group 
(n = 63)
Control group 
(n = 160) P  value
IVS thickness (mm) 5.4 (4.3 -  7.5) 5.4 (3.7-7.2) NS*
LVPW thickness (mm) 5.8 (4.3 -  6.9) 5.4 (4.0-7.0) NS*
LVDD (mm)* 45.8 (40.1 -  56.0) 42.5 (35.6-53.4) <0.01*
LVSD (mm) * 30.9 (25.8 -  38.2) 27.4 (22.1-34.7) <0.001*
FS (%) 33.0 (27.0 -  39.0) 36 (28.5-45.0) <0.001§
RVAW thickness (mm) 1.9 (1.2 -  2.5) 2.0 (1.4-2.9) <0.01
RVAW thickness (mm) * 3.7 (2.9 -  5.0) 4.2 (2.8-6.1) <0.01
MV max. E wave velocity (cm/s) 86.0 (61.6-114) 85.2 (57.9-114.5) NS§
max. A wave velocity (cm/s) 38.7 (25.7-59.7) 40.5 (20.8-61.8) NS§
E:A ratio 2.2 (1.4-3.6) 2.2 (1.4-4.0) NS§
In diastole; * in systole. IVS = interventricular septum; LVPW = left ventricle posterior wall; LVDD =
LV diastolic diameter; LVSD = LV systolic diameter; FS = LV fractional shortening; RVAW = right 
ventricle anterior wall; MV = mitral valve.
NS = not significant (p > 0.05). ^Regression analysis, after correction for effects of body weight. §Two- 
sample t-test.
Tissue Doppler Imaging
Adequate 2-D (B-mode) color-coded and M-mode TDI images, as well as single-gated tissue 
Doppler tracings, could be easily obtained from all 63 patients. Representative examples of normal 
B-mode and M-mode TDI of a subject are shown in Fig 2. During systole, the peak wall velocities 
of the RVAW and both sides of IVS are negative (direction of tissue movement away from the 
transducer) (i.e., blue-green colors). At the same heart phase, the peak wall velocities of the 
LVPWendo and LVPWepi are positive because the LVPW is contracting towards the cavity of the 
LV; thus, moving towards the transducer (i.e., red-yellow colors). During early and late diastole, the 
peak wall velocities of the RVAW and IVS are expressed as positive; those of the LVPW as 
negative. Consequently, during systole, the velocity difference is negative when the left side of the 
IVS is moving faster than the right side of the IVS (because both IVS velocities are expressed as 
negative), and is positive when the endocardium of the LVPW is moving faster than the epicardium.
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Fig. 2. (a) Parasternal long-axis 2-D TD image, systole: LV posterior wall (LVPW) moves toward the transducer 
(red to yellow color), whereas the septum (IVS) moves away from it (blue to green), toward the contraction center 
in the LV, (b) Early diastole, as in (a) but with reversed movements of the LVPW (blue) and the IVS (red), (c) TDI 
M-mode obtained along a scan line at the level of the mitral valve leaflets. LV contraction is seen to occur after the 
QRS complex of the ECG and to last until the end of the T -wave (red band in LVPW, blue band in IVS and RV 
anterior wall). LV dilation yields reverse colors (blue and red). Posterior (lower) color band comprises both LVPW 
and pericardium (white on conventional B-mode/ M-mode).
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Table 2 presents median values (and 5th to 95th percentiles) of the peak myocardial velocities of 
the study group, obtained from parasternal long-axis view. The results show a wide range of peak 
wall velocities. The early diastolic myocardial velocities are the highest. The various cardiac phases 
have distinctly different peak myocardial velocities and different directions of wall motion. 
Moreover, when compared to the TDI data obtained from the control group, the peak late diastolic 
myocardial velocities were significantly decreased in both sides of the IVS (left side more than the 
right side), as well as in the endocardium and epicardium of the LVPW (p < 0.01).
Table 2. Median (and their 5th to95th percentiles) of peak myocardial velocities (cm/s) obtained 
from long-axis view, using TDI (study group, n = 63)
Peak systolic Peak early diastolic Peak late diastolic 
wall velocity (S)_______ wall velocity (De)_______wall velocity (Da)
RVAW -2.0 (-1.3 -  -4.2) 2.9 (1.1 -  5.7) 1.2 (0.4 -  2.9)
IVSR -1.9 (-0.9 -  -3.3) 3.6 (1.5 -  6.6) 1.3* (0.5 -  2.5)
IVSL -3.0 (-1.9 -  -4.4) 4.6 (2.5 -  8.1) 1.6* (0.7 -  3.1)
LVPWen 4.1 (2.6 -  5.4) -10.3 (-5.9 -  -13.5) -0.8* (-0.4 -  -1.7)
LVPWepi 2.4 (1.3 -  3.3) -4.5 (-2.0 -  -6.1) -0.4* (-0.1 -  -1.0)
Significant p  value (p < 0.01) for the comparison with the healthy controls (by f-test, after 
logarithmic transformation of the TDI data)
Table 3 presents median values (and 5th to 95th percentiles) of the transmyocardial velocity 
differences both in the IVS and LVPW (i.e., AS, ADe and ADa). The peak velocities assessed from 
left side of the IVS were always higher than those obtained from the right side of the IVS. 
Similarly, the peak velocities obtained from the endocardium were always higher than those 
obtained from the epicardium of the LVPW. These differences in peak velocities were present in 
systole, early and late diastole. During the systole, early and late diastole, the transmyocardial 
velocity differences were statistically higher within the LVPW than within the IVS (Wilcoxon 
signed rank tests, p  < 0.001).
Table 3. Median (and 5th to 95th percentiles) of the velocity differences (A, cm/s) across the IVS and 
LVPW obtained from long-axis view, using TDI (study group, n = 63)
D S D De D Da
IVS (L-R) -1.0* (-0.5 --1 .5 ) 1.0* (0.1 -  2.3) 0.2* (0.0 -  0.8)
LVPW (endo-epi) 1.6 (0.7 -  2.7) -6.1 (-2.3 -  -9.8) -0.4* (0.0 -  -0.9)
Wilcoxon signed rank test p < 0.001 p < 0.001 p < 0.001
Significant p  value (p < 0.01) for the comparison with the healthy controls.
^Significant p  value (p < 0.05) for the comparison with the healthy controls (TDI data of the controls 
are summarized in Kapusta et a/.)18
When comparing the data to those obtained from the control group, the transmyocardial 
velocity differences of the IVS were significantly decreased in systole, early and late diastole (p < 
0.01). In the LVPW, however, the transmyocardial velocity difference was significantly diminished 
only in late diastole (p < 0.05).
Using single-gated TDI from apical 4-CV, the maximal myocardial velocities and their 
directions were measured as described in the Methods section. Examples of normal color-coded 
TDI and the velocity traces within the LVW are shown in Fig. 3. The myocardial velocity pattern 
within each part of the wall showed three major distinctive waves: a positive wave (S) towards the 
apex (and hence, also towards the transducer) during systole and two negative waves away from the
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transducer during diastole. The first diastolic wave (De) occurs during early filling, and the second 
(Da) corresponds to atrial contraction. As can be seen in Figs. 1 and 3, the cardiac walls display 
different systolic and diastolic velocity patterns.
After logarithmic transformation of the peak myocardial velocities, the data were compared to 
those obtained from the 160 volunteers. No statistically significant differences were found between 
the two groups.
Fig. 3. (a) Normal apical four-chamber view (4-CV) during mid diastole; the three positions of 
the single-gated TDI measurements are indicated as: prox (equiv. basal), mid and apical, (b)
Pattern of single-gated TDI at basal position in LV free wall (cf. Fig. 1).
Using color-coded, as well as single-gated TDI from the apical 4-CV, 16 patients showed wall 
movement abnormalities. A total of 12 patients had abnormal LVW relaxation pattern; namely, 
paradoxical contraction of the basal- or mid-LVW between early and late diastole (Fig. 4). Only 
three patients had local longitudinal contraction abnormalities in the IVS expressed as akinesis or 
“drop out” in the color-coded TDI scans (Fig. 5). One patient had the same local contraction 
abnormality in the LVW. The examiner immediately and easily observed all these qualitative wall 
abnormalities.
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Fig. 4. (a) Abnormal color in LV free wall during mid diastole 
(red color rather than blue, see arrows), (b) Abnormal pattern of 
single-gated TDI at the same location (arrows) as in (a).
Fig. 5. Local longitudinal contraction abnormality (“drop out”) within 
the whole interventricular septum (IVS), in systole.
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R isk factors
Using the multiple regression analyses, the length of the follow-up show to have a negative effect 
on the peak late diastolic (Da) velocities of both the right and left side of the IVS (p < 0.05 and p  <
0.01 respectively). Female gender in combination with younger age at diagnosis was a risk factor 
for decreased peak late diastolic myocardial velocities in the LVPW (p < 0.05).
Cumulative anthracycline dose seems to be a risk factor for the decreased early diastolic 
transmyocardial velocity differences in the septum of the patients (p < 0.05). The potential effects 
of gender, younger age at diagnosis and length of follow-up on the other transmyocardial velocity 
differences could not be confirmed.
DISCUSSION
Late clinical cardiotoxicity due to anthracycline therapy has become a common problem during the 
follow-up of patients treated for childhood cancer. It presents 2 to 19 y after therapy, with a median 
of 10 y, and occurs in 5-10% of the long- term survivors of a childhood malignancy.3 Subclinical 
cardiotoxicity is more common and occurs in 20-75% of the patients; this prevalence varies greatly 
within different studies.4,21-24 The incidence of severe echocardiographic abnormalities increases 
with the duration of follow-up.23,25 These findings indicate that the full extent of the problem has 
yet to unfold in many asymptomatic patients. In addition, late-onset arrhythmias and sudden death 
have been reported to have occurred in patients more than 15 y after anthracycline treatment.2,23,26 
Incidence of nonsustained ventricular tachycardia ranging between 3%-5% in anthracycline-treated 
patients, at long-term follow-up, has been reported.4,5,26,27 The incidence of late-onset cardiac 
decompensation increases with higher cumulative doses,4,23,28 higher rates of anthracycline 
administration,6,21 and mediastinal irradiation.23 Young age at the time of treatment4,21,29 and
21 28 29female gender may be risk factors for late-onset cardiotoxicity, but these factors are still
controversial. Recent evidence appears to support that female gender and higher rate of 
administration are independent risk factors for late-onset cardiotocixicity.21
According to Lipshultz et a t 21, most echocardiographic measurements (left ventricular 
fractional shortening, contractility, wall thickness, dimensions, mass and afterload) were abnormal 
at follow-up duration of more than 2 y. This patient group consisted of 120 children and adults who 
had received anthracycline chemotherapy for childhood ALL or osteogenic sarcoma at a mean of 
8.1 y earlier. We could only reconfirm part of these results. In our survivors, the cardiotoxicity 
detected by the standard echocardiograpy (Table 1), consisted of a significant increase of the left 
ventricular dimensions (as compared to the healthy group), a decrease of the left ventricular 
shortening fraction and a thinner right ventricular anterior wall (both in systole and diastole). 
However, no significant decrease in the septal or the posterior wall thickness was detected. In the 
study of Nysom et a t 22, depressed left ventricular fractional shortening and left ventricular 
dilatation were considered uncommon y after treatment of childhood leukemia when cumulative 
anthracycline doses were < 300 mg/m2. A threshold of 300 mg/m2 is suggested for the development 
of late asymptomatic left ventricular dysfunction. However, this is not supported by subclinical 
endomyocardial biopsy findings, which are already seen at cumulative doses greater than 240 
mg/m2.30 An individual sensitivity (threshold) for anthracycline cardiotoxicity is also mentioned in 
the literature, mainly in adults. Cardiac biopsy, however, is often taken from the walls of the right 
ventricle. The significantly decreased thickness of the RVAW found in our patients could explain 
the subclinical abnormalities often found with this invasive method.
None of the methods of screening for anthracycline cardiotoxicity has been shown to be 
adequately predictive of late cardiac outcomes. Tissue Doppler imaging is used to measure 
myocardial wall motion velocity. Therefore, it might be possible to detect myocardial damage at an 
early stage with this technique. The predictive value of tests for regional vs. global left ventricular
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dysfunction is expected to be quite different. Relaxation properties of the myocardium are complex 
and involve intrinsic properties of the heart (such as active and passive myocardial stiffness) in 
addition to other external factors (such as right ventricular pressure, pericardial pressure, pleural 
pressure, etc). Contrary to standard Doppler echocardiography, TDI can measure myocardial tissue 
velocity, which directly reflects contractile and relaxation properties of the myocardium.31 Recently, 
TDI has been used for noninvasive detection of allograft rejection in heart transplant recipients.32 
During moderate allograft rejection, peak early diastolic myocardial velocities (De) significantly 
decreased, and subsequently increased after successful treatment. Peak systolic velocities did not 
change during rejection. The detection of rejection by TDI is based on the principle that, during 
allograft rejection, cellular infiltration and tissue edema results in relaxation abnormalities.33 
Anthracycline cardiotoxicity result in cellular injury. Because a change in left ventricular diastolic 
function can occur before ejection fraction falls to subnormal levels, diastolic function, as well as 
systolic function, should be examined for early detection of anthracycline cardiotoxicity.34
In our present study, the TDI was applied to children, all of them late survivors of childhood 
malignancies. TDI M-mode images were first employed to quantify the velocities of the different 
wall movements throughout the heart cycle. As seen in healthy children, the early diastolic 
myocardial velocities are the highest and the directions of wall motion in systole, early, and late 
diastole are similar (Table 2). Contrarily, the peak late diastolic myocardial velocities in the left side 
of the septum, as well as in the endocardium and epicardium of the LVPW, were significantly 
decreased in the patients (p < 0.01). Using the standard echocardiography, these children did not 
show decreased thickness of the interventricular septum, nor of the left ventricular posterior wall. 
Thus, using the noninvasive TDI technique, functional impairment of the myocardium could be 
detected. Furthermore, transmyocardial velocity differences across the IVS or LVPW were 
measured as in healthy myocardium, with the one in the LVPW always higher than in the IVS 
(Table 3). The velocity differences across the IVS were significantly decreased throughout the 
whole heart cycle, when compared to the velocity differences measured in healthy children. In the 
LVPW, however, the velocity difference was significantly lower in the study group only during late 
diastole. A decrease in the velocity difference across the wall, in systole or early diastole, might be 
an important predictor of myocardial contractility or relaxation deficiency. The decreased late 
diastolic velocity difference found in the LVPW could be a result of increased wall stiffness or 
decreased atrial contraction force.
Using single-gated TDI from the apical 4-CV, the maximal myocardial velocities were 
measured within the basal parts in all myocardial walls. As described earlier in healthy hearts of 
children and adults, a marked heterogeneity of regional myocardial velocities was found.18,35,36 The 
assessed myocardial velocities of our patients were not significantly different from those obtained 
from the control group. Moreover, our results reassure that, in certain cardiac phases, the different 
myocardial wall parts have distinctly different patterns and magnitudes of wall velocity, all of 
which can be easily seen on 4-CV view using the single-gated TDI technique (see Figs. 1 and 3).
Earlier qualitative and quantitative evaluations of LVPW and septal contraction toward the 
contraction center of the ventricle showed that patients who had received doxorubicin had 
contraction deficits with slow relaxation.9 The greatest contraction deficit occurred in the LVPW 
behind the posterior mitral leaflet. Patients with more extensive involvement had an additional 
contraction deficit extending to the apex. Because TDI can measure myocardial velocities directly, 
one can expect that, in patients with myocardial fibrosis or with ventricles with decreased 
compliance for other reasons, the peak early diastolic velocity (De) will diminish as compared to 
the velocities measured in healthy children. In our study, we could not find a significant decrease of 
myocardial velocities in the apical 4-CV. Nevertheless, using color-coded, as well as single-gated 
TDI, 20% of our late survivors showed local, paradoxical myocardial movements involving mainly 
the basal and mid part of the LVW (which is in line with the previously mentioned literature data). 
Although area-limited, these abnormalities could be easily recognized and, because of the high
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pulse-repetition frequency in single-gated TDI, cannot be attributed to aliasing. The clinical 
consequences of the local myocardial impairment are not yet known. TDI is of particular 
importance in the early detection of these local myocardial abnormalities, even before any change 
is apparent in global function measurements.
The TDI technique is attractive because it is noninvasive and relatively simple. Technically 
satisfactory recordings can be obtained in most patients, in a relative short time. No sedation is 
needed. Furthermore, tissue Doppler imaging has recently been shown to be useful in the detection 
of allograft rejection, 32 which is accompanied by cellular infiltration and tissue edema. The 
myocardial relaxation velocities were not affected by left ventricular loading conditions,31 
suggesting that tissue Doppler imaging might be capable of detecting functional myocardial 
impairment during or shortly after therapy, in spite of diverse loading conditions. Further 
prospective studies are warranted.
The clinical implications of our observations can only be established by a long-term 
prospective analysis of left ventricular function in patients receiving anthracycline therapy.
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CHAPTER 6
Discriminative ability of conventional echocardiography and tisssue 
Doppler imaging techniques for the detection of subclinical 
cardiotoxic effects of treatment with anthracyclines
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ABSTRACT
This study investigated improvement of diagnosing myocardial damage caused by anthracyclines
using tissue Doppler imaging (TDI). The optimal set of conventional echocardiographic and/or TDI 
parameters, needed for the discrimination of survivors from healthy controls, was retrospectively 
assessed. A total of 60 patients and 99 controls, age range 8.5 to 17.6 years, were studied. The 
survivors received 50 to 400 mg/m2 cumulative dose of anthracyclines, with a mean follow-up of 
7.3 (± 2.3) years. The parameters used in the discriminant score (S-score) were selected from a large 
set of 51 echocardiographic parameters, using logistic regression analysis (stepwise selection). The 
correct classification probability (C-index) and the generalized distance (d) between the 
distributions of S-scores were used to measure the overall discriminative performance of each 
echocardiographic technique separately and in combination. The overall discriminative performance 
of the conventional echo-Doppler parameters (C = 77.3%, d  = 1.04) was lower than that of the TDI 
(C = 84.2%, d  = 1.37); the highest C-index was obtained using both techniques (C = 89.2%, d  = 
1.66). The set of parameters includes: LV fractional shortening and MV early diastolic flow 
velocity, two long-axis and five apical 4-CV TDI wall velocities (systolic and diastolic). In the 
patient group, the S-score was positively associated with cumulative dose of anthracyclines (p =
0.05) and duration of treatment (p = 0.01). The diagnostic index S-score, based on a limited number 
of variables from both techniques simultaneously, could retrospectively discriminate asymptomatic 
children with anthracycline-induced cardiomyopathy from healthy controls. The potentials of the S- 
score for serial and prospective studies are further investigated.
Key Words: Tissue Doppler imaging, Echocardiography, Anthracyclines, Cardiotoxicity, 
Discriminative ability, Multivariate statistics.
INTRODUCTION
Anthracyclines are potent drugs for the treatment of cancer. However, “...Late cardiotoxicity after 
anthracycline therapy for childhood cancer is frequent, mostly subclinical, often progressive, 
potentially severe and sometimes f a t a l . ”.1,2 Early detection of the subclinical dysfunction might 
facilitate the decision for cardiac treatment and, therefore, improve the survival rates.3,4
The diagnostic approach to children suspected of anthracycline-induced cardiotoxicity is 
mainly based on noninvasive echocardiographic techniques. The incidence of cardiotoxicity, as 
diagnosed by endomyocardial biopsy, can be as high as 85%.5,6 Because serial myocardial biopsies 
and stress testing are not practical in younger children and radionuclide angiography is not 
appropriate for frequent application, noninvasive tests such as echocardiography and 
electrocardiography (ECG) still play the main role for serial cardiac monitoring in these age groups. 
Mild to significant left ventricular systolic and diastolic dysfunction, detected by standard echo­
Doppler cardiography, have been frequently reported.7-12 It often requires serial echocardiographic 
measurements, before, during and after treatments. There has been considerable discussion about 
both the value and timing of monitoring for anthracycline cardiotoxicity, resulting in American 
guidelines,13 which have already been criticized by Lipshultz et al.14 as being both unproven and as 
having potential negative consequences for antitumor treatment. The utility of this widely accepted 
and used echocardiographic technique is also limited in the presence of regional wall motion 
abnormalities or dyskinesia.
A new noninvasive echocardiographic technique, namely tissue Doppler imaging (TDI), 
promises to further enhance the value of echocardiography. This technique enables online 
quantitative assessment of myocardial tissue velocity magnitudes and directions along the radial and 
longitudinal axes.15-17 Until now, it has been mainly applied to adults with ischemic heart
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18 21 * 22 23 * 24diseases, " cardiomyopathies, ’ rhythm disturbances, or to patients suspected of acute 
allograft rejection.25 It has been used in combination with conventional echo-Doppler cardiography 
for the assessment of diastolic function.26-29 The determination of normal pattern and magnitude of 
myocardial velocities in children30,31 has given an opportunity to apply this technique to the 
pediatric patients with congenital or acquired heart diseases, too. This technique has already been 
used to localize the origin of premature beats in children with various forms of arrhythmia.32 
Recently, its usefulness has been reported for the detection of myocardial dysfunction in survivors 
of childhood cancer treated with anthracyclines. 33
Conventional echo-Doppler examination yields a different set of parameters than the TDI 
technique.34,35 Both methods are time-consuming and result in a large set of variables. Furthermore, 
the different parameters do not unanimously point to normal or abnormal myocardial function. To 
facilitate the use, as well as the interpretation, of all these data, we searched for a method to 
summarize these different variables in one discriminant score that would enable classification of the 
children involved in this study in patients and control groups. So, the aim of this study was to 
determine retrospectively a useful set of conventional echocardiographic and/or TDI parameters 
needed for discrimination of survivors of childhood cancer treated with anthracyclines from healthy 
controls. The use of the score simplifies correlation studies between the different echocardiographic 
data and risk factors known from earlier studies that influence the outcome of childhood 
malignancies (e.g., cumulative dose anthracyclines, age at start of therapy, duration of follow-up, 
female gender).12,36,37 The discriminative ability of the different echocardiographic techniques for 
the detection of the effects of treatment with anthracyclines may then be based on the diagnostic 
index scores of the techniques separately, or in combination.
MATERIALS AND METHODS 
M aterial
All survivors of childhood malignancy (in remission), in the age range of 5 to 18 years, who were 
treated with moderated doses of anthracyclines more than 5 years before the study took place, were 
recruited from our outpatient clinics and asked to participate in the study. The echocardiographic 
measurements of 99 healthy children and 60 late survivors were incorporated in this retrospective 
study, after balancing the age distribution. The mean (± SD) age, weight, BSA, gender and heart 
rate distributions of both groups of children are shown in Table 1. Most of the survivors were 
treated for leukemia (ALL = 36, ANLL = 2) or non-Hodgkins lymphoma (n = 11). The remainder 
of the malignancies included solid tumors such as Wilm’s tumor (n = 3), Ewing sarcoma (n = 2), 
osteosarcoma (n = 2), rhabdomyosarcoma (n = 1), neuroblastoma (n = 2) and hepatoblastoma (n = 
1). The mean age (± SD) of the patients at start of chemotherapy was 4.8 (± 2.6) years, with a mean 
(± SD) follow-up period of 7.3 (± 2.3) years after anthracycline therapy had been completed. We 
considered the sum of the cumulative doxorubicin and daunorubicin doses as the cumulative 
anthracycline dose; the mean (± SD) cumulative dose given to the patients was 217 (± 81) mg/m2, 
range 50 to 400 mg/m2. All patients received anthracyclines as part of combination chemotherapy; 
other chemotherapeutic agents used included vincristine, methotrexate, bleomycine, etoposide, 
cyclophosphamide and cisplatin. No patient underwent mediastinal or spinal irradiation. None of 
the patients had symptomatic cardiovascular disease, ischemic heart disease, or cardiomyopathy 
before receiving anthracyclines. None of the patients had suffered from rhythm disturbances or 
from symptomatic congestive heart failure after therapy. The physical examination revealed normal 
findings in all patients, except for a systolic heart murmur in two cases, considered to be innocent. 
This protocol had institutional review board approval.
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Table 1. Characteristics of controls and patients
Controls (n = 99) Patients (n = 60) p  value
Age (±SD) (years) 13.2 (2.9) 13.4 (2.6) 0.65*
Weight (±SD) (kg) 48.1 (14.6) 48.4 (15.3) 0.92*
BSA (±SD) (m2) 1.46 (0.29) 1.45 (0.29) 0.81*
Gender: boys (%) 42 (42%) 32 (53%) -
girls (%) 57 (57%) 28 (47%) 0.19*
Heart rate (±SD) (bpm) 74 (11) 74 (11) 0.85*
Cumulative dose anthracyclines (±SD) (mg/m2) 217 (81) -
Age at start of chemotherapy (±SD) (years) 4.8 (2.6) -
Duration of follow-up (±SD) (years) 7.3 (2.3) -
* Student f-test; *Fisher exact test
Methods
The conventional echocardiographic study and subsequent tissue Doppler imaging were carried out 
with the “Powervision” echographic scanner (model SSA-380A software version 2.5 0ER000, 
Toshiba, Nasu, Japan). A 5-MHz phased-array sector transducer was used.
The same experienced pediatric cardiologist who was assisted by a sonographer performed all 
echocardiographic examinations. Before the TDI measurements were performed, the children 
underwent a detailed standard echocardiographic examination. Electrocardiographic recordings 
were made simultaneously with the ultrasound (US) images. The children did not receive sedation, 
and all were shown to have normal sinus rhythm and regular breathing patterns at the time of study. 
To reduce the influence of respiration on myocardial velocities (and for the fact that breath hold is 
not feasible in young children), three cardiac cycles were recorded and the cycle with the highest 
velocity was selected for further analysis.
Standard echocardiographic study
The images were evaluated online. M-mode measurements were taken at the level of the tips of the 
mitral valve leaflets in the parasternal long-axis view of the left ventricle. Standard parameters 
measured were: left ventricular dimensions in systole and diastole, right ventricular anterior wall 
(RVAW) thickness in systole and diastole, interventricular septum (IVS)- and left ventricular 
posterior wall (LPVW) thickness in diastole. Left ventricular fractional shortening (FS) was 
calculated from the left ventricular dimensions. Using the apical four-chamber view, peak early and 
late (after atrial contraction) diastolic Doppler blood flow velocities of the mitral valve were 
measured. Accordingly, the E:A ratio was calculated from these measured peak velocities. The 
mean heart rate was obtained from three to five successive cardiac cycles.
Tissue Doppler imaging
Using M-mode TDI from parasternal long-axis view, we measured peak myocardial velocities of 
the ventricles during systole, early and late diastole (after atrial contraction). The peak myocardial 
velocities were obtained at standardized sites: the RVAW, the right ventricular side of the IVS  
(IVSR), the left ventricular side of the IV S  (IVSL), and both the endocardial and epicardial sides of 
the LPVW  (LPVWendo and LPVWepi, respectively) at the level of the mitral valve leaflets. The 
peak wall velocity was expressed as positive when movement was toward the transducer and 
negative for movement away from it. Tissue Doppler imaging was also obtained from apical four- 
chamber view (4-CV). After visualization of a color-coded signal, single-gated TDI wall velocity 
measurement was performed (with 5-MHz transducer frequency and a sample gate size of 2 or 3 
mm) and a velocity-time display was registered. Care was taken to aim the US beam along the IVS  
and both right and left ventricular free walls (RVW and LVW, respectively) to minimize the angle
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of incidence between the US beam and the longitudinal direction of the wall motion. We assessed 
longitudinal peak velocities during systole, early and late diastole, within the basal, mid and apical 
parts of the RVW, interventricular septum (IVS), and LVW  (Fig. 1). These velocities were expressed 
as positive or negative when moving toward the transducer, or away from it, respectively.
“
mid L.VW
b
Fig. 1. (a) Schematic apical 4-CV with the measurement position 
indicated by the white squares.31 (b) Pattern of single-gated TDI at 
mid position in LV free wall.
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Statistical analysis
The Student’s t-test was used to compare the distribution of age, weight, BSA, and heart rate in the 
study group vs. the controls. The distribution of gender was compared with Fisher’s exact test 
(2-tail) for the comparison of two proportions. A p-value < 0.05 was considered to be statistically 
significant.
To determine a diagnostic index score (S) that could classify children in survivors and control 
group, a logistic discriminant analysis based on logistic regression analysis was used. Using the S- 
score, one can predict the probability p  that an individual with characteristics xi,..., Xj will belong to 
the patient group. In the logistic regression analysis, patients received code 1, controls code 0.
The logistic regression model was defined as
loge [p /(l - p)] =S = bo +biXi + ...+bjXj (1)
where S  = the diagnostic index score,p  = the probability that an individual with characteristic x l, ..., 
Xj will belong to the patient group (anthracycline-induced cardiotoxicity), x l,..., Xj = 
echocardiographic data, and b0,..., bj = regression coefficients.
The variables that contributed significantly to the diagnostic index score were selected, 
applying stepwise selection (implemented in the SASTM package version 6.12). The significance 
levels for entry and for stay in the model were chosen to be 0.05 (SLE = 0.05 and SLS = 0.05, 
respectively).
Five discriminant scores (S-scores) were calculated from different sets of echocardiographic 
variables: conventional echo-Doppler (n = 10), TDI long-axis view (n = 15), TDI 4-CV (n = 26), 
TDI total (n = 41), and a combination of both conventional echo-Doppler with TDI technique (n = 
51). Because it was reported that the TDI parameters were not Gaussain (normal) distributed,31 the 
natural logarithm of the absolute value of these parameters was calculated and inserted in the 
statistical analysis. Based on the S-scores, the effectiveness of discrimination was measured both by 
the C -index and the generalized distance between the distribution of S-scores in the patient and the 
control group (d). A C -index of 100% indicates the ability to make a perfect prediction based on the 
discriminant S-score. A C -index of 50% indicates that the predictions based on the discriminant 
score S  are comparable to a flip of a coin (no discriminative ability, d  = 0). The receiver operating 
characteristic curves (ROC curves) were plotted. The area under the ROC curve (C-index) and the 
generalized distance (d) between the S-score distributions of both groups were used to measure the 
overall discriminative performance.
The generalized distance was defined as
d  = (^ patients - c^ontrolsVs  (2)
where d  = generalized distance, m = mean of the S-score in the patient group or the controls, and s  = 
square root of pooled variance of the S-scores of both groups.
After identifying the set of parameters and regression coefficients with the best discriminative 
ability, the distributions of the S-scores of children in the study group (survivors) and the control 
group were assessed.
The potential influence of subject characteristics (gender and age) respectively, treatment 
characteristics (age at start of chemotherapy, duration of treatment, cumulative dose of 
anthracyclines and duration of follow-up) on the S-score was studied using multiple linear 
regression analysis. Because the treatment might have influence on the weight or BSA, these 
variables were not included in the regression analysis.
For all statistical tests, a p-value of 0.05 or less was considered significant.
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RESULTS
The five discriminant scores S , based on sets from conventional echo-Doppler, TDI long-axis view, 
TDI 4-CV, TDI total and a combination of both conventional echo-Doppler with TDI technique, 
respectively, are described in Table 2. The discriminative performance of each S-score, as expressed 
by the C -index (area under the ROC curve) and the generalized distance (d), is given as well.
Table 2. Overall discriminative performance: C-index and generalized distance (d) for each technique
Technique
No. of entry 
variables
No. of variables 
selected C-index (%)
Generalized 
distance (d)
Conventional ED 10 4 77.3 1.04
TDI long-axis view 15 2 66.5 0.62
TDI 4-CV 26 5 78.1 1.08
TDI total 41 7 84.2 1.37
Conventional + TDI 51 9 89.2 1.66
Conventional ED = conventional echo-Doppler cardiography; TDI = tissue Doppler Imaging; 4-CV = apical four- 
chamber view. C-index based on logistic discriminant analysis (stepwise selection, SLE = 0.05, SLE = 0.05). 
Generalized distance (d) obtained from S-score distributions.
Conventional echo-Doppler param eters (using stepwise selection)
A set of 10 echo-Doppler cardiographic data was included in this analysis. A subset of four 
variables was selected by the logistic discriminant analysis. These four variables contribute most 
significantly to the diagnostic index score S . The selected variables were: left ventricular fractional 
shortening (FS), mitral valve blood flow velocity during early diastole (mitral E-max), right 
ventricular anterior wall thickness in systole (RVAWS) and left ventricular dimension in diastole 
(LVDD). Both forward and backward selection resulted in the same set of variables. Using only this 
technique, the C-index was C = 77.3% and d  = 1.04 (see Table 2).
Tissue Doppler imaging param eters
A total of 41 variables were included in the data set of the TDI: 15 variables obtained from the LV 
long-axis view and 26 variables obtained from the apical 4-CV. Two of the fifteen variables were 
selected by the logistic discriminant analysis, while using the TDI method from the long-axis view 
solely. For a diagnostic index score S  based only on the TDI 4-CV data set, 5 of the 26 variables 
were selected. When combining both views, 7 variables of the total TDI data set (n = 41) were 
selected. Within the TDI method, the variables obtained from the 4-CV revealed a higher 
discriminative performance than was obtained from the long-axis view (C = 78.1% and C = 66.5%, 
respectively, corresponding d  = 1.08 and d  = 0.62) (see Table 2). A higher C-index (area under the 
ROC curve) was obtained using both views simultaneously (C = 84.2%, d  = 1.37).
Conventional echo- Doppler and tissue Doppler imaging param eters
A total of 9 variables of 51 were selected by the stepwise analysis for the discrimination of patients 
from the controls. This resulted in the highest overall discriminative performance (C = 89.2%, d  =
1.66, Table 2) as compared to both conventional echo-Doppler and tissue Doppler imaging 
techniques when used separately (Fig. 2). The backward selection procedure revealed the same nine 
variables as the originally applied stepwise selection procedure.
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1-specificity
Fig. 2. ROC curves using the different echocardiographic techniques: 1 =
Conventional echo-Doppler and TDI techniques (C-index = 89.2%); 2 = TDI technique 
(C-index = 84.2%); and 3 = Conventional echo-Doppler technique (C -index = 77.3%)
The characteristics of these nine variables selected for the discriminative score S are described 
in Table 3. The discriminative score S is calculated as follows:
S = 10.3 - (0.15 * FS) + (0.06 * mitral E -max) - (2.9 * IVSL in systole) - (1.1 * LPVWendo in 
late diastole) + (9.3 * basal IVS in systole) - (5.0 * basal IVS in late diastole) - (5.2 * mid IVS in 
early diastole) + (6.2 * distal IVS in late diastole) - (5.0 * basal LVW in early diastole).
In the above formula for calculating the S-score, a plus sign refers to a positive contribution of 
the variable, and the reverse for the minus sign.
Table 3. The characteristics of the discriminant score S  in the controls (n = 99) and the study group (n = 60), using 
both echocardiographic techniques simultaneously
Controls Study group Regression 
Median (5th; 95th Median (5th; 95th coefficient 
Technique_______________ Selected variable____________percentiles)__________percentiles)_________(± SE)*
Intercept (b0) 10.3 (6.1)
Conventional ED ‘FS (%) 36 (28;46) 33 (27;40) -0.15 (0.06)
(n = 2) 2mitralis E-max 83 (58;113) 87 (60;115) +0.06 (0.02)
TDI long axis view 3IVSL in systole^ -3.2 (-4.6;-1.9) -3.1 (-4.7;-1.8) -2.9 (0.9)
(n = 2) 6LVPWendo in late diastole^ -1.1 (-3.2;-0.4) -0.8 (-1.7;-0.4) -1.1 (0.4)
TDI 4-CV 4basal IVS in systole^ 8.3 (6.4;10.1) 8.7 (6.8;10.0) +9.3 (2.5)
(n = 5) 9basal IVS in late diastole^ -5.9 (-7.9;-4.4) -6.0 (-7.9;-4.5) -5.0 (1.8)
5mid IVS in early diastole^ -12.9 (-16.9;-9.0) -11.8 (-15.3;-8.0) -5.2 (1.5)
8distal IVS in late diastole^ -3.6 (-5.0;-2.2) -3.8 (-5.0;-3.3) +6.2 (1.7)
7basal LVW  in early diastole^ -18.5 (-23.2;-14.0) -17.8 .0)2..8;
<N -5.0 (1.5)
Stepwise logistic regression analysis, SLE = SLS = 0.05
* = based on natural logarithm of (absolute value of) peak myocardial velocities. " = order of entry in the stepwise 
analysis. FS  = fractional shortening; mitralis E-max = mitral valve blood flow velocity during early diastole; IVSL 
= left ventricular side of interventricular septum; LVPWendo = endocardium of left ventricular posterior wall; IVS 
= interventricular septum; LVW  = left ventricular free wall;  ^= peak myocardial velocities [cm/s], before the 
natural logarithm is used.
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The distribution of the estimated index score S  in the study group (survivors) and the control 
group is plotted in Fig. 3. The distribution of the diagnostic index score S  is clearly different 
between the groups, as may be expected from the ROC curve (Fig. 2).
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Fig. 3. The distribution of the diagnostic index score S  in the controls 
(n = 99) and the patient group (n = 60).
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Gender had no independent influence on the S-score (p = 0.56). The relationship between the S- 
score and age is plotted in Fig. 4. In the control group, an older age at the time of the 
echocardiographic examination resulted in a significantly higher S-score. On the contrary, no 
significant correlation between the S-score and age could be shown in the patient group. The slopes 
of these regressions are significantly different (p = 0.04).
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Fig. 4. The relationship between the S-score and age at the time of the echocardiographic 
examination. 1 = study group; 2 = control group
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Age at start of chemotherapy had no independent influence on the S-score (p = 0.79). The 
effects of the other treatment characteristics on the S-score were investigated (Table 4). The S-score 
of the survivors was positively associated with the cumulative dose of anthracyclines (p = 0.05), 
and with the duration of the treatment (p = 0.01).
Table 4. Relationship* between the S-score and the treatment characteristics
Variable
Regression coefficient (± 
SE) ^-value
Intercept -2.68 (1.15) 0.02
Duration of treatment 0.84 (0.32) 0.01
Cumulative dose anthracyclines 0.006 (0.003) 0.05
Duration of follow-up 0.17 (0.12) 0.14
*S  = -2.68 + 0.84 (duration of treatment) + 0.006 (cumulative dose anthracyclines) + 
0.17 (duration of follow-up).
DISCUSSION
Congestive heart failure, high-grade arrhythmias, cardiac conduction abnormalities, and sudden 
death are clinically significant anthracycline cardiotoxicity effects that may occur even many years 
after completion of therapy.1,9,10,38-41 Subclinical cardiotoxicity, detected by conventional 
echocardiography, is more common and might occur in 20% to 75% of the patients; this prevalence 
varies greatly among different studies.2,7,9,10,12,33,36,42 A threshold as low as 300 mg/m2 is suggested 
for the development of late asymptomatic left ventricular dysfunction.43 However, this is not 
supported by subclinical endomyocardial biopsy abnormalities, which are already seen at 
cumulative doses higher than 240 mg/m2.44 An individual sensitivity and threshold for anthracycline 
cardiotoxicity is apparent from very early in the treatment.3
Two-dimensional echocardiography in late survivors treated with anthracyclines may reveal 
cardiac enlargement and diffuse hypokinesis.4 The predictive value of tests for regional vs. global 
left ventricular dysfunction is expected to be quite different. Tissue Doppler imaging, another 
noninvasive echocardiographic technique, is used to measure regional myocardial wall motion 
velocity. It might be of particular importance in the early detection of local abnormalities (i.e., 
before any change is apparent in global function measurements). Relaxation properties of the 
myocardium are complex and involve intrinsic properties of the heart (such as active and passive 
myocardial stiffness), in addition to other factors (such as right ventricular pressure, pericardial 
pressure, pleural pressure, etc.). Contrary to standard Doppler echocardiography, TDI can measure 
myocardial tissue velocity, which directly reflects contractile and relaxation properties of the 
myocardium.45 Recently, this technique was applied for detecting subclinical myocardial damage in 
otherwise apparently normal children who received moderate doses of anthracyclines for treatment 
of childhood malignancy.33 Peak late diastolic myocardial velocities, as well as transmyocardial 
systolic and diastolic velocity differences were significantly lower in those late survivors.
In our present study, we used both echocardiographic techniques to enhance the diagnosis of 
subclinical anthracycline-induced cardiotoxicity. To illustrate the discriminative ability of the 
different echocardiographic techniques, ROC curves were plotted (Fig. 2). The best discriminative 
ability (C-index = 89.2%, d  = 1.66) could be achieved using both echocardiographic techniques 
simultaneously. Both C-index and d  emphasize the additional diagnostic value of the TDI technique 
as compared to the conventional echocardiography (Table 2).
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It is thought that occult cardiac abnormalities may progress to a more permanent form of 
myocardial disease, resulting in cardiomyopathy, which may progress to chronic heart failure. 
Unfortunately, none of the methods of screening for anthracycline cardiotoxicity has been shown to 
be adequately predictive of late cardiac outcomes. In many studies, the outcome variable of interest 
is the presence or absence of some condition, such as having a subclinical cardiomyopathy. 
Frequently, however, data are collected on many different variables. In our present study, we 
present a regression model in which the outcome (S-score) is expressed as a combination of selected 
echocardiographic variables. As shown in Fig. 3, the distribution of the S-score in the patient group 
is shifted to the right as compared to the control group.
The contribution of the different variables to the S-score (Table 3) is complex. A lower LV 
fractional shortening in the patient group is frequently reported by others.1,10 A slightly higher 
mitral valve blood flow velocity during early diastole in the patient group could be a sign of 
(pseudonormalization) diastolic dysfunction (cf., Sohn et al.),46 as do the lower systolic and 
diastolic TDI velocities (n = 2) selected from the long-axis view (cf., Faries et a l.)26 Using the 
apical 4-CV (n = 5), the median values of some wall velocities of the study group appear to be 
higher than those of the controls. This is also reflected in the sign of the regression coefficient. The 
contribution of the variable “basal IVS  in late diastole” may not be obvious because the median 
value found for both groups is almost identical. In a multivariate analysis, however, the 
combination of the whole set of variables is involved and univariate characteristics are not decisive 
for the contribution to the set (p = 0.005 in this particular case). The higher systolic velocity in the 
basal part of the IVS  and the late diastolic velocity of the distal part of the IVS  are not clearly 
understood. A more general observation from our study is that the myocardial velocities of the 
interventricular septum, and not only those of the left ventricular wall, seem to play an important 
role in the assessment of the subclinical echocardiographic abnormalities.
In the medical literature, the incidence of late echocardiographic abnormalities detected by 
conventional echocardiography increases with the duration of follow-up,9,12 higher cumulative 
doses of anthracyclines,9,12,37 higher rates of anthracycline administration,36 and mediastinal 
irradiation.7,12 Young age at the time of treatment,9,10 female gender,10 black race, presence of
37 38 9,12trisomy 21, exposure to amascarine, and early onset of cardiotoxicity ’ are all reported as risk 
factors for late-onset cardiotoxicity, but these factors are still controversial. In the present study, 
gender and age at start of chemotherapy were not independent predictors of the S-score. A higher 
cumulative dose of anthracyclines and a longer duration of treatment predicted independently a 
higher S-score (Table 4). We did not find a clear positive association between the duration of 
follow-up and S-score (p = 0.14). Other authors reported that the incidence of abnormal diastolic 
function was higher within the first 2 years after anthracycline therapy, but abnormal systolic 
function was detected more frequently later after treatment.47 Because both diastolic and systolic 
variables are involved in the S-score (Table 3), our results should not necessarily be interpreted as 
in other studies.
Our study suggests that chemotherapy with anthracyclines, even in low dosage (50 to 400 
mg/m2), is associated with increased incidence of subclinical cardiac abnormalities, as already 
reported by others.12,47 Treatment with digoxin, diuretics, and vasodilators can lead to complete 
clinical response when chronic heart failure is present.4,48 The right moment for supportive cardiac 
treatment in survivors without manifest heart failure has not yet been established. Our results could 
be used to unravel the effects caused by adjuvant therapeutic drugs on the diastolic and systolic 
function. A straightforward approach might be to use the S-score for risk stratification, as well as 
for follow-up of children treated with anthracyclines. This idea is illustrated in Fig. 4, where the S- 
score obtained for patients in the study group is plotted vs. the age at the time of the 
echocardiographic examination. When controlled for age, clear recognition of patients with S-scores 
higher than two SD (from the average S-score of the controls) becomes evident. The survivors in 
our study did not show an increase of the S-score with age, suggesting that the normal growth
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pattern of the heart is disturbed. An extrapolation of the S-scores to younger and older age groups 
might be attractive, yet the authors prefer to base any further conclusion on extended patient 
studies.
Assuming that patients with high S-score have limited cardiac reserve, their S-score should be 
frequently assessed and carefully evaluated during viral illness or surgical procedures. The 
discriminative ability of this simple and noninvasive S-score estimation to detect subclinical 
myocardial alterations may also facilitate prognostic stratification of asymptomatic cancer survivors 
for the timing of introducing supportive cardiac treatment. The clinical value of this score remains, 
nevertheless, to be established in a larger and a longer study.
Limitations
In our study we involved healthy children as controls. The possible additive effect of concurrently 
given chemotherapeutic agents on cardiotoxicity could not be ruled out.
By selecting 99 healthy, resting but nonsedated children, the values obtained in this study 
incorporate normal variations in physiologic loading conditions without pharmacological or 
physical manipulations, as reflected in the recorded measurements of blood pressure and heart rate. 
The use of a respiratory phase detector was not possible in this study. However, the strategy, of 
using the highest echocardiographic parameter value out of several measurements made during 
subsequent heart cycles was likely to minimize the variability due to the respiratory cycle.
The clinical value of the S-score has not yet been investigated by independent functional tests 
(e.g., stress test or cardiac output measurement). At the time of the present study, the new strain and 
strain-rate imaging techniques were not available for clinical use. Their introduction might further 
enhance the value of echocardiography by overcoming the limitations of the TDI technique (e.g., 
the dependency of the velocity measurements on the total movement of the heart).
To avoid interoperator variability, one cardiologist did all the studies. Therefore, observer bias 
might be involved in the estimation of exact parameter values, but not in the final regression (S- 
score) or performance studies (ROC, diagnostic index).
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ABSTRACT
Objectives. To determine retrospectively the best set of standard echocardiographic and/or tissue 
Doppler imaging (TDI) parameters needed for early discrimination of survivors of childhood cancer 
treated with anthracyclines from healthy controls.
Background. Previous studies have shown that TDI, in combination with standard 
echocardiography, is useful for the detection of sub clinical cardiotoxic effects in late survivors. 
Methods. The study comprised 140 subjects (43 patients, 97 volunteers), age range 4.4-16.0 y. The 
survivors received median cumulative dose of 180 (range 120-450) mg/m2 of anthracyclines, with 
mean follow-up of 2.1 (± 1.3) y. All underwent standard echocardiographic examination followed 
by TDI from long-axis and apical 4-chamber views (51 parameters). The multivariate discriminant 
S-score and correct classification probability (C-index) were used to measure the overall 
discriminative performance of conventional and TDI techniques separately and in combination. 
Results. Based on univariate analysis, mainly the diastolic tissue velocities were significantly 
different between the survivors and the controls. In multivariate analysis, the overall discriminative 
performance of the standard echo-Doppler parameters was C = 67.7% (with the fractional 
shortening as the only selected parameter), that of the TDI C = 92.1%. The best set of parameters 
needed for the discrimination of the patients from the controls included systolic and diastolic (TDI) 
myocardial wall velocities (n = 7), mainly of the interventricular septum (IVS). The distribution of 
the S-score was significantly different between the survivors and the controls (p < 0.001), 
particularely at younger age.
Conclusions. TDI is superior to the standard echocardiography for the discrimination of 
asymptomatic survivors (from the controls) even early after receiving moderate doses of 
anthracyclines. Diastolic (and systolic) myocardial velocities, mainly from the IVS, are needed for 
this multivariate discrimination.
Keywords: Anthracyclines; Cardiotoxicity; Children; Discriminative ability; Echocardiography; 
Tissue Doppler imaging.
Condensed abstract
Forty-three asymptomatic early survivors of childhood cancer treated with moderated doses of 
anthracyclines, and 97 healthy children, underwent standard echo-Doppler and tissue Doppler 
imaging (TDI) examinations. Based on univariate analysis, mainly the diastolic velocities were 
significantly different between the survivors and the controls. The discriminative ability (C-index) 
of early asymptomatic survivors from controls was higher using the TDI technique (C = 92.1%) 
than the standard echocardiography (C = 67.7%). TDI parameters selected in this multivariate 
analysis were mainly diastolic myocardial velocities from the interventricular septum.
INTRODUCTION
Acute and subacute cardiotoxicity, which can occur immediately after a single dose of 
anthracyclines, during or short after completion of therapy, are uncommon under the current 
treatment protocols (cum. dose <300 mg/m2).1,2 A high maximal dose, or cumulative dose of 
anthracyclines (>550 mg/m2), female sex, black race, presence of trisomy 21 and treatment with 
amascarine increase the risk for early anthracycline-associated cardiotoxicity.3 The occurrence of 
early cardiotoxicity is considered as one of the major risk factors for developing late 
cardiotoxicity.4-6 Most studies report a prevalence of (late) subclinical cardiac abnormalities 
between 20% and 75%, thus this prevalence varies greatly within different studies.2,4-6 These 
abnormalities include parameters of increased afterload, decreased contractility, or both, seem to be
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progressive and can eventually lead to heart failure.2 The incidence of severe echocardiographic 
abnormalities increases with the duration of follow-up.1,6 These findings indicate that the full extent 
of the problem has yet to unfold in many asymptomatic patients. Thus, progressive, irreversible 
cardiomyopathy (late cardiotoxicity) is the dose-limiting factor of these otherwise widely used, very 
potent anticancer drugs.
Different methods of cardiac evaluation have been described in many publications. Almost 
each significant report was disapproved by other ones, making its clinical significance 
controversy.1,2 According to the recommendations of the Cardiology Committee of the Children's 
Cancer study group,7 standard echocardiography plays the main role in the non-invasive monitoring 
for anthracycline cardiotoxicity. Unfortunately, none of the studies cited in developing these 
recommendations, when used for guidance in dose modification have proven to have positive effect 
on the overall morbidity and mortality.8 Therefore, the need for a new screening method that would 
enhance the prediction of early and late cardiac outcomes still exists.
The contribution of tissue Doppler imaging (TDI), another parametric non-invasive 
echocardiographic method, to the diagnosis of subclinical myocardial damage was recently reported 
by us in long-term survivors (median 7.1 y, range 3.5-13.5 y after end of therapy) of childhood 
cancer treated with moderated doses of anthracyclines.9 The use of TDI, in combination with the 
standard echocardiography, seems to improve the discrimination of asymptomatic late survivors 
from healthy controls.10 The applicability of TDI to detect sub-clinical myocardial abnormalities in 
apparently healthy children shortly after treatment with moderate doses of anthracyclines was yet to 
be revealed.
Conventional echo-Doppler examination determining wall motion and cavity volume changes 
yields a different set of parameters than wall velocity measurements available from the TDI 
technique. To facilitate the use and interpretation of the data assessed from both techniques, we 
have previously employed discriminant score (S-score) analysis.10 The aim of the present study was 
to determine retrospectively a useful set of conventional echocardiographic- and/or TDI parameters 
needed for discrimination of asymptomatic survivors from healthy controls, already in an early 
phase after receiving moderated doses of anthracyclines. The potential influence of subject 
characteristics (gender and age), respectively treatment characteristics (age at start of 
chemotherapy, cumulative dose of anthracyclines, duration of treatment and duration of follow-up) 
on the S-score was studied.
PATIENTS AND METHODS 
Study population
All survivors of childhood cancer (in remission), in the age range of 4-18 years, who were treated 
with anthracyclines in the last 5 y before the present study took place, were recruited from our 
outpatient’s clinics and asked to participate in this study. Forty-three survivors and their parents 
gave an informed consent. This group of early survivors included 27 (63%) boys and 16 (37%) 
girls, mean (± SD) age of 9.9 (±3.1) y, with mean (± SD) body surface area of 1.17 (± 0.27) m2. 
Patient information was obtained by medical record review. The children were treated for leukemia 
(n = 21), lymphoma (n = 13), and solid tumors (n = 9), with a median cumulative dose of 180 
(range 120-450) mg/m2 of anthracyclines. The mean (± SD) age of the patients at start of therapy 
was 7.1 (± 3.3) y, with a mean (± SD) follow-up period of 2.1 (± 1.3) y after treatment with 
anthracyclines had been completed. All patients received anthracyclines as part of combination 
chemotherapy; other chemotherapeutic agents used included vincristine, methotrexate, etoposide, 
cyclophosphamide and cisplatin. No patients underwent mediastinal or spinal irradiation. None of 
the patients had symptomatic cardiovascular disease, ischemic heart disease, or cardiomyopathy
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before receiving anthracyclines. None of the patients had suffered from rhythm disturbances or 
from symptomatic congestive heart failure after therapy.
The physical examination revealed normal cardiac findings in all patients. The echocardiographic 
measurements of 97 of 160 healthy children11 were incorporated in this retrospective study, after 
balancing for age and gender distribution. The control group included 61 (63 %) boys and 36 (37 
%) girls, mean (± SD) age of 9.9 (±3.0) y, with mean (± SD) body surface area of 1.17 (± 0.28) m2. 
This protocol had institutional review board approval.
Methods
Both the conventional echocardiographic study and tissue Doppler imaging were carried out during 
each examination with the "Powervision" echographic scanner (model SSA-380A software version
2.5 0ER000, Toshiba, Nasu, Japan). A 5-MHz phased array sector transducer was used.
The same experienced pediatric cardiologist who was assisted by a sonographer performed all 
echocardiographic examinations. Before the TDI measurements were performed, the children 
underwent a detailed standard echocardiographic examination (see next section). 
Electrocardiographic recordings were made simultaneously with the ultrasound images. The 
children did not receive sedation, and all were shown to have normal sinus rhythm and regular 
breathing pattern at the time of study. To reduce the influence of respiration on myocardial 
velocities (and since the fact that breath hold is not feasible in young children), three cardiac cycles 
were recorded and the cycle with the highest velocities selected from each sampled region for 
further analysis.
Standard echocardiographic study
As the images were evaluated, on-line M-mode measurements were made at the level of the tips of 
the mitral valve leaflets in the parasternal long-axis view of the left ventricle. Standard parameters 
measured were: left ventricular dimensions in systole and diastole, right ventricular anterior wall 
(RVAW) thickness in systole and diastole, interventricular septum (IVS) and left ventricular 
posterior wall (LVPW) thickness in diastole. Left ventricular fractional shortening was calculated 
from the left ventricular dimensions. Using the apical four-chamber view with spectral Doppler 
sampling performed at the mitral leaflet tips, peak early (E) and late (A) diastolic blood ffow 
velocities of mitral inflow were measured, and the E:A ratio was calculated. The mean heart rate 
was obtained from three to five successive cardiac cycles.
Tissue Doppler imaging
Using M-mode TDI from parasternal long-axis view, we measured peak myocardial velocities of 
the ventricles during systole, early and late diastole (after atrial contraction). The peak myocardial 
velocities were obtained at standardized sites: the RVAW, the right ventricular side of the IVS, the 
left ventricular side of the IVS, and both the endocardial and epicardial sides of the LVPW 
(LVPWendo and LVPWepi, respectively) at the level of the mitral valve leaflets (Fig. 1).
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Fig. 1 TDI M-mode obtained along a scan line at the level of the mitral valve leaflets.
In systole, left ventricular posterior wall (LVPW) moves toward the transducer (red to 
yellow color), whereas the septum (IVS) moves away from it (blue to green).
Reversed movements are seen in early and late diastole. IVSR and IVSL = left
and right sides of the IVS. LVPWendo and LVPWepi = endocard and epicard of the LVPW.
The peak wall velocity was expressed as positive when movement was towards the transducer 
and negative for movement away from it. Tissue Doppler imaging was also obtained from apical 
four-chamber view (4-CV). After visualization of a color-coded signal, single-gated TDI wall 
velocity measurement was performed (with 5-MHz transducer frequency and a sample gate size of
2 or 3 mm) and a velocity-time display was registered. Care was taken to aim the ultrasound beam 
along the IVS and both right and left ventricular free walls (RVW and LVW, respectively) to 
minimize the angle of incidence between the ultrasound beam and the longitudinal direction of the 
wall motion. We assessed longitudinal peak velocities during systole, early and late diastole, within 
the basal, mid and apical parts of the RVW, interventricular septum (IVS) (Fig.2), and LVW. These 
velocities were expressed as positive or negative when moving towards the transducer, or away 
from it, respectively.
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Fig. 2 Pattern of single-gated TDI at basal part of the IVS. S, De and Da = systolic, early and late 
diastolic myocardial velocities
Statistical analysis
The two-sample Student's t-test was used to compare the left ventricular size, wall thickness, 
fractional shortening, and mitral valve blood flow velocities of the study group with those obtained 
from the controls.
All TDI measurements are presented as median, 5th and 95th percentiles. After logarithmic 
transformation of the absolute TDI data (except for the transmyocardial velocity differences), the 
myocardial velocities of the patient group were compared with the data obtained from the controls, 
again using the two-sample Student's t-test. In the long-axis view, the transmyocardial velocity 
differences across the IVS and LVPW during systole, early and late diastole were compared with 
those obtained from the controls by the Mann-Whitney test.
To determine a diagnostic index score (S) that could classify children in early survivors and control 
group, a logistic discriminant analysis based on logistic regression analysis (see Appendix) was 
carried out (SAS -procedure LOGISTIC). By means of the S-score, one can predict the probability 
that an individual with characteristics {x^..., xj} will belong to the patient group. In the logistic 
regression analysis, patients received code 1 and controls code 0. Variables that contributed 
significantly to the diagnostic index score were selected, applying stepwise selection. The 
significance levels for entry and for stay in the model were chosen to be 0.05.
Five discriminant scores (S-scores) were calculated successively from the following sets of 
echocardiographic variables: conventional echo-Doppler (n = 10), TDI long-axis view (n = 15), TDI
4-CV (n = 26), TDI total (n = 41), and a combination of both conventional echo-Doppler with TDI 
technique (n = 51). Because it has been reported that the TDI parameters are not Gaussian 
(normally) distributed,11 the natural logarithm of the absolute value of these parameters was 
calculated and used in the statistical analysis. Based on the S-scores, the effectiveness of 
discrimination was measured both by the C-index (see below) and the generalized distance (d) 
between the distribution of S-scores in the patient and the control group (see Appendix). The area 
under the receiver operating characteristic curve was defined as the C -index. A C -index of 100% 
indicates the ability to make a perfect prediction based on the discriminant S-score. A C -index of
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50% indicates that the predictions based on the discriminant score S are comparable to the results 
by pure chance (no discriminative ability, d  = 0).
After identifying the set of parameters with the best discriminative ability and calculating the 
corresponding regression coefficients, the distributions of the S-scores of children in the study 
group (early survivors) and the control group were assessed and compared by the two-sample 
Student's /-test.
The potential influence of subject characteristics (gender and age), respectively treatment 
characteristics (age at start of chemotherapy, cumulative dose of anthracyclines, duration of 
treatment and duration of follow-up) on the S-score was studied by using two separate multiple 
linear regression analyses. Because the treatment might have influence on the weight or body 
surface area, these variables were not included in the regression analysis. The examination on 
subject characteristics was carried out both for patients and controls. In addition, the parallelism of 
the regression of the S-score on age for both groups was tested by a joint linear regression analysis 
without accounting for gender.
For all statistical tests, a p-value of 0.05 or less was considered to be significant.
RESULTS 
Standard echocardiographic study
Standard echocardiographic results are summarized in Table 1. The diastolic thickness of the IVS 
was slightly, yet significantly increased within the early survivors (p < 0.05). LVPW thickness did 
not differ significantly between the patient and the control groups, nor did the LV dimensions. The 
calculated left ventricular fractional shortening was significantly decreased as compared with the 
controls (p < 0.001), yet only one patient had a value lower than 28%. The thickness of the right 
ventricular anterior wall was slightly but significantly decreased, both in systole and diastole p  < 
0.05). The mitral valve blood flow velocities did not differ significantly between the patient and the 
control groups, nor did the calculated E:A ratio.
Table 1. Standard echocardiographic results
Study group (n = 43) 
Mean (± SD)
Control group (n = 97) 
mean (± SD) p-value
IVS thickness (mm) * 5.6 (10) 5.3 (10) 0.04
LVPW thickness (mm) * 5.6 (10) 5.3 (0.9) 0.10
LVDD (mm)1 41.3 (3.9) 42.7 (4.3) 0.07
LVSD (mm)* 27.3 (3.0) 27.0 (3.4) 0.63
Fractional shortening (%) 33.9 (4.4) 36.8 (4.8) 0.0008
RVAW thickness (mm)* 1.9 (0.6) 2.1 (0.5) 0.03
RVAW thickness (mm)* 4.0 (11) 4.4 (10) 0.04
MV max. E wave velocity (cm/s) 88 (15) 88 (18) 0.89
max. A wave velocity (cm/s) 44 (13) 41 (13) 0.16
E/A ratio 2.2 (10) 2.4 (0.9) 0.34
*Two-sample Student's /-test. * In systole, * in diastole. IVS = interventricular septum; LVPW = left 
ventricle posterior wall; LVDD = LV diastolic diameter; LVSD = LV systolic diameter; RVAW = right 
ventricle anterior wall; MV = mitral valve.
Tissue Doppler imaging and cardiotoxicity in children treated with anthracyclines 95
Tissue Doppler imaging
Adequate 2-D (B-mode) color-coded and M-mode TDI images, as well as single-gated tissue 
Doppler tracings could be easily obtained from all subjects, using the long-axis view (radial 
myocardial wall velocities). During systole, the peak wall velocities of the RVAW and both sides of 
IVS are negative. At the same heart phase, the peak wall velocities of the LVPWendo and 
LVPWepi are positive, since the LVPW is contracting towards the cavity of the LV. During early 
and late diastole, the peak wall velocities of the RVAW and IVS are positive; those of the LVPW 
negative. Consequently, during systole, the velocity difference is negative when the left side of the 
IVS is moving faster than the right side of the IVS (since both IVS velocities are expressed as 
negative), and is positive when the endocardium of the LVPW is moving faster than the epicardium.
Table 2. Median (with 5th and 95th percentiles) of peak myocardial velocities (cm/s) obtained 
from the TDI long-axis view (study group, n = 43)
Peak systolic 
wall velocity (S)
Peak early diastolic 
Wall velocity (De)
Peak late diastolic 
wall velocity (Da)
RVAW -2.1 (-0.9 -  -3.8) 2.8 (1.6 -  5.0) 1.0 (0.3 -  2.5)
IVSR -1.7* (-0.7 -  -3.5) 3.5 (2.1 -  6.3) 1
IVSL .2)-.7
"*00-2. 7* 3. - 7. 5) 1.5* (0.7 -  3.2)
LVPWendo 3.8 (3.1 -  5.1) 9.5 (-6.1 -  -14.4) -1.0* (-0.5 -  -1.8)
LVPWepi 2.1 (1.5 -  2.9) -3.3 (-1.3 -  -5.3) -0.6 (-0.2 -  -1.1)
Significant p-value (p<0.05) for the comparison with the normal controls (by Student's f-test, 
after logarithmic transformation of the absolute TDI data). ^Highly significant p-value (p < 0.01).
*Very highly significant p-value (p < 0.001). IVSR = right ventricular side of IVS, IVSL = left 
ventricular side ofthe IVS. LVPWendo = endocard of LVPW; LVPWepi = epicard of LVPW.
Table 2 presents median values (with 5th and 95th percentiles) of the peak myocardial 
velocities of the study group, obtained from parasternal long-axis view. These results show a wide 
range of peak wall velocities. The various cardiac phases have distinctly different peak myocardial 
velocities and different directions of wall motion. The early diastolic myocardial velocities are the 
highest. When compared to the TDI data obtained for the control group, the absolute peak systolic 
myocardial velocities were significantly decreased at both sides of the IVS (left side more than the 
right side). The absolute peak early diastolic myocardial velocities were only significantly 
decreased within the left side of the IVS. No differences in peak systolic and early diastolic 
myocardial velocities within the endocardium and epicardium of the LVPW were present. 
Furthermore, the absolute peak late diastolic myocardial velocities were significantly decreased in 
both sides of the IVS, as well as in the endocardium of the LVPW. The absolute transmyocardial 
velocity difference across the IVS was significantly decreased only during early diastole (Table 3). 
In the LVPW, the transmyocardial velocity difference was not significantly different between the 
early survivors and the controls.
Table 3. Median (with 5th and 95th percentiles) of the velocity differences (A, cm/s) across the IVS and 
LVPW obtained from the TDI long-axis view (study group, n = 43)
A S A De A Da
IVS (L-R) -1.0 (-0.2 -  -1.8) 1.0* (0.2 -  2.4) 0.4 (0.1 --  1.0)
LVPW (endo-epi) 1.6 (1.0 -  2.9) -6.2 (-3.1 -  -9.5) -0.4 (-0.1 -  -11)
*Highly significant p-value (p<0.01) for the comparison with the 97 healthy controls, based on Mann­
Whitney test.
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Using the 4-CV (longitudinal myocardial wall velocities), a wide range of peak wall velocities 
were assessed, again with the various cardiac phases having distinctly different peak myocardial 
velocities and different directions of wall motion. The peak late diastolic myocardial velocity in the 
apical part of the LV free wall could not be always assessed, and was therefore excluded from the 
further analysis. When compared to the TDI data (n = 26) obtained for the control group, the peak 
myocardial velocities were significantly different in 13 / 26 parameters (50%); 6 out of these 13 
were measured in IVS. Furthermore, an increased late diastolic myocardial velocity (Da) within the 
study group was found in 8 of the 13 parameters, and decreased early diastolic velocities in another
3 areas sampled.
Discriminant score
Five discriminant score functions S, based on respectively sets of variables from conventional echo­
Doppler, TDI long-axis view, TDI 4-CV, TDI total and a combination of both conventional echo­
Doppler with TDI technique, were determined. In Table 4, the number of selected variables and the 
discriminative performance of each score function, as expressed by the C-index (area under the 
receiver operating characteristic curve) and the generalized distance (d), are given.
Table 4. Overall performance (C-index and generalized distance) of discrimination between patients and 
controls for different sets of variables (on the basis of logistic regression analysis)
Technique
No. of entry 
variables No. of variables selected
C-index
(%)
Generalized 
distance d
Conventional ED 10 1 (SF%) 67.7 0.63
TDI long-axis view 15 3 (1 systolic, 2 diastolic) 72.5 0.84
TDI 4-CV 26 3 (all diastolic) 87.0 1.49
TDI total 41 7 (2 systolic, 5 diastolic) 92.1 1.81
Conventional + TDI 51 7 (see above TDI total) 92.1 1.81
Conventional ED = conventional echo-Doppler cardiography; TDI = tissue Doppler imaging; 4-CV = apical 
four-chamber view. A stepwise selection procedure with p  = 0.05 as level of significance for entry and for 
stay has been applied.
Convenfional echo-Dopplerparamefers
A set of 10 echo-Doppler cardiographic variables was included in this analysis. Only one variable, 
namely the left ventricular fractional shortening, was selected by the logistic discriminant analysis. 
This variable contributed most significantly to the diagnostic index score S . The C -index was 
67.7%, and the generalized distance d  was 0.63 (see Table 4).
Tissue Doppler imaging paramefers (LV long-axis, 4-CV and fofal TDI paramefers)
A total of 41 variables were included in the data set of the TDI: 15 variables obtained from the LV 
long-axis view and 26 variables obtained from the apical 4-CV. Three of the 15 variables were 
selected by the logistic discriminant analysis, while using the TDI method from the long-axis view 
solely (Table 4). For a diagnostic index score S based only on the TDI 4-CV data set, 3 of the 26 
variables were selected. When combining both views, 7 variables of the total TDI data set (n = 41) 
were selected. Within the TDI method, the variables obtained from the 4-CV revealed a higher 
discriminative performance than that obtained from the long-axis view (C = 87.0% vs. C = 72.5% 
and d  = 1.49 vs. d  = 0.84, respectively) (see Table 4). An even higher performance was obtained 
using both views simultaneously (C = 92.1%, d  = 1.81).
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Convenfional echo-Doppler and fissue Doppler imaging paramefers
Seven of 51 variables were selected by the stepwise analysis for the discrimination between patients 
and controls; these 7 variables being only TDI parameters. Thus, combining conventional echo­
Doppler and tissue Doppler imaging techniques resulted in the same index score and overall 
discriminative performance (C = 92.1% and d  = 1.81, corresponding to a sensitivity and specificity 
of over 80%) as was achieved by using the tissue Doppler imaging technique solely.
The characteristics of these seven variables selected for the discriminative score S  are described in 
Table 5. The discriminative score S  is calculated as follows:
S = -5.25 - 3.38 * ln | IVSL m systole I - 1.02 * ln | LVPWepi in late diastole I + 5.24 * ln |m id  IVS m 
systole I - 5.33 * ln I mid IVS in early diastole |-  3.61 * ln | distal IVS in early diastole I + 8.62 * ln
[ distal IVS in late diastole | + 3.14 * ln | distal LV"W in early diastole |
Table 5. The characteristics of the discriminant score S in the controls (n = 97) and the study group (n = 43), using 
both echocardiographic techniques simultaneously___________________________________________________________
Technique Selected variable
Confrols 
Median (5fh; 95fh 
percenfiles)
Study group
Median (5fh; 95fh 
percenfiles)
Regression 
coefficienf(± SE) *
Intercept (b0) -5.25 (5.2)
TDI long axis view 3IVSL in systole* -3 .2  (-4 .6 ;-2 .1 ) -2.8 (-4.2;-1.7) -3.38 (1.17)
(n = 2) 5LVPW epi in late diastole* -0 .7  (-2 .5 ;-0 .2 ) -0.6 (—1.1;—0.2) -1.02 (0.44)
TDI 4-CV 6mid IVS in systole* 6.0 (4.8;7.5) 6.4 (5.1;7.4) +5.24 (2.32)
(n = 5) 2mid IVS in early diastole* -13.3 (-16.9;-9.2) -12.2 (-15.9;-7.8) -5.33 (2.19)
7distal IVS in early diastole* -9.1 (-13.2;-6.0) -8 .4  (—11.4;—5.1) -3.61 (169)
'distal IVS in late diastole* -3.6 (-5.0;-2.4) -4.3 (-5.8;-3.3) +8.62 (2.0)
4distal LVW in early diastole* -10.6 (-15.3;-6.3) -11.2 (-14.8;-8.2) +3.14 (1.22)
Stepwise logistic regression analysis, SLE=SLS=0.05.
* Based on natural logarithm of (absolute value of) peak myocardial velocities. 1-7 = order of entry in the stepwise 
analysis. IVSL = left ventricular side of interventricular septum; LVPW epi = epicard of left ventricular posterior wall; 
IVS = interventricular septum; LVW = left ventricular free wall; * peak myocardial velocities [cm/s], before the natural 
logarithm is used.
In the above formula for calculating the S-score, a plus sign refers to a positive contribution of 
the variable, and the reverse for the minus sign.
The distribution of the estimated index score S  in the study group (early survivors) and the 
control group is plotted in Fig. 3. The distribution of this diagnostic score is significantly different 
between both groups (p < 0.001).
Gender had no independent influence on the S-score, both for the patients and the controls (p = 
0.57). A positive relationship between the S-score and age was found in the control group; an older 
age at the time of the echocardiographic examination resulted in a significantly higher S-score (p = 
0.03) (Fig. 4). On the contrary, no independent significant relation between the S-score and age 
could be shown in the patient group (p = 0.26). The slopes of the regression lines for both groups 
were significantly different (p = 0.03) according to a joint regression analysis without accounting 
for gender.
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Fig. 3. The distribution of the diagnostic index score S’ in the 
controls (n = 97) and the patient group (n = 43)
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Fig. 4. The relationship between the S-score and age at the time of the echocardiographic examination. 1 = study 
group; 2 = control group;
Age at start of chemotherapy, cumulative dose of anthracyclines, duration of treatment and duration 
of follow-up had no independent influence on the S-score (p = 0.20, 0.17, 0.14 and 0.79, 
respectively).
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DISCUSSION
A n th racy c lin es a re  p o ten t d rugs in  the  m an ag em en t o f  ch ild h o o d  cancer. S u b clin ical ab n o rm alitie s  
o f  the  left v en tricu la r structure  an d  fu n c tio n  are v ery  co m m o n  y ears  a fte r therapy .2’5 It is " . ..o f te n  
p rogressiv e , p o ten tia lly  severe  an d  som etim es fa ta l" .4 T he challenge  o f  cu rren t day trea tm en t o f  
ch ild h o o d  m alig n an cy  lies in  fin d in g  a b a lan ce  b e tw ee n  m ax im iz in g  the  therap eu tic  e fficacy  w h ile  
m in im iz in g  the  r isk  o f  acu te  an d  late  un d esirab le  side e ffec ts o f  the  treatm ent.
T he m o st co m m o n  ech ocard iog raph ic  p a ram ete r rep o rted  in  the  early  d e tec tio n  o f  
card io tox ic ity  w as a  d ecrease  o f  th e  frac tiona l sh o rten ing  o r th e  left v en tricu la r e jec tio n  frac tio n .1 
U sin g  th is echocard io g rap h ic  tech n iq u e  in  o u r early  surv ivors, w e  co n firm ed  d ecreased  frac tiona l 
sho rten in g  as co m p ared  w ith  h ealth y  con tro ls (T ab le  1). N o  o th er d iasto lic  L V  ab n o rm alitie s  w ere  
found. H o w ev er, standard  echocard io g rap h ic  m o n ito rin g  stud ies du rin g  an d  shortly  a fte r co m p le tio n  
o f  an th racy c lin e  trea tm en t fa iled  to  p red ic t th e  in cidence  o f  p a tien ts  w ith  late  asy m p to m atic  card iac  
d y sfu n c tio n .12
T issue  D o p p le r im ag in g , an o th er n o n -in v as iv e  ech o card io g rap h ic  tech n iq u e , is u sed  to  m easu re  
reg io n a l m y o card ia l w a ll m o tio n  ve lo c ity  w h ic h  d irec tly  re flec ts  con tractile  an d  re lax a tio n  
p rop erties  o f  the  m y o ca rd iu m .13-16 It m ig h t b e  o f  p a rticu la r im p o rtan ce  in  the  early  de tection  o f  
m y o card ia l ab norm alities, i.e. a lready  b e fo re  s ig n ifican t ch an g e  is a p p aren t in  g lo b al fu n c tio n  
m easu rem en ts. Its u se fu lln ess  is freq u en tly  rep o rte d  in  adu lts , m a in ly  in  p a tien ts  w ith  coronary
17 1 8 *  * 1 9  20 * 21arte ry  d isease, ’ card io m y o p a th ies, ’ an d  afte r surg ical rep a ir o f  te tra logy  o f  Fallo t. A lth o u g h  
n o rm al m y o ca rd ia l v e lo c ities  have  a lready  b een  a ssessed  in  c h ild ren ,11,22 little  is k n o w n  ab o u t the  
c lin ica l ap p lica tio n  in  th is  p o p u la tio n  group. R ecen tly , w e  rep o rted  th a t p eak  la te  d iasto lic  
m y o card ia l v e lo c ities  a lo n g  th e  rad ia l ax is o f  the  h e a rt w ere  sign ifican tly  lo w er in  late  surv ivors o f  
ch ild h o o d  can cer w ho  rece iv ed  m o d era te  doses o f  an th racy c lin es.9 In  th e  p re sen t study , th e  sam e 
p ro to co l w as ap p lied  to  early  asy m p to m atic  survivors. D ecreased  abso lu te  p e ak  systo lic  an d  early  
d iasto lic  m y o card ia l velocities , m ain ly  o f  the  left side o f  the  I V S have  b e en  de tected  (u sin g  the  
lo n g -ax is v iew ). T he abso lu te  p e ak  late  d iasto lic  m y o card ia l v e lo c ities  sh o w ed  no  sign ifican t 
d ifference  w h e n  co m p ared  w ith  the  contro ls. A s w ith  the  late  su rv ivors, no  d ifference  in  the  
ab so lu te  p e ak  systo lic  an d  early  d iasto lic  m y o card ia l v e loc ities w ith in  th e  e n d o ca rd iu m  and  
ep icard iu m  o f  th e  L V P W  w ere  p resen t, em p h asiz in g  th e  m ajo r ro le  o f  th e  in te rv en tricu la r sep tum , 
ra th e r th an  the  L V P W  in  the  p a th o g en esis  o f  the  card io tox ic ity . F u rth e rm o re , in  th e  early  survivors, 
th e  ab so lu te  tran sm yocard ia l ve loc ity  d ifferen ce  across the  IV S w as sign ifican tly  d ecreased  only 
du rin g  early  d iasto le . In  the  late  su rv iv o rs,9 the  abso lu te  tran sm yocard ia l v e loc ity  d ifferences across 
th e  IV S  w ere  d ecreased  in  all th ree  h e a rt p h ases, w h ich  m ay  rep re sen t a  m o re  ad v an ced  stage o f  the  
(subclin ical) card iom yopathy . D ecreased  transm y o card ia l v e loc ity  g rad ien ts , m ain ly  in  the  L V P W ,
12 23 25w ere  a lso  re p o rte d  in  adu lts w ith  h y p ertro p h ic  an d  d ila ted  card iom yopath ies. U s in g  th e  ap ical
4 -C V  (long itu d in a l ve lo c ities), 13/26 (50% ) T D I p a ram ete rs  w ere  sta tis tica lly  d ifferen t b e tw een  the  
su rv ivo rs an d  the  con tro ls. T h is very  p ro m is in g  re su lt is n ev erth e less  n o t very  h e lp fu l fo r an  easy 
d isc rim in a tio n  b e tw een  th e  tw o  groups. H o w ev e r, m o s t abnorm alities w ere  a lso  d e tec ted  w ith in  the  
IV S , w ith  m y o card ia l v e lo c ities  du rin g  (early  an d  late) d iasto le  p lay in g  a m ajo r role.
T rea tm en t w ith  an th racy c lin es m ay  n ecessita te  life long  m o n ito rin g  o f  the  patien t. B a esed  on 
the  m y o card ia l veloc ities , w e  fo u n d  th a t T D I a llo w s early  d isc rim in atio n  o f  su rv ivo rs fro m  healthy  
contro ls. T he au tho rs p ro p o se  to  include  th e  S -score  in  the  ech o card io g rap h ic  m o n ito rin g  program . 
A ssu m in g  th a t p a tie n ts  w ith  h ig h  S -score  hav e  lim ited  card iac  reserv e , th e ir  S -score  sh o u ld  be  
freq u en tly  asse ssed  a n d  care fu lly  ev a lu a ted  d u rin g  v ira l illness, p reg n an cy  o r su rg ical p rocedures. 
T he c lin ica l v a lu e  o f  th is score  rem ains, n ev erth e le ss , to  be  e s tab lish ed  in  a  la rg e r study  popu la tio n , 
as w e ll as track in g  th e  ch an g es ag a in st th em se lv es  (a lo n g itu d in a l study), in  o rd e r to  de te rm in e  a 
sm alle r n u m b er o f  ta rg e t m easu rem en ts  on  w h ich  a a lin ic ian  can  focus h is  ex am ination .
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Limitations
In our study we involved healthy children as controls. Therefore, the possible additive effect of 
concurrently given chemotherapeutic agents on cardiotoxicity can not be ruled out.
The clinical value of the S-score has not yet been investigated by independent functional tests, 
e.g., stress test or cardiac output measurement. At the time of the present study, the new strain and 
strain rate imaging techniques were not available for clinical use. Their introduction might further 
enhance the value of echocardiography by overcoming the limitations of the TDI technique, e.g., 
the dependency of the velocity measurements on the total movement of the heart.
Also, to avoid inter-operator variability, one cardiologist did all the studies. Therefore, observer 
bias might be involved in the estimation of exact parameter values, but not in the final regression 
(S-score), or performance studies (C-index).
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APPENDIX
1. The logistic regression model was defined as:
loge [p/(1-p)] = S  = bo + biXi+...+bjXj,
Where S  = the diagnostic index score, p  = the probability that an individual with characteristic x¡,..., 
Xj will belong to the patient group (anthracycline-induced cardiotoxicity), x¡,..., Xj = 
echocardiographic data, and b o , . ,  bj = regression coefficients.
2. The generalized distance (d) was defined as:
d  (^ patients - c^ontrols) / s
Where m = mean of the S-score in the patient group or the controls, and s  = square root of pooled 
variance of the S-scores of both groups.
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ABSTRACT
Background: Tissue Doppler Imaging (TDI) is a new non-invasive ultrasound technique that 
enables assessment of regional myocardial velocities. Previous study on survivors of childhood 
malignancies illustrated the presence of regional myocardial wall velocity abnormalities during 
diastole, many years after treatment with anthracyclines. The purpose of the present study was to 
investigate this phenomenon during and shortly after treatment.
Procedure: A total of 60 patients, age range 4.4-16.0 years, were included in this study: 43 early 
survivors, with a mean follow-up duration of 2.1 (range 0.3-5.2) years after end of anthracyclines 
therapy, were evaluated retrospectively. Seventeen other patients were evaluated before, during, and 
six months after end of anthracyclines therapy. All patients received moderate cumulative dose of 
anthracyclines (range 120-450 mg/m2). Echocardiographic examination was performed using 
conventional and TDI techniques, on transthoracic apical 4-chamber view.
Results: Of the early survivors, 26 (60%) demonstrated regional LV free wall velocity 
abnormalities. In the prospective group, serial echocardiographic studies revealed 3 patients (18%) 
with regional LV free wall velocity abnormalities before start chemotherapy, 14 (82%) at the end of 
anthracyclines therapy. Six months later, however, the incidence decreased to 61% of the survivors. 
Subject and treatment characteristics, as well as LV wall diameters and shortening fraction 
measured by conventional echocardiography were not significantly different for children with or 
without this phenomenon. Regional wall velocity abnormalities, although less frequent, were also 
present in the interventricular septum.
Conclusions: Regional diastolic myocardial velocity abnormalities during and shortly after 
anthracyclines therapy are common, and sometimes transient. The authors recommend simultaneous 
use of both techniques for the monitoring of anthracycline-induced cardiotoxicity.
INTRODUCTION
Anthracyclines are potent drugs in the treatment of cancer. However, "late cardiotoxicity after 
anthracyclines therapy for childhood cancer is frequent, mostly subclinical, often progressive, 
potentially severe and sometimes fatal".1,2 The incidence of cardiotoxicity, as diagnosed by 
endomyocardial biopsy, can be as high as 85%.3,4 Because serial myocardial biopsies and cardiac 
stress testing are not practical in younger children, and radionuclide angiography is not appropriate 
for frequent application, the diagnostic approach of children suspected of anthracycline-induced 
cardiotoxicity is mainly based on non-invasive echocardiographic technique.5 Mild to significant 
left ventricular systolic and diastolic dysfunction, detected by standard echo-Doppler cardiography 
(e.g., decreased fractional shortening), has been frequently reported.6-11 With the current diagnostic 
methods, however, it remains difficult to select those patients who are at risk for developing severe 
or fatal cardiomyopathy.
A new non-invasive echocardiographic technique, namely Tissue Doppler Imaging (TDI), promises 
to further enhance the value of echocardiography. This technique enables (on-line) assessment of 
myocardial tissue velocity magnitudes and directions, along the radial and longitudinal axes.12,13 
Until now, it has been mainly applied to adults with ischemic heart diseases,14,15 
cardiomyopathies,16-18 rhythm disturbance,19 and to patients suspected for acute allograft rejection.20 
Determination of the normal pattern and magnitude of myocardial velocities in children has given 
an opportunity to apply this technique to the pediatric patients with congenital or acquired heart 
diseases.21 It has been used to localize the origin of premature beats in fetuses and children with 
various forms of arrhythmia.22 Regional right ventricular wall motion abnormalities were reported 
late after Tetralogy of Fallot repair.23
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Recently, the TDI technique was applied to detect subclinical myocardial damage in apparently 
normal children who received moderate doses of anthracyclines as part of the treatment for 
childhood cancer.24 Abnormal regional diastolic velocities of the left ventricular walls were 
detected in 20% of these late survivors. Currently, it is unknown whether these regional wall 
velocity abnormalities, which could not be detected with conventional echocardiography, are due to 
early or late cardiotoxic effects. The aim of this study is to investigate whether these LV wall 
velocity abnormalities also occur during and shortly after treatment with anthracyclines.
MATERIAL AND METHODS 
Patients
Between February 1999 and March 2001, two groups of patients were included in our present study: 
Group 1 (retrospective)
A single, retrospective, echocardiographic evaluation was carried out in survivors of childhood 
cancer, who were treated with anthracyclines 5 years or less before the present study took place. 
This group included 43 survivors (27 boys, 16 girls), mean (± SD) age of 9.9 (± 3.1) years, with 
mean (± SD) body surface area (BSA) of 1.17 (± 0.27) m2. The children were treated for leukemia 
(n = 21), lymphoma (n = 13), and solid tumors (n = 9), with a median cumulative dose of 180 
(range 120-450) mg/m2 of anthracyclines. The mean (± SD) age of the patients at start of therapy 
was 7.1 (±3.3) years, with a mean follow-up period of 2.1 (range 0.3-5.2) years after treatment with 
anthracyclines had been completed.
Group 2 (prospective)
A second, prospective, echocardiographic study was carried out in 17 newly diagnosed 
patients, admitted to our Division of Pediatric Hematology-Oncology, at the University Medical 
Center Nijmegen, who received anthracyclines as part of their treatment. This group included 11 
boys and 6 girls, mean (± SD) age at diagnosis of 10.0 (± 3.5) years, with a mean (± SD) BSA of
1.19 (± 0.36) m2. The children were treated for leukemia (n = 6), lymphoma (n = 9), and solid 
tumors (n = 2), with a median cumulative dose of 175 (range 150-432) mg/m2 of anthracyclines. In 
the prospective study, however, serial echocardiographic evaluations were done before start of 
chemotherapy (at the time of diagnosis), within 1 week after each dose of 50-60 mg/m2 of 
anthracyclines, and 6 months after end of anthracyclines therapy.
None of the patients had high fever or severe anemia at the time of the echocardiographic 
examination. We considered the sum of the cumulative doxorubicin and daunorubicin doses as the 
cumulative anthracycline dose. Two patients in group 2 received mitoxantrone; its therapeutically 
equivalent effect was considered as 4 times higher than other anthracyclines. All patients received 
anthracyclines infusions as part of combination chemotherapy. No patients underwent mediastinal 
or spinal irradiation before the last echocardiographic examination. Cardioprotectants and liposomal 
anthracyclines were not given. None of the patients had ischemic heart disease or cardiomyopathy 
before receiving anthracyclines. Pericardial drainage at diagnosis was done in a single prospective 
patient with symptoms of heart tamponade, before start of therapy. None of the patients had 
suffered from rhythm disturbances or from symptomatic congestive heart failure after therapy. The 
physical examination revealed normal cardiac findings in all patients but the one with tamponade. 
Written informed consent was obtained from all patients or their parents. The children were 
comforted by their parents, and could enjoy music or friendly video film during the examinations. 
The study was reviewed and approved by the institution's ethical committee on human 
experimentation.
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Methods
The conventional echocardiographic study and subsequent tissue Doppler imaging were carried out 
with the "Powervision" echographic scanner (model SSA-380A software version 2.5 0ER000, 
Toshiba, Nasu, Japan) while using a 5 MHz phased array sector transducer. The same, experienced, 
pediatric cardiologist who was assisted by a sonographer performed all echocardiographic 
examinations. Before the TDI examination was performed, the children underwent a detailed 
standard echocardiographic examination, including the following parameters: interventricular 
septum (IVS) end diastolic thickness, left ventricular posterior wall (LVPW) end diastolic 
thickness, LV end diastolic dimension (LVDD), and LV end systolic dimension (LVSD), all using 
M-mode echocardiography of the LV long-axis view. Left ventricular fractional shortening (FS%) 
was calculated from the left ventricular dimensions. Using the transthoracic parasternal apical 4- 
chamber view (4-CV), blood flow velocities over the mitral valve (Mitr-E and Mitr-A wave 
velocities) were measured, and E/A ratio calculated. Electrocardiographic recordings were made 
simultaneously with the ultrasound images. The children did not receive sedation, and all showed to 
have normal sinus rhythm and regular breathing pattern at the time of study. In order to reduce the 
influence of respiration on myocardial velocities (and for the fact that breath hold is not always 
feasible in young children), three cardiac cycles were recorded and the cycle with the highest 
velocity was selected for further analysis.
Tissue Doppler Imaging
The same Toshiba scanner was switched to TDI mode, thereby resulting in: 1) lowering of the 
velocity range (0 to 20.5 cm/s) to encode myocardial velocities; 2) changing of the image 
magnification to display optimally the region occupied by the moving cardiac wall under study; 3) 
setting of the Doppler receive gain to achieve maximum color Doppler information in the 
myocardium while suppressing the color appearing in the blood pool. The TDI software provided 
with the scanner was capable of displaying color-coded velocities of the myocardium as numerical 
data. After visualization of tissue Doppler images from the parasternal apical 4-CV (Figure 1), local 
single gated TDI wall velocity measurement was performed by positioning a sample gate, with a 
size of 2, or 3 mm, and a tissue velocity-time curve was registered at various locations. We assessed 
longitudinal peak velocities during systole, early- and late diastole (after atrial contraction), within 
the basal-, mid- and apical parts of the interventricular septum, and the LV free wall (Figure 2). 
These velocities were expressed as positive or negative when directed towards the transducer, or 
away from it, respectively. In systole, a positive velocity wave is detected, corresponding to the 
contraction and inward motion of the LV myocardium. The subsequent, bi-phasic, diastolic TDI 
pulsed waves are always negative and correspond to the relaxation outward motion of the LV 
myocardium (early- and late diastolic velocity, respectively). Therefore, a regional abnormal 
velocity was defined as a longitudinal myocardial movement opposite to the one expected from the 
study of the normal subjects during the diastolic phase of the heart cycle.21
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Fig. 1. Two-dimensional TDI images during systole (a) and diastole (b), using the apical 
4-chamber view. Assessment of myocardial velocities was done within the basal, mid and 
apical parts of the interventricular septum and LV free wall. RV = right ventricle; LV = 
left ventricle.
Regional cardiac wall velocity abnormalities during and shortly after anthracyclines therapy 109
E S O - 5  LI 
* ï» l! r  
B l £ 7*Ui i
' V  Tn«
R V  *  L V  -t  
>
P3 
De V
I / O
* /  7 *  
U . H b
LI
S t
L .
r V1
4 r  v LV
Mid LV free wall
Fig. 2. Patterns of single-gated TDI at mid position in the interventricular septum (IVS) (a) and LV 
free wall (b). Peak myocardial velocities in systole (S), early- (De) and late diastole (Da).
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Statistical analysis
Retrospective group
The children were divided into 2 subgroups: those with (group 1a) or without (group 1b) regional 
abnormal LV wall velocity. Differences in subject and treatment characteristics between both 
subgroups were assessed. Fisher's exact test was used for studying gender differences, Student's 
tests of two samples for the differences between both subgroups with respect to age at the time of 
the present echocardiographic study, weight, length, BSA, heart rate (HR), conventional 
echocardiographic parameters (LV wall thickness, dimensions, shortening fraction, mitral valve 
blood flow velocity during early and late diastole, and calculated E/A ratio), and myocardial wall 
velocities (TDI parameters). Because it was reported that the TDI parameters were not Gaussian 
(normally) distributed,21 the natural logarithm of the absolute values was inserted for the statistical 
analysis of the latter variables.
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Regarding the treatment characteristics, we examined whether the two subgroups were different 
with respect to age at start of chemotherapy and duration of follow-up period by the two-sample 
Student's test, and with respect to the cumulative dose of anthracyclines by the Mann-Whitney test.
Prospective group:
The 17 children were divided into subgroups: those with regional abnormal wall velocities in 
the LV free wall or IVS, and those patients without regional abnormal wall velocities. Serial 
echocardiographic studies were done before, during and shortly after end of anthracyclines therapy. 
However, because of the small size of the subgroups, the statistical analysis had to be limited. 
Comparison between the subgroups was done with respect to age (at the time of the present study), 
gender, BSA, cumulative dose of anthracyclines, as well as with respect to the same 
echocardiographic and TDI parameters as mentioned for the retrospective group. Similar tests were 
applied as mentioned above.
For all statistical tests a p-value of 0.05 or less was considered significant.
Results
Retrospective group
Assessment of standard echocardiographic parameters, followed by tissue Doppler imaging 
examination, was made from all 43 children (Group 1). Of these early survivors, 26 (60%) 
demonstrated regional LV free wall velocity abnormalities between early and late diastole 
(Subgroup 1a) (Figure 3). Seventeen (40%) survivors demonstrated normal regional wall velocities 
(Subgroup 1b). No significant differences in the distribution of age (at the time of the present 
study), gender, weight, length, BSA, HR, age at start of chemotherapy, duration of follow-up and 
cumulative dose of anthracyclines were found between the two subgroups (p > 0.10).
Data of the standard- and TDI echocardiographic parameters are summarized in Tables I and II, 
respectively.
Regional cardiac wall velocity abnormalities during and shortly after anthracyclines therapy 111
b
Fig. 3. Abnormal regional LV free wall velocity pattern between early and late diastole. 
(a) color-coded TDI image (see arrows), (b) two-dimensional and single-gated TDI 
(abnormalities indicated by arrows or astrix).
a
Table 1. Differences in standard echocardiographic parameters (retrospective group)
Subgroup 1a Subgroup 1b
(n=26) (n=17) p-value
IVS thickness (mm) * 5.8 ± 0.9 5.3 ± 1.0 0.08
LVPW thickness (mm) * 5.7 ± 0.8 5.4 ± 1.3 0.38
LVDD (mm) * 42.2 ± 3.8 39.9 ± 3.6 0.05
LVSD (mm) * 27.8 ± 3.1 26.5 ± 2.6 0.19
FS (%) ±4 5 33 ± 4 0.52
Mitr-E velocity (cm/s) ±8 14 86 ± 18 0.61
Mitr-A velocity (cm/s) 42 ± 10 47 ± 16 0.30
E/A ratio 2.3 ± 0.8 2.2 ± 1.2 0.76
Subgroup 1a = patients with LV cardiac wall velocity abnormalities. Subgroup 1b = patients 
without LV cardiac wall velocity abnormalities. IVS = interventricular septum; LVPW = left 
ventricle posterior wall; LVDD = LV diastolic diameter; LVSD = LV systolic diameter; * in 
end diastole; * in systole. FS = calculated LV fractional shortening. Mitr-E and Mitr-A = 
Mitral valve E and A wave velocities, respectively, Standard echocardiographic 
measurements presented as mean ± SD.
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Table 2. Differences in TDI parameters (retrospective group)
Subgroup 1a Subgroup 1b p-value 
(n=26)____________ (n=17)________________
IVS basal during systole 8.0 ± 1.1 8.4 ± 0.9 0.25
early diastole -13.8 ± 2.1 -14.8 ± 2.1 0.14
late diastole -6.3 ± 1.0 -7.1 ± 1.5 0.08
IVS mid during systole 6.3 ± 0.9 6.4 ± 0.8 0.51
early diastole -11.4 ± 2.3 -12.8 ± 2.4 0.07
late diastole -5.2 ± 0.9 -6.2 ± 1.3 0.005
IVS apical during systole 4.8 ± 0.8 4.8 ± 0.8 0.92
early diastole -8.2 ± 1.9 -8.6 ± 2.2 0.55
late diastole -4.1 ± 0.6 -4.6 ± 0.8 0.05
LVW basal during systole 10.3 ± 2.3 9.5 ± 2.0 0.18
early diastole -18.7 ± 2.6 -16.7 ± 3.2 0.02
late diastole -6.2 ± 1.3 -6.4 ± 1.2 0.73
LVW mid during systole 9.6 ± 2.1 -9.1 ± 2.2 0.42
early diastole -16.4 ± 2.8 -15.1 ± 3.0 0.15
late diastole -5.3 ± 0.9 -5.5 ± 1.5 0.84
alicpiaLVW during systole 8.9 ± 2.1 8.8 ± 1.8 0.86
early diastole -12.0 ± 2.4 -11.2 ± 2.6 0.29
Subgroup 1a = patients with LV cardiac wall velocity abnormalities. Subgroup 1b = patients 
without LV cardiac wall velocity abnormalities. IVS = interventricular septum; LVW = left 
ventricle free wall. TDI measurements presented as mean ± SD (in cm/s); p-value based on 
natural logarithm of (absolute) peak myocardial velocities.
Standard echocardiography (Table 1): IVS and LVPW thicknesses were within the normal 
range, and did not differ significantly between both subgroups, nor did the LVSD, mitral valve 
blood flow velocities and E/A ratio. Left ventricular end-diastolic diameter (LVDD) was slightly 
increased in the survivors with residual wall velocity abnormality (p = 0.05), yet no significant 
difference in the shortening fraction was found (34% in subgroup 1a, 33% in subgroup 1b).
M yocardial velocities (Table 2): the peak systolic and early diastolic myocardial velocities 
within the interventricular septum did not differ significantly between the subgroups. Peak late 
diastolic myocardial velocities within the interventricular septum were (nearly) significantly 
decreased (p = 0.08, 0.005 and 0.05 at the basal, mid and apical parts, respectively) in the survivors 
with regional LV free wall velocity abnormalities. Considering the myocardial velocities measured 
within the LV free wall, no significant difference was found between the two subgroups, except for 
an increased early diastolic myocardial velocity within the basal part (p = 0.02) in the survivors 
with regional wall velocity abnormalities.
Only two survivors (5%) presented with regional wall velocity abnormalities within the 
interventricular septum (Figure 4). Both children had shown to have regional wall velocity 
abnormalities within the LV free wall as well.
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Fig. 4. Abnormal myocardial wall velocity pattern within the mid part of the interventricular septum 
(IVS). (a): color-coded TDI image. (b): two-dimensional and single-gated TDI (abnormalities 
indicated by arrows or astrix).
Prospective group
Seventeen newly diagnosed patients (group 2) were incorporated in the prospective study. 
Assessment of standard echocardiographic parameters, followed by tissue Doppler imaging 
examination was obtained from all of the children before start of chemotherapy, during, and at the 
end of anthracyclines treatment. However, six months after cessation of anthracycline therapy, no 
echocardiographic study could take place in four patients because of death (1), relapse of the 
disease (2), and lack of cooperation (1).
Table 3 shows the number of patients with or without regional LV walls velocity abnormalities. 
Before start of chemotherapy, three patients (18%) demonstrated regional LV free wall velocity 
abnormalities between early and late diastole. Only one of these three patients had also regional IVS 
wall velocity abnormality (6%). At the end of anthracyclines therapy, 14 (82%) patients 
demonstrated abnormal regional LV free wall velocities, 6 (35%) patients with regional IVS wall 
velocity abnormalities. However, 6 months later, the frequency of regional wall velocity 
abnormalities decreased to 8 (61%) and 1 (8%) in LV free wall and IVS, respectively.
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Table 3. Number o f  patients with or without myocardial wall velocity abnormalities (prospective group)
LV free wall IVS Total
with without with without
Before start therapy 3 14 1 16 17
End of anthracyclines therapy 14 3 6 11 17
6 months after end of therapy 8 5 1 12 13
LV free wall = left ventricular free wall; IVS = interventricular septum, using the apical four-chamber 
view
Due to a small number of patients in one of the subgroups (before start of chemotherapy and at 
the end of anthracyclines therapy), statistical analysis of possible differences between presence and 
absence of LV free wall velocity abnormalities with respect to subject and treatment characteristics, 
as well as the echocardiographic parameters, has been limited to six months after end of 
anthracyclines therapy (n =8 and 5, respectively). No significant differences in the distribution of 
age (at the time of the study), gender, BSA, and cumulative dose of anthracyclines were found 
between the patients with LV free wall velocity abnormality or without it (p>0.60). Neither were 
significant differences observed with respect to the standard- and TDI echocardiographic 
parameters (p > 0.11).
Looking at the patients with or without IVS wall velocity abnormalities, statistical analysis 
could only take place at the end of anthracyclines therapy (n = 6 and 11 respectively). Again, no 
significant differences in the distribution of age (at the time of the study), gender, BSA, and 
cumulative dose of anthracyclines were found between the patients with IVS wall velocity 
abnormality or without it (p > 0.38). Neither were there significant differences with respect to any 
of the standard (e.g., fractional shortening, mitral valve blood flow velocities) and TDI 
echocardiographic parameters (p > 0.24).
Figure 5 illustrates the cumulative frequency of appearance of regional wall velocity 
abnormalities in the LV walls (both IVS and LV free wall) in relation to the cumulative dose of 
anthracyclines. During therapy, most of the abnormal regional cardiac wall velocities were already 
detected after low to modest cumulative dose of anthracyclines. Once an abnormality was detected, 
it could always be seen till the end of the anthracyclines therapy of that specific patient. Moreover, 
the probability of developing regional wall velocity abnormality in the LV walls during treatment 
was 79% for the LV free wall (95%CI: 49-95%) and 31% for the IVS (95 percent confidential 
interval, 95%CI: 11-59%). Finally, a partial recovery seems to occur at six months follow-up 
duration.
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Fig. 5. The relationship between the cumulative frequency of appearance of 
abnormal regional cardiac wall velocities and cumulative dose of anthracyclines.
DISCUSSION
The present study demonstrates the potentials of Tissue Doppler Imaging, a new, non-invasive 
echocardiographic technique, for the evaluation of myocardial wall velocities during and after 
treatment with anthracyclines. In particular TDI is able to detect abnormal diastolic myocardial 
velocities, which might be a new sign of early anthracycline-induced cardiotoxicity.
Acute anthracycline-induced cardiac toxicity is most frequently characterized by arrhythmias 
and conduction abnormalities. It may occur immediately after a single dose of anthracycline or after 
a course of anthracyclines therapy,25 but is uncommon under current treatment protocols. Although 
acute LV failure, pericarditis, and a fatal pericarditis-myocarditis syndrome have been reported,3 
acute asymptomatic cardiac changes are transient and do not contraindicate the further use of 
anthracyclines.26,27 Furthermore, chronic cardiac toxic effects such as congestive heart failure, high­
grade arrhythmia’s, cardiac conduction abnormalities and sudden death, are clinically significant 
anthracycline cardiotoxicity effects, which may occur even many years after completion of 
therapy.2,9,28
It is thought that occult cardiac abnormalities may progress to a more permanent form of 
myocardial disease, resulting in cardiomyopathy, which could progress to chronic heart failure. 
Evaluation of the degree of cardiac damage in patients is crucial for further management and long 
term follow-up. Unfortunately, none of the methods of screening for anthracycline cardiotoxicity 
has been shown to be adequately predictive of late cardiac outcomes. The need for monitoring 
methods that will help detect and predict long-term cardiac impairment in asymptomatic patients 
has become evident.
Tissue Doppler Imaging, that is used to measure regional myocardial wall velocity velocities, 
might be of particular importance in the early detection of local abnormalities, i.e. before any 
change is apparent in global function measurements. In a previous study the authors applied the TDI 
technique to apparently normal children who were treated for childhood cancer more than 5 years 
before.24 These late survivors had also received moderate doses of anthracyclines. The quantitative 
TDI parameters (i.e., peak late diastolic myocardial velocities, as well as transmyocardial systolic 
and diastolic velocity differences) were significantly lower in the late survivors than in healthy age- 
and gender-matched pediatric population. Moreover, regional velocity pattern abnormalities of the
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left ventricular walls were demonstrated in 20% of the late survivors (using the apical 4-CV). In the 
present study attention was focused on these regional wall velocity abnormalities, during and 
shortly after treatment with anthracyclines, in order to see whether these abnormalities might be a 
new, pathognomonic sign of anthracycline induced cardiotoxicity. Indeed, during therapy, up to 
82% of the patients showed to have these abnormalities in the LV free wall, and less often in the 
IVS (35%). In the first 5 years after treatment, this phenomenon was still very common in the LV 
free wall (60%).
A threshold of 300 mg/m2 anthracyclines is suggested for the development of late 
asymptomatic left ventricular dysfunction. However, this is not supported by subclinical 
endomyocardial biopsy abnormalities, which are already seen at cumulative doses higher than 
240mg/m2.2,29 Individual sensitivity and threshold for anthracycline cardiotoxicity are apparent 
from very early on in the treatment.11 The results of the present study are coherent with this 
statement. In some patients of the prospective group, the appearance of abnormal myocardial 
velocities pattern was seen even after the first dose of anthracyclines. The higher the cumulative 
dose of anthracyclines, the higher the incidence of abnormal myocardial movements that was 
observed (Fig. 5). Once exhibiting this phenomenon, abnormal regional myocardial velocities 
within the wall were always present until the end of anthracyclines therapy. Six months later, the 
incidence decreased considerably, suggesting these regional abnormalities might resolve. However, 
the relative high incidence of appearance was identical to the one detected in the early survivors 
group (subgroup 1a = 60%). The previously reported incidence in the late survivors (20%) 
emphasizes that this phenomenon does not need to be transient in all patients.24 Other authors 
reported that the incidence of abnormal diastolic function, detected by conventional 
echocardiography, was higher within the first two years after anthracycline therapy than in a later 
phase, while abnormal systolic function was detected more frequently later after treatment.30
One might expect that the anthracyclines will damage the whole myocardium rather than 
particular segmental regions of the myocardium. Endomyocardial biopsy (in adults), which is 
considered as the diagnostic test with the greatest specificity and sensitivity for doxorubicin- 
induced cardiomyopathy,29,31 can show typical histopathological changes. However, early in the 
development of the toxicity, these changes appear focally in scattered myocytes surrounded by 
normal appearing cells. As the toxicity progresses, the frequency of these altered cells increase until 
a significant proportion of the myocardium is involved. Late in the development of this toxicity, the 
picture is complicated by the development of diffuse myocardial fibrosis. Recently, Dazzi and 
colleagues32 reported on patients with acute, fatal, anthracycline induced cardiotoxicity. Interesting 
is that in one (out of 7) patient the myocardial necrosis was subendocardial, in one diffuse and one 
patient had papillary muscle necrosis. Only one patient had endomyocardial fibrosis. The authors 
therefore concluded that, in contrast to chronic cardiotoxicity (where the cumulative dose of 
anthracyclines is the most important risk factor), acute cardiotoxicity is not predictable and occurs 
with large variation in individual sensitivity. Less severe episodes are probably missed.
Myocardial damage as a result of myocytes loss heals by fibrosis, resulting in a measurable 
thinning of the ventricular wall. This fibrosis may also cause other disturbances such as an 
increased left ventricular diameter, decrease in the shortening fraction,6-11 and decreased LV 
compliance. In the present study, the LV shortening fraction was not significantly decreased 
between patients with or without reversed diastolic myocardial wall velocities. This is 
fundamentally important to the technique as studied here, because we examined cardiac long-axis 
rather than short axis parameters, and it potentially bears increased significance in relationship to 
the early and late diastolic filling parameters (which were also not different between both 
subgroups, as measured by the standard echocardiography). Relaxation properties of the 
myocardium are complex and involve intrinsic properties of the heart (such as active and passive 
myocardial stiffness) in addition to other factors (such as right ventricular pressure, pericardial 
pressure, pleural pressure, etc). Contrary to standard Doppler echocardiography, TDI measures
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myocardial tissue velocity, which directly reflects contractile, and relaxation properties of the 
myocardium.33 The wall movement abnormalities are not necessary specific for anthracycline 
toxicity as three patients already had these abnormalities before the start of their treatment. Yet, the 
incidence increased substantially during treatment. A similar mid-diastolic wall velocity 
abnormality was recently reported by Oki et a l.34 in patients with constrictive pericarditis. It was 
described as a “rebound” motion related to LV diastolic filling impairment due to epicardial and 
pericardial lesions. We interpret the abnormal movement as a regional increase in wall stiffness, 
perhaps due to tissue edema (in the early phase) or focal cell damage.
The influence of heart rate and body surface area (BSA) on the myocardial velocities could be 
excluded because there were no significant differences in these characteristics between the children 
with or without regional wall velocity abnormalities.
Late echocardiographic abnormalities, detected by conventional echocardiography, increase with
7,9 7,9,35the duration of follow-up, ’ higher cumulative doses of anthracyclines, ’ ’ higher rates of 
anthracycline administration,36 and mediastinal irradiation.8,10 Young age at the time of treatment,9
36 35 28female sex, black race, presence of trisomy 21, exposure to amascarine, and early onset of 
cardiotoxicity7,9 are all reported as risk factors for late-onset cardiotoxicity, but these factors are still 
controversial. In the present study, no difference was found between the subgroups with respect to 
age at (first) echocardiographic examination, gender, or age at start of chemotherapy, cumulative 
dose of anthracyclines and the follow-up duration. It could be confirmed that chemotherapy with 
anthracyclines, even in low to moderate dosage, is associated with increased incidence of sub- 
clinical cardiac abnormalities.
Assuming that patients with residual abnormal wall velocities have limited cardiac reserve, 
their cardiac function should be frequently assessed and carefully evaluated during viral illness, 
surgical procedures and pregnancy. Treatment with digoxin, diuretics, and vasodilators can lead to 
complete clinical response when chronic heart failure is present.37 Early detection of subclinical 
dysfunction might facilitate the decision for cardiac treatment and therefore improve the survival 
rate. The clinical value of the diastolic wall velocity abnormalities, detected by TDI, remains to be 
established in a larger and longer follow-up study.
CONCLUSIONS
Regional myocardial wall velocity abnormalities were detected by TDI early in the treatment, even 
after the first dose of anthracyclines. This new echocardiographic phenomenon may be an early 
predictor of anthracycline-induced cardiomyopathy. During anthracycline treatment an increasing 
number of patients with this phenomenon was involved. After cessation of anthracycline therapy, 
the incidence decreased up to 60% in the early survivors (this study), and up to 20% in late 
survivors (earlier study). The question arises whether these patients are at higher risk for developing 
late anthracycline-induced cardiomyopathy. As no significant difference was demonstrated in 
patient characteristics and cumulative dose of anthracyclines between patients with and without 
abnormal wall velocities, TDI is the only method to diagnose these subclinical cardiac 
abnormalities. The authors recommend the use of both conventional and TDI methods 
simultaneously for the long-term follow-up of survivors of childhood cancer treated with 
anthracyclines.
Limitations
Echocardiograms ‘before the next treatment’, rather than ‘within 1 week of after (each 50-60 
mg/m2) dose of anthracycline’ could minimise possible acute cardiotoxic or hemodynamic effects 
of any element of the chemotherapy regime. However, the authors decided for the latter to avoid
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wide disparity of the time interval after the various anthracyclines administrations, a variable that 
could also influence the results.
The possible additive effect of concurrently given chemotherapeutic agents on cardiotoxicity 
could not be ruled out. By selecting 43 resting but non-sedated survivors, the values obtained in this 
study incorporate normal variations in physiological loading conditions without pharmacological or 
physical manipulations, as reflected in the recorded measurements of blood pressure and heart rate. 
The clinical value of the TDI method should in the future be investigated by independent functional 
tests, e.g., stress echocardiography.
At the time of the present study, the more advanced strain and strain rate imaging techniques 
were not yet available for clinical use.38 Their introduction might further enhance the value of 
echocardiography by overcoming the limitation of the TDI technique, i.e., the dependency of the 
velocity measurements on the total movement of the heart.
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SUMMARY
Anthracycline-induced cardiotoxicity is often defined as a condition in which (conventional) 
echocardiographic parameters may deteriorate, with or without clinical symptoms, after a single 
dose or after a complete treatment with anthracyclines. Unfortunately, none of the methods of 
screening for anthracycline cardiotoxicity has been shown to be adequately predictive of late 
cardiac outcome.
Tissue Doppler imaging (TDI), a rather new echocardiographic technique, is used to 
measure regional myocardial wall motion velocity which directly reflects contractile, relaxation and 
elastic properties of the myocardium. The question was addressed whether this technique could play 
a role in the early detection of myocardial abnormalities, i.e., already before any significant change 
is apparent in global function measurements
This thesis presents the first study to establish the usefulness of TDI in the presymptomatic 
diagnosis of anthracycline-induced cardiomyopathy, in the pediatric population. This technique is 
non-invasive, does not yield radiation damage, is user friendly and therefore repeatable. In the 
proper clinical setting, detection of (congestive, less often restrictive) cardiomyopathy by 
echocardiography is a sign of an advanced stage of the disease. Early detection of cardiotoxicity 
could offer the opportunity to prevent development of cardiomyopathy with adequate drug therapy 
or even induce a change in protocols of further chemotherapy.
In chapter 1 a general introduction is given and the aim of this study is outlined. Background 
information about anthracyclines and the TDI technique is given in chapters 2 and 3. The 
applications of this ultrasound technique in the pediatric population, both in healthy children and 
patients are described in chapters 4 through 8.
In chapter 2 the current knowledge of anthracycline-induced cardiotoxicity is given. The 
possible mechanisms of cardiotoxicity are described, suggesting that the development of cardiac 
damage is multifactorial. A number of risk factors may predispose a patient to cardiotoxicity, e.g., 
cumulative dose of anthracyclines, mediastinal radiation, young age at diagnosis (start of therapy), 
and female gender. Other risk factors are also described, as well as the clinical forms (i.e. early and 
late cardiotoxicity), the different methods of cardiac monitoring (in children mainly the standard 
echocardiography) and the advisable therapy of anthracycline-induced cardiotoxicity.
In chapter 3 the basic principles and clinical applications of TDI are reviewed to promote 
understanding of its utility in the evaluation of left ventricular (LV) myocardial function. TDI 
allows local evaluation of the LV (systolic and diastolic) function in radial and longitudinal 
directions. Most of the studies described in the literature were performed in adults. The most 
frequent clinical applications for assessing LV function are in patients with cardiomyopathies and 
ischemic heart diseases. The limitations of the TDI technique and the perspectives of new 
techniques, i.e., myocardial strain and strain rate imaging, are also discussed.
In chapter 4 assessment of normal velocity-time pattern and magnitude of myocardial 
velocity in healthy children (n = 160; age range 4-18 y), during systole, early and late diastole, is 
reported. The radial velocities were assessed using the TDI from the LV long-axis view (LAV). 
The existence of transmyocardial velocity differences between the left and right side of the 
interventricular septum (IVS), as well as between the endocardium and epicardium of the left 
ventricular posterior wall was observed throughout the heart cycle. The longitudinal velocities were 
assessed using the TDI from the apical four-chamber view (4-CV). The highest peak systolic, early 
and late diastolic velocities were measured within the basal parts of the myocardial walls; the 
longitudinal myocardial velocities decreased from base to apex.
These normal values of peak myocardial velocities, transmyocardial velocity differences and 
the ratios of peak wall velocities have been used as reference values in further investigations of 
ventricular dysfunction in this age group, as reported further in this thesis.
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In chapter 5 a study is presented, concerning the clinical applicability of the TDI in late 
survivors (n = 63, median 7.1 years, range 3.5-13.5 y, after end of therapy) of childhood cancer 
treated with anthracyclines. Using the standard echo Doppler cardiography, LV dimensions and 
calculated fractional shortening (FS) were decreased as compared to the controls. Using the TDI 
technique, peak late diastolic radial myocardial velocities, as well as transmyocardial systolic and 
diastolic velocity differences were significantly lower in late survivors compared to the healthy 
subjects (p < 0.01). Furthermore, qualitative local abnormality of the movement of the left 
ventricular wall was detected in 20% of the patients. Based on the findings of myocardial velocity 
abnormalities in these late survivors, it is suggested that, TDI might become a useful non-invasive 
method for detecting subclinical myocardial damage in apparently normal children who received 
moderate doses of anthracyclines for treatment of childhood malignancy. Further studies, i.e., of 
early survivors, were recommended.
In chapter 6 the optimal set of conventional echocardiographic and TDI parameters, needed 
for the discrimination of late survivors from matched healthy controls, is retrospectively determed. 
The parameters used in the multivariate discriminant score (S-score) were selected from a large set 
of 51 echocardiographic parameters, using logistic regression analysis (stepwise selection). The 
correct classification probability (C-index) and the generalized distance (d) between the 
distributions of S-scores were used to measure the overall discriminative performance of each 
echocardiographic technique separately and in combination. The overall discriminative performance 
of the conventional echo-Doppler parameters (C = 77.3%, d  = 1.04) was lower than that of the TDI 
(C = 84.2%, d  = 1.37), the highest C-index was obtained using both techniques (C = 89.2%, d  = 
1.66). The set of parameters includes: LV fractional shortening and mitral valve early diastolic 
bloodflow velocity, 2 LAV and 5 apical 4-CV wall velocities (systolic and diastolic). In the patients 
group the S-score was positively associated with cumulative dose of anthracyclines (p = 0.05), and 
duration of treatment (p = 0.01). The authors concluded that the S-score, based on a limited number 
of variables from both techniques simultaneously, could retrospectively discriminate asymptomatic 
children with anthraycline-induced cardiomyopathy from healthy controls. In contrast to the healthy 
controls, the survivors in this study did not show an increase of the S-score with age, suggesting that 
the normal growth pattern of the heart is disturbed in the treated children.
In chapter 7 the possible improvement of diagnosing myocardial damage in early survivors 
of childhood cancer treated with moderated doses of anthracyclines, using TDI, is reported. Forty- 
three patients, with mean follow-up of 2.1 (range 0.3-5.2) years, and 97 healthy controls were 
enrolled in this retrospective study. The best set of standard echocardiographic and tissue Doppler 
imaging (TDI) was needed for the discrimination of asymptomatic survivors was retrospectively 
assessed. Based on univariate analysis, mainly the diastolic wall velocities were significantly 
different between the early survivors and the controls. Furthermore, in the patient group, the 
absolute transmyocardial velocity difference across the IVS was significantly decreased only during 
early diastole. In the late survivors (see chapter 5), the absolute transmyocardial velocity differences 
across the IVS were decreased in all three heart phases, which may represent a more advanced stage 
of the (subclinical) cardiomyopathy. Using the 4-CV (longitudinal velocities), 13/26 (50%) TDI 
parameters were statistically different between the early survivors and the controls. This rather 
promising result appeared, nevertheless, not very helpful for a consistent discrimination between the 
two groups, due to the disparity in timing and location of these parameters.
As in the previous chapter (see chapter 6), the parameters used in the discriminant score (S- 
score) were selected from a large set of 51 echocardiographic parameters, using logistic regression 
analysis (stepwise selection). The discriminative ability (C-index) of early asymptomatic survivors 
from controls was higher using the TDI technique (C = 92.1%) than the standard echocardiography 
(C = 67.7%). TDI parameters selected in this multivariate analysis were mainly diastolic myocardial 
velocities from the interventricular septum. The distribution of the S-score was significantly 
different between the survivors and the controls (p < 0.001), particularly at younger age. Based on
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the multivariate discriminant analysis, the authors concluded that TDI is superior to the standard 
echocardiography for the discrimination of asymptomatic survivors (from the controls) even early 
after receiving moderate doses of anthracyclines.
In chapter 8 the TDI technique was applied to detect the prevalence of regional cardiac wall 
velocity abnormalities during and shortly after anthracyclines therapy. Previous study on late 
survivors illustrated the presence of abnormal regional myocardial wall velocity abnormalities 
during diastole, in 20 % of these patients (chapter 5). It was unknown whether these regional wall 
velocity abnormalities are due to early or late cardiotoxic effects. A total of 60 patients, age range 
4.4-16.0 y, were included in this study: 43 early survivors, with a mean follow-up duration of 2.1 
(range 0.3-5.2) years after end of anthracyclines therapy, were evaluated retrospectively. Seventeen 
other patients were evaluated before, during, and six months after end of anthracyclines therapy. All 
patients received a moderate cumulative dose of anthracyclines (range 120-450 mg/m2). 
Echocardiographic examination was performed using conventional and TDI techniques, from 
transthoracic apical 4-CV. Of the early survivors, 26 (60%) demonstrated regional LV free wall 
velocity abnormalities. In the prospective group, serial TDI studies revealed 3 patients (18%) with 
regional LV free wall velocity abnormalities before start chemotherapy, and 14 (82%) at the end of 
anthracyclines therapy. Six months later, however, the incidence was decreased to 61% of the 
survivors. Subject and treatment characteristics, as well as LV wall diameters and shortening 
fraction measured by conventional echocardiography were not significantly different for children 
with or without this phenomenon. Regional wall velocity abnormalities, although less frequent, 
were also present in the I VS. It is concluded that regional diastolic myocardial velocity 
abnormalities during and shortly after anthracyclines therapy are common, and sometimes transient. 
The authors recommend simultaneous use of both echographic techniques for the monitoring of 
anthracycline-induced cardiotoxicity.
GENERAL CONCLUSIONS
In  conclusion, TDI is able to detect signs of myocardial dysfunction in asymptomatic patients and 
survivors of childhood cancer treated with anthracyclines, even without standard echocardiographic 
features of cardiomyopathy. To determine whether TDI, in comparison with the conventional 
echocardiographic screening, will play an augmenting diagnostic role requires a further, maybe 
even multicenter, study. Nevertheless, it is proposed to include the TDI modality in the 
echocardiographic monitoring program. Assuming that patients with high S -score have limited 
cardiac reserve, their S -score should be frequently assessed and carefully evaluated during viral 
illness, surgical procedures and pregnancy. The discriminative ability of this simple and non­
invasive S -score estimation to detect subclinical myocardial alterations may also facilitate 
prognostic stratification of asymptomatic cancer survivors for the timing of introducing supportive 
cardiac treatment. Its potentials should also be investigated in patients with clinical symptoms of 
anthracycline-induced cardiotoxicity. The clinical value of this score remains, nevertheless, to be 
established in a larger study population. In the end, this would result in a considerably smaller 
number of targeted measurements on which a clinician can focus his examination. For this purpose, 
the combined data of the groups of early and late survivors were analysed. It appeared that the 
multivariate regression analysis yielded a set of 8 parameters and a C-index of 86.3% when both 
techniques were applied. The significance of discrimination of the patients from the group of 
healthy controls was p  < 0.001. The obtained set of parameters might be used to estimate the S- 
score of individual patients (starting at any stage of their history) and may then be used for their 
follow-up, but also in longitudinal assessment studies.
Last but not least, the author believes that TDI can be a useful addition to the standard 
echocardiography. Further investigations are needed to address these potentially useful applications
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of TDI and also SRI for regional and global LV systolic and diastolic functions, in children. Areas 
of further research could be the estimation of reference values of TDI parameters in very young 
children and TDI measurements before and after interventions in case of congenital heart disease. 
Finally, it is considered of interest to make comparison with other imaging modalities, such as 
cardiac magnetic resonance imaging, and the effects of congenital cardiac diseases before and after 
intervention on global and regional TDI myocardial velocities.
SAMENVATTING EN ALGEMENE DISCUSSIE
Anthracycline gerelateerde cardiotoxiciteit wordt vaak gedefinieerd als een conditie waarbij 
(conventionele) echocardiografische parameters verslechteren, hetgeen al of niet gepaard kan gaan 
met klinische symptomen. Deze conditie kan zich voordoen na één enkele dosis of na een complete 
behandeling. Helaas heeft tot nu toe geen enkele van de bekende “screenings”-methoden voldoende 
voorspellende waarde voor de conditie van het hart op langere termijn.
Tissue Doppler Imaging (TDI), een tamelijk nieuwe echocardiografische techniek, wordt 
gebruikt voor het regionaal meten van de snelheid van de beweging van de hartspier. De grootte en 
het tijdsverloop van deze wandsnelheden zijn gerelateerd aan de contractie en relaxatie 
eigenschappen, alsmede aan de mechanische elasticiteit van de hartspier. Deze techniek zou in het 
bijzonder van belang kunnen zijn voor de vroege detectie van afwijkingen van het myocard, d.i., al 
voordat enige significante verandering wordt opgemerkt in metingen van de globale hartfunctie.
In dit proefschrift wordt de eerste studie gepresenteerd waarin de bruikbaarheid van TDI voor 
de pre-symptomatische diagnose van anthracycline-gerelateerde cardiomyopathie bij kinderen 
wordt onderzocht. Deze techniek is niet-invasief, brengt geen stralingsbelasting met zich mee, is 
gebruiksvriendelijk en om deze reden herhaald inzetbaar. In een juiste klinische “setting” is de 
ontdekking van cardiomyopathie (congestief, soms ook restrictief) met echocardiografische 
technieken een teken dat de ziekte al gevorderd is tot een ernstig stadium. Vroeg-detectie van 
cardiotoxiciteit zou de mogelijkheid openen tot preventie van cardiomyopathie met een adequate 
(pharmaco-) therapie. Een andere mogelijkheid zou het aanpassen zijn van het protocol voor 
verdere chemotherapie behandeling.
In hoofdstuk 1 wordt een algemene inleiding, alsmede het doel van de studie, gepresenteerd. 
In hoofdstukken 2 en 3 wordt achtergrondinformatie gegeven over anthracyclines en de TDI- 
techniek. De toepassing van deze techniek in de pediatrische populatie, zowel bij gezonde kinderen 
als bij patiëntjes, wordt beschreven in de hoofdstukken 4 tot 8.
In hoofdstuk 2 wordt de huidige kennis over anthracycline-gerelateerde cardiotoxiciteit 
beschreven. De mogelijke mechanismen van cardiotoxiciteit worden toegelicht en de suggestie 
wordt gedaan dat het proces van de ontwikkeling van hartschade multi-factoriëel is. Een aantal 
risicofactoren, dat betrokken is bij de predispositie van een patiënt voor cardiotoxiciteit, is bekend, 
b.v. de cumulatieve dosis van anthracyclines, röntgenbestraling van het mediastinum, jonge leeftijd 
ten tijde van de diagnose (ofwel van de start van de therapie) en vrouwelijk geslacht. Verder 
worden in dit hoofdstuk nog andere risicofactoren beschreven, alsmede de klinische vormen 
(vroege en late cardiotoxiciteit), de diverse methoden van cardiale monitoring (bij kinderen in 
hoofdzaak de conventionele echocardiografie) en tenslotte de aanbevolen therapie.
In hoofdstuk 3 worden de principes en klinische toepassingen van TDI toegelicht. Daarmee 
wordt de basis gelegd voor het begrijpen van de bruikbaarheid van deze techniek voor de evaluatie 
van de myocardfunctie van de linkerventrikel (LV). De LV functie (zowel systolisch, als 
diastolisch) kan lokaal worden gemeten langs de radiale en de longitudinale richtingen van het hart. 
De meeste tot nu toe gepubliceerde TDI-studies hebben betrekking op volwassenen. Deze klinische 
studies zijn gewijd aan de LV-functie in patiënten met cardiomyopathie en ischemische hartkwalen.
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De beperkingen van de TDI-techniek, alsmede het perspectief van meer recente technieken, d.i. 
“strain”en “strain rate” imaging, worden eveneens bediscussieerd.
In hoofdstuk 4 worden de resultaten beschreven van het TDI-onderzoek bij gezonde 
kinderen (n = 160; leeftijdgebied 4-18 y). De normale snelheden in de hartcyclus en de 
(piek)waarden van de locale myocardiale snelheden, met name de piekwaarden in de systolische, 
vroeg-diastolische en laat-diastolische fasen van de hartslag worden vermeld. De radiale 
wandsnelheden worden gemeten in de lange-as doorsnede (LAV) van de LV. Aangetoond werd dat 
gedurende de hartslag een snelheidsgradiënt bestaat tussen de linker- en rechterzijde van het 
interventriculaire septum (IVS), en tussen de endocardiale en epicardiale zijde van de LV 
achterwand. De longitudinale wandsnelheden worden gemeten met TDI in de apicale 
vierkamerdoorsnede (4-CV). De hoogste piekwaarden van deze snelheden bleken aanwezig in de 
basale meetpositie, waarbij een geleidelijke afname van basis naar apex werd geregistreerd. De 
aldus verkregen normaalwaarden van de piek myocardiale snelheden, de transmyocardiale 
snelheidsverschillen en de verhouding van pieksnelheden worden gebruikt als referentie voor 
dezelfde leeftijdsgroep.
In hoofdstuk 5 wordt het onderzoek gerapporteerd naar de klinische betekenis van TDI voor 
detectie van cardiotoxische schade na behandeling met anthracyclines in de groep “late survivors” 
(n = 63; periode na eind therapie: mediaan 7.1 jaar; uitersten: 3,5 -  13,5 jaar). Gebruikmakend van 
standaard echo-Doppler cardiografie bleek dat de LV-dimensies en de berekende 
“verkortingsfractie” (FS) in de patiëntengroep lager waren dan in de controlegroep. Met de TDI- 
techniek kon worden aangetoond dat zowel de laat-diastolische radiale wandsnelheden, alsmede de 
transmyocardiale systolische en diastolische snelheidsverschillen significant lager waren bij de 
patiënten (p < 0,01). Verder werd abnormale locale myocardbeweging met name in de LV-wand 
waargenomen in 20% van de patiënten. Op basis van deze bevindingen wordt gesteld dat TDI een 
bruikbare, niet-invasieve methode zou kunnen worden voor het opsporen van subklinische 
myocardschade in schijnbaar normale kinderen die zijn behandeld met anthracyclines. Verder 
onderzoek, met name kort na de behandeling ( “early survivors”), wordt aanbevolen.
In hoofdstuk 6 wordt, retrospectief, de optimale set van conventionele echocardiografische 
en TDI-parameters bepaald voor het onderscheiden van “late survivors” van gezonde controles van 
dezelfde leeftijdsgroep. De parameters, die in de multivariate logistische regressie analyse werden 
gebruikt, werden geselecteerd uit een totale set van 51 echoparameters. Voor alle kinderen in deze 
studie werd met de gevonden regressie-coëfficiënten de individuele “discriminant score” (S-score) 
berekend en in een histogram van S -scores voor beide groepen verwerkt. De gegeneraliseerde 
afstand tussen deze histogrammen (d) en de kans op correcte classificatie (C-index) van de 
patiëntengroep ten opzichte van de controlegroep zijn vervolgens gebruikt om de bruikbaarheid van 
de conventionele en TDI-echotechnieken zowel apart, alsook in combinatie, te onderzoeken. Het 
discriminerend vermogen van de conventionele echocardiografische parameters (C = 77,3%; d  = 
1,04) was lager dan dat van de TDI-parameters (C = 84,2%; d  = 1,37). De hoogste C-index werd 
geleverd door een combinatie van parameters van beide technieken (C = 89,2%; d  = 1,66). De 
optimale set van parameters omvat: LV-verkortingsfractie (FS), vroeg-diastolische 
bloedstroomsnelheid over de mitralisklep, alsmede twee LAV en vijf 4-CV wandsnelheden (zowel 
systolische als diastolische). De S-score in de patiëntengroep was positief gerelateerd met de 
cumulatieve dosis anthracyclines (p = 0,05) en met de duur van de behandeling (p = 0,01). De 
auteurs trekken de conclusie dat de geïntroduceerde diagnostische index, d.i., de S-score, de 
mogelijkheid biedt retrospectief de behandelde asymptomatische kinderen te onderscheiden van 
gezonde controlekinderen in dezelfde leeftijdsgroep. In tegenstelling tot de controlegroep bleek de
S -score van de patiëntjes niet toe te nemen met de leeftijd. Deze observatie zou er op kunnen wijzen 
dat het normale groeipatroon van het hart bij de behandelde kinderen verstoord is.
In hoofdstuk 7 wordt verslag gedaan van het onderzoek naar de mogelijke verbetering met 
behulp van TDI van de diagnostiek van myocardschade bij kinderen kort na de behandeling met
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anthracyclines, dit is de groep “early survivors”. In een retrospectieve studie werd standaard 
echocardiografisch en TDI-onderzoek verricht bij asymptomatische patiëntjes (n = 43) met een 
gemiddelde duur van de follow-up periode van 2,1 (range 0,3- 5,2) jaar. De optimale set van 
parameters voor het onderscheid van deze groep ten opzichte van een gepaarde groep gezonde 
kinderen (n = 97) werd bepaald. Uit een univariate analyse van de echografische/TDI-parameters 
bleek dat in hoofdzaak de diastolische wandsnelheden significant afwijkend waren bij de 
patiëntengroep. Het absolute transmyocardiale snelheidsverschil bleek slechts afwijkend in de 
vroegdiastole fase, vooral wanneer gemeten over het IVS. In de groep “late survivors” (hoofdstuk
5) is daarentegen gerapporteerd dat dit snelheidsverschil afwijkend is in alle drie de fasen van de 
hartslag. Dit zou kunnen betekenen, dat deze laatste groep in een verder gevorderd stadium van 
(subklinische) cardiomyopathie is gekomen. In de 4-CV (longitudinale wandsnelheden) bleken 13 
van de 26 (50%) TDI parameters in de “early survivor” groep afwijkend te zijn. Hoewel dit een 
veelbelovend resultaat is, wordt gesteld dat daarmee nog niet sprake is van een eenvoudige methode 
voor het onderscheid tussen de 2 groepen.
Een meer adequate methode kan worden verkregen met multivariate analyse (zie ook hoofdstuk
6). De parameters (n = 51) werden als voorheen verkregen uit standaard echo-Doppler metingen en 
uit TDI. De “discriminant score” (S-score) werd bepaald met multipele logistische regressie 
analyse. Het percentage correcte classificatie bedroeg: C = 92,1% voor de set van TDI-parameters 
en C = 67,7% voor de echo-Doppler parameters. Combinatie van beide soorten parameters leverde 
geen extra winst op. In de regressie-analyse werden in hoofdzaak diastolische wandsnelheden van 
het IVS geselecteerd. De histogrammen van de patiëntengroep en de controlegroep waren 
significant verschillend (p < 0.001). Het verschil tussen beide groepen is het duidelijkst op een 
jonge leeftijd. De conclusie lijkt dus gerechtvaardigd dat TDI superieur is ten opzichte van 
standaard echo-Doppler cardiografie voor het onderscheid van asymptomatische patiëntjes, zelfs 
vroeg na de behandeling met een matige dosis anthracyclines.
In hoofdstuk 8 wordt de TDI-techniek gebruikt voor het onderzoek van de prevalentie van 
abnormaliteit van de regionale hartwandsnelheid. In de groep van “late survivors” bleek dit 
fenomeen zich voor te doen bij 20% van de kinderen gedurende de diastolische fase (hoofdstuk 5). 
Het is niet duidelijk of deze abnormale bewegingen zijn te relateren aan vroege of aan late 
cardiotoxische effecten. In dit hoofdstuk worden de resultaten gepresenteerd van een groep van 60 
patiëntjes in de leeftijd van 4,4 tot 16 jaar. Deze groep omvat de eerder besproken groep van “early 
survivors” (n = 43; hoofdstuk 7). Tevens zijn 17 kinderen bij het onderzoek betrokken, die werden 
onderzocht vóór, tijdens en 6 maanden ná de behandeling met anthracyclines d.i. de "prospectieve 
groep”. Alle patiëntjes ontvingen een matige dosis (tussen de 120 en 450 mg/m2 BSA) van 
anthracyclines.
De kinderen ondergingen steeds het volledige onderzoeksprotocol. In de subgroep “early 
survivors” bleken 26 (60%) van de kinderen abnormale LV-wandbeweging te vertonen. In de 
prospectieve groep bleken 3 (18%) kinderen al vóór de start van de behandeling abnormale 
wandbeweging te hebben. Dit aantal groeide aan tot 14 (82%) gedurende het verloop van de 
behandeling. Zes maanden ná de behandeling was deze incidentie gedaald tot 61%. De subject- en 
behandelingskenmerken, LV-wanddiktes en LV-verkortingsfractie waren niet significant afwijkend 
bij de aangedane kinderen. Bij een aantal kinderen werden ook abnormale wand bewegingen 
waargenomen in het IVS. De conclusie wordt getrokken dat regionale diastolische myocardiale 
snelheden vaak een abnormaal tijdspatroon vertonen gedurende en kort na therapie met 
anthracyclines en dat deze afwijking in sommige gevallen van voorbijgaande aard is. Op grond 
daarvan wordt de aanbeveling gedaan om steeds zowel standaard echo-Doppler cardiografie als ook 
TDI-onderzoek te doen bij het vervolgen van behandelde kinderen.
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ALGEMENE CONCLUSIES
TDI is in staat tekenen van myocardiale dysfunctie te ontdekken in asymptomatische patiënten die 
behandeld zijn met anthracyclines, zelfs al zijn er geen kenmerken van cardiomyopathie waar te 
nemen met standaard echocardiografie. Verdere, misschien zelfs multicenter, studies zijn nodig om 
te kunnen achterhalen of TDI een gescheiden, danwel ondersteunende, rol zal spelen ten opzichte 
van de conventionele echocardiografie. Niettemin wordt nu reeds het voorstel geformuleerd TDI 
onderdeel te maken van het echocardiologische protocol voor het vervolgen van deze patiënten. 
Indien wordt aangenomen dat patiënten met een hoge S -score een gelimiteerde cardiale 
reservecapaciteit hebben, dan dient deze S -score regelmatig te worden bepaald en ook gevolgd te 
worden bij virale infecties, chirurgische ingrepen en zwangerschap. Ook zou het hoge 
discriminerend vermogen van de S -score faciliterend kunnen zijn in een prognostische stratificatie 
van asymptomatische behandelde patiënten ten behoeve van een tijdige beleidsbepaling ten aanzien 
van cardiale ondersteuningsbehandeling. De mogelijke bruikbaarheid van de S -score zou ook 
dienen te worden onderzocht in symptomatische patiënten. Niettemin blijft het gewenst een studie 
met een grotere patiëntenpopulatie uit te voeren. Het resultaat zal zijn dat de arts met een 
aanzienlijk gereduceerd aantal meetwaarden kan opereren.
In een eerste poging een betere statistische onderbouwing aan de S -score te geven, is recent 
het materiaal van beide groepen “survivors” samengevoegd en is de multivariate analyse daarop 
uitgevoerd. Hieruit bleek dat het aantal parameters geselecteerd in de regressie analyse 8 bedroeg. 
De totale kans op correcte classificatie van de patiënten en controles was C = 86,3 % mits beide 
technieken werden gebruikt. De betrouwbaarheid van het onderscheid van beide groepen op grond 
van de S-score was p  < 0.001. De aldus verkregen set van parameters zou voortaan kunnen worden 
gebruikt voor de follow-up van de patiënten en voor toekomstige, longitudinale, studies.
De auteur van dit proefschrift is ervan overtuigd dat TDI een bruikbare toevoeging is aan de 
bestaande standaard echocardiografische technieken. Verder onderzoek is gewenst naar mogelijke 
andere toepassingen van TDI en ook van SRI bij kinderen. Gedacht kan worden aan regionale of 
globale afwijkingen van de functie van de linkerhartkamer, zowel systolische als diastolische. Het 
verkrijgen van normaalwaarden van het hart van zeer jonge kinderen dient ook een aandachtsgebied 
te zijn. Ook zou het van belang kunnen zijn TDI metingen te verrichten vóór en na interventie bij 
congenitale hartafwijkingen. Tenslotte is het van belang de relaties en afstemming met andere 
beeldvormende technieken zoals magnetische resonantie te onderzoeken.
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ondersteuning, vooral op die memorabele dag toen alle resultaten van mijn kast waren 
“verdwenen”.
Rien Cuypers, jouw deur stond altijd voor mij open. Ik neem mijn petje af voor jouw 
computerkennis, maar vooral voor je ongelooflijke geduld en bescheidenheid in deze competitieve 
maatschappij. Samen met enkele ijverige studenten, met name Tim Antonius, hebben wij uren op 
jouw kamer doorgebracht, met veel plezier en veel resultaat.
Many thanks to Prof. David Sahn for the great opportunity you gave me to work and publish with 
you.
Hartelijk dank aan twee van mijn goede vriendinnen, mijn paranimfen, Tiny en Ineke. Ook nu zal 
het weer heerlijk zijn om jullie aan mijn zijde te hebben.
Lieve Renske, zonder jouw hulp thuis had ik nooit de rust gehad om zo ver te komen.
Finally, I would like to use this precious moment to thank those who are everything for me, my 
family.
Dear Ima, how much I would have given to see Aba sitting near you on the first row during the 
ceremony. You never approved my choice to become a medical doctor, yet you both supported me 
unconditionally, with a heart full of warmth and love. Shelly and Tamy, forever we are connected 
by “blood and tears”. Hadassah Hospital, Jerusalem, has made us (un)fortunately understand what 
life is all about. How much I love you all!
Alon, Guy and Ranny, wat ben ik trots op jullie! Niet vanwege jullie prestaties, maar vooral als ik 
jullie teamwerk zie iedere zaterdagochtend op het hockeyveld. Of als jullie voor een gekwetste 
schoolvriend durven op te komen! En ook wanneer jullie ons vroegen die arme, oude taxichauffeur 
te helpen (tegen de brutale buschauffeur, weten jullie nog?). Mijn wens is, om er samen met pappa, 
altijd voor jullie te zijn.
Lieve Robert, ik heb bewondering voor jouw positieve blik op en betrokkenheid bij het leven.
Jouw fantastische steun in de periode van ziekte van Aba and Shelly, die parallel liep aan de periode 
waarin dit proefschrift tot stand kwam, was geen toeval. Zo ben je!
The challenge for women in this era is to find a balance between motherhood and being a 
supporting wife, between having a career and a full family life, between keeping their own tradition 
and adapting to the “hutspot” of modern society. These are the true values and colors of life.
Shalom and Lechaim (= to life)!
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Curriculum vitae
De auteur van dit proefschrift is geboren en getogen in Tel-Aviv, Israël. De middelbare school 
opleiding (1971-1975) werd gevolgd door verplichte militaire dienst op de Military Cadet 
Academy, Israeli Defense Force (1975-1977). Van 1977 tot 1985 volgde zij de studie Geneeskunde 
aan de Sackler Medical School te Tel-Aviv. Tijdens haar studie heeft zij gedurende 3 jaar als 
(ongediplomeerd) verpleegster op de spoedeisende hulp afdeling van het Sheba Medical Center 
gewerkt en nam zij deel aan verschillende internationale studenten uitwisselingsprogramma's. 
Aansluitend aan de studie Geneeskunde heeft zij gedurende een jaar een roterend assistentschap (op 
verschillende afdelingen) ververvuld. Het Medical Doctor (M.D.) diploma (magna cum laude) 
kreeg zij uitgereikt op 30 juni 1986 in Tel-Aviv.
Op 1 augustus 1985 kwam zij in dienst als eerste echolaborant van de afdeling kindercardiologie 
(hoofd: Dr. H.J. Busch), St. Radboud ziekenhuis. Van 1986-1991 volgde zij de opleiding tot 
kinderarts in het St. Radboud ziekenhuis (opleider: Prof.dr. G.B.A. Stoelinga) en het Canisius- 
Wilhelmina ziekenhuis te Nijmegen (opleider: Dr. P. van Wieringen). Op 21 september 1991 werd 
zij als kinderarts ingeschreven in het Specialisten Register.
Vanaf 1 augustus 1991 was zij gedurende drie jaar fellow bij het Kinderhartcentrum te Nijmegen 
(hoofd: Prof.dr. O. Daniëls). Sinds 14 november 1994 tot op heden is zij als kindercardioloog 
verbonden aan het Kinderhartcentrum en aan de afdeling Kindergeneeskunde (hoofd: Prof.dr.
R.C.A. Sengers) van het UMC St. Radboud, Nijmegen.
Zij is getrouwd met Robert J. Baruch en samen hebben zij drie zonen: Alon, Guy en Ranny.
STELLINGEN
1. Met TDI kan. beter dan met standaard echocardiografie, een groep asymptomatische 
kinderoncologische patiënten worden onderscheiden van een groep gezonde kinderen. 
Zelfs na milde doses van anthracyclines (dit proefschrift).
2. Locale afwijkingen van diastolische snelheden, gedurende en kort na therapie met 
anthracyclines, komen vaak voor en zijn soms van voorbijgaande aard (dit proefschrift).
3. Geadviseerd wordt zowel conventionele echocardiografie als TDI te gebruiken voor de 
follow-up van. met anthracyclines behandelde, kinderoncologische patiënten (dit 
proefschrift).
4. Chronisch hartfalen is niet leeftijdsgebonden.
5. In de nabije toekomst zal het aantal volwassenen met een aangeboren hartafwijking het 
aantal kinderen met een dergelijke afwijking overtreffen.
6. Een verstoord homocysteine metabolisme is een belangrijke risicofactor voor veel 
aangeboren afwijkingen.
7. Tissue engineering biedt een nieuw perspectief voor het tekort aan operatiekamer- 
personeel.
8. Aangezien stamceltherapie voorlopig geen alternatief vormt voor orgaandonatie zou 
iedereen zich als potentieel donor moeten melden.
9. Hoe meer iemand zijn grenzen stelt, des te groter is zijn vrijheid.
10. Jewish feminism: He-brew is not She-brevv.
11. De uitspraak van de Joods-Poolse kinderarts, pedagoog en schrijver Janusz Korczak 
(1878-1942) “grote mensen zijn niks beter’ is een gezond uitgangspunt bij het 
opvoeden van een kind.
12. Allochtonen geven kleur aan ons leven!
13. Dit boek had de auteur graag van achteren naar voren geschreven.
Nijmegen, 3 december 2002 
Livia Kapusta

